var title_f36_10_37024="Prenatal ultrasound bilateral MCDK";
var content_f36_10_37024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of bilateral multicystic dysplastic kidneys showing the circumferential arrangement of the cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up ultrasound examination of this pregnancy in the third trimester revealed anyhydramnios and reduction in size of both kidneys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37024=[""].join("\n");
var outline_f36_10_37024=null;
var title_f36_10_37025="Contents: International drug information";
var content_f36_10_37025=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?32/20/33101\">",
"       Drug Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       International drug information",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			International drug information",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/52/9025\">",
"           Aceclofenac: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/49/13073\">",
"           Acemetacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/46/4833\">",
"           Acipimox: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/42/18081\">",
"           Acyclovir (ophthalmic): International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/54/11105\">",
"           Almitrine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/3/37937\">",
"           Alverine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/35/40497\">",
"           Ambroxol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/2/11297\">",
"           Amorolfine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/58/15265\">",
"           Amoxicillin and cloxacillin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/55/23409\">",
"           Ampicillin and cloxacillin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/53/10065\">",
"           Ancestim: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7089\">",
"           Aniracetam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/12/8385\">",
"           Atosiban: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/20/7489\">",
"           Azapropazone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/35/1585\">",
"           Azelnidipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/18/4385\">",
"           Azosemide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/19/15665\">",
"           Bambuterol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/46/10977\">",
"           Bamifylline: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/33/2577\">",
"           Barbexaclone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/52/8001\">",
"           Barnidipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/33/8721\">",
"           Befunolol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/10/7329\">",
"           Bencyclane: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/46/5857\">",
"           Benperidol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/6/4193\">",
"           Benzylthiouracil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/2/5153\">",
"           Beraprost: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/53/15185\">",
"           Bifonazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/8/13441\">",
"           Bimatoprost and timolol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/41/35473\">",
"           Brivudine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/48/28417\">",
"           Bromhexine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15233\">",
"           Bromperidol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/1/5137\">",
"           Brotizolam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15025\">",
"           Bupranolol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/50/11041\">",
"           Carbenoxolone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/52/14145\">",
"           Carbimazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/5/3154\">",
"           Carbocysteine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/58/7073\">",
"           Carpipramine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/8/14465\">",
"           Cefoperazone and sulbactam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/13/11473\">",
"           Cefpirome: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/10/9377\">",
"           Cefsulodin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/2/41\">",
"           Celiprolol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/8/7297\">",
"           Cetiedil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/21/31057\">",
"           Cinnarizine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/22/6497\">",
"           Ciprofibrate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/39/14961\">",
"           Clenbuterol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/13/7377\">",
"           Clobenzorex: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/42/12961\">",
"           Clobutinol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/23/29041\">",
"           Clofazimine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/11/9393\">",
"           Deflazacort: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/31/6641\">",
"           Delapril: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7601\">",
"           Deptropine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/33/9745\">",
"           Dexketoprofen: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/44/8897\">",
"           Diacerein: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/4/10305\">",
"           Dibekacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/9/8337\">",
"           Diethylamine salicylate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/34/7713\">",
"           Difluprednate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/41/16017\">",
"           Digitoxin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/11/5297\">",
"           Dimemorfan: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/24/9601\">",
"           Dimethindene: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/34/39457\">",
"           Dipyrone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/45/7889\">",
"           Dopexamine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17505\">",
"           Dosulepin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/49/4881\">",
"           Doxofylline: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/38/5729\">",
"           Dydrogesterone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/63/9201\">",
"           Ebastine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/5/4177\">",
"           Edoxudine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/34/11809\">",
"           Enoximone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/45/14033\">",
"           Ephedrine and theophylline: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/35/4657\">",
"           Eptaplatin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/0/9217\">",
"           Erdosteine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18785\">",
"           Etamsylate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/19/6450\">",
"           Etilefrine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/9/13457\">",
"           Etofenamate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10097\">",
"           Etoricoxib: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3985\">",
"           Etozolin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/63/8177\">",
"           Felbinac: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/34/9761\">",
"           Fenbufen: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/44/11969\">",
"           Fenoterol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/47/7921\">",
"           Fenoverine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/39/15985\">",
"           Fenticonazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/46/16097\">",
"           Flucloxacillin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/3/6193\">",
"           Fluindione: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/28/37313\">",
"           Formestane: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/55/7025\">",
"           Fotemustine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/6/16481\">",
"           Framycetin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/9/5265\">",
"           Furazolidone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/12/7361\">",
"           Gallamine triethiodide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/13/6353\">",
"           Gestrinone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5569\">",
"           Gliquidone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/25/7569\">",
"           Glutethimide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/45/13009\">",
"           Halofantrine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/63/5105\">",
"           Halometasone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/26/4513\">",
"           Idrocilamide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/50/8993\">",
"           Imidapril: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37825\">",
"           Indobufen: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/37/12881\">",
"           Indoramin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/30/15841\">",
"           Interferon alpha multi-subtype (natural human interferon alpha): International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/27/8625\">",
"           Isepamicin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/23/15729\">",
"           Isoconazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/44/5825\">",
"           Isoniazid and thiacetazone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/62/8161\">",
"           Isoproterenol and phenylephrine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/50/6945\">",
"           Itopride: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/37/7761\">",
"           Ivabradine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/3/12337\">",
"           Josamycin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/11/8369\">",
"           Ketanserin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9921\">",
"           Ketazolam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/31/7665\">",
"           Lacidipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/15/13553\">",
"           Lafutidine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12657\">",
"           Lenograstim: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/35/10801\">",
"           Lercanidipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/41/4753\">",
"           Levosimendan: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/29/7633\">",
"           Lofepramine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/37/10833\">",
"           Lofexidine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/21/12625\">",
"           Lomefloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/11/7345\">",
"           Loprazolam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/52/11073\">",
"           Lormetazepam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/13/14545\">",
"           Lornoxicam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/10/8353\">",
"           Loxoprofen: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/35/8753\">",
"           Lynestrenol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/54/8033\">",
"           Manidipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/9/15505\">",
"           Mebeverine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/43/6833\">",
"           Mebhydrolin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/2/13345\">",
"           Mecysteine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/63/7153\">",
"           Medazepam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/11/3249\">",
"           Mefruside: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/55/4977\">",
"           Meglumine antimoniate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/42/6817\">",
"           Melitracen: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/17/5393\">",
"           Mesterolone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/35/9777\">",
"           Midecamycin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/61/7121\">",
"           Miltefosine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/10/5281\">",
"           Mizolastine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/22/16737\">",
"           Molgramostim: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/42/10913\">",
"           Mosapride: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/18/3361\">",
"           Nadifloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/30/16865\">",
"           Naftidrofuryl: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/60/26561\">",
"           Nalidixic acid: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/46/6881\">",
"           Nicorandil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/54/15201\">",
"           Niflumic acid: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/16/43265\">",
"           Nifuroxazide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/44/4801\">",
"           Nilvadipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/35/22065\">",
"           Nimesulide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/41/8849\">",
"           Nimotuzumab: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/42/8865\">",
"           Nimustine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/55/16241\">",
"           Nitrendipine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4481\">",
"           Nitroxoline: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/26/10657\">",
"           Omoconazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/62/18401\">",
"           Ornidazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/53/12113\">",
"           Ornipressin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/7/12401\">",
"           Oxatomide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/17/9489\">",
"           Oxitropium: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/57/15249\">",
"           Parecoxib: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/54/19297\">",
"           Pefloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/17/8465\">",
"           Perhexiline: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/53/9041\">",
"           Phenprocoumon: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/26/12705\">",
"           Pholcodine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/7/4209\">",
"           Pinacidil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/0/6145\">",
"           Pinazepam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/18/10529\">",
"           Pipamperone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/19/20785\">",
"           Pipemidic acid: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12609\">",
"           Pipoxolan: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/16/29953\">",
"           Piracetam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/32/8705\">",
"           Pirenzepine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/27/9649\">",
"           Piribedil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/13/8401\">",
"           Pivmecillinam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/16/9473\">",
"           Polyestradiol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/30/7649\">",
"           Prazepam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/22/11617\">",
"           Prifinium: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/23/40305\">",
"           Propiverine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/9/4241\">",
"           Prulifloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/29/4561\">",
"           Racecadotril: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9313\">",
"           Ramosetron: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/29/35281\">",
"           Rebamipide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/61/10193\">",
"           Reboxetine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/15/7409\">",
"           Rimonabant: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/45/25297\">",
"           Roxithromycin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/23/9585\">",
"           Rufloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/7/6257\">",
"           Rupatadine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/51/7985\">",
"           Secnidazole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/23/1393\">",
"           Sertindole: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/32/2561\">",
"           Sodium stibogluconate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/7/14449\">",
"           Sparfloxacin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/36/6721\">",
"           Spirapril: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/43/16049\">",
"           Stiripentol: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/14/4321\">",
"           Strontium ranelate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/27/18865\">",
"           Sugammadex: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/28/43457\">",
"           Tafluprost: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/44/12993\">",
"           Teicoplanin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/35/6705\">",
"           Temocapril: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/48/16129\">",
"           Tenoxicam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/62/10209\">",
"           Terlipressin: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/50/14113\">",
"           Tetrazepam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/38/9825\">",
"           Tianeptine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/27/11697\">",
"           Tibolone: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/14/3297\">",
"           Tofisopam: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/33/6673\">",
"           Tolciclate: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/62/6113\">",
"           Trapidil: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/34/4641\">",
"           Triflusal: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11233\">",
"           Trimetazidine: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/38/2658\">",
"           Tropisetron: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/58/9121\">",
"           Xipamide: International drug information",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/27/22961\">",
"           Zofenopril: International drug information",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-65C359293F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_10_37025=[""].join("\n");
var outline_f36_10_37025=null;
var title_f36_10_37026="Apert syndrome dental features";
var content_f36_10_37026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dental features of Apert syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with Apert syndrome, the maxillary dental arch is V-shaped, and a class 3 malocclusion (prognathism, or underbite) with an associated open bite is nearly universal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37026=[""].join("\n");
var outline_f36_10_37026=null;
var title_f36_10_37027="Check rein ligaments";
var content_f36_10_37027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Check rein ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The volar plate is a fibrocartilagenous thickening that stabilizes the proximal interphalangeal joint (PIPJ) and prevents hyperextension. The proximal end of the volar plate is free and attached to the proximal phalanx by the check rein ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37027=[""].join("\n");
var outline_f36_10_37027=null;
var title_f36_10_37028="Labia minora hypertrophy";
var content_f36_10_37028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Labia minora hypertrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Jhansi Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37028/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37028/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing numbers of girls and young women are seeking medical and surgical attention due to concerns about the appearance of their external genitalia. One area of concern is enlarged labia minora, which usually are a variant of normal anatomy. Clinical labial hypertrophy remains a poorly defined diagnosis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis and treatment of hypertrophy of the labia minora will be reviewed here. Congenital anomalies of the reproductive tract and vulvovaginal discomfort syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8295?source=see_link\">",
"     \"Clinical manifestations and diagnosis of generalized vulvodynia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/46/37609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no standard diagnostic criteria for the diagnosis of labia minora hypertrophy. Clinicians generally use labial width measurements or the presence of symptoms to determine treatment options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Labial width",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labia minora hypertrophy is generally described as protuberant labial tissue that projects beyond the labia majora. However, there is no consensus among gynecologists, pediatricians, or plastic surgeons regarding the use of objective clinical measurements to confirm the diagnosis.",
"   </p>",
"   <p>",
"    In an early description of this condition, Friedrich classified labia minora as hypertrophic when the maximal width between the midline and the lateral free edge of the labia minora (when the labia were extended laterally by the examiner) measured greater than 5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/1\">",
"     1",
"    </a>",
"    ]. Others have proposed that the normal width of the labia minora should be less than 3 to 4 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, some have argued that patients should be offered surgical correction if they present with persistent symptoms, regardless of measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms are either functional or psychological. Hypertrophy of one or both labia minora can result in irritation, chronic infection, poor hygiene, pain or interference with sexual activity and sports (eg, running, cycling, horseback riding, or swimming). As an example, a woman may describe discomfort with the fact that there is a \"bulge\" in her underwear. She may report that she needs to \"fold up\" her labia and push them into the vagina to reduce the bulge.",
"   </p>",
"   <p>",
"    In addition, concerns about the appearance of the labia minora can result in considerable psychological and emotional distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Given the physical and emotional changes that accompany puberty, adolescent girls are a particularly vulnerable group. For example, girls may become very self conscious about the size of the labia if they need to change their clothes within the presence of their peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach is utilized for the gynecological examination. It is helpful for the examining clinician to be familiar with the normal variants of the external female genitalia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42681?source=see_link\">",
"     \"The gynecologic history and pelvic examination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=see_link&amp;anchor=H3#H3\">",
"     \"Gynecologic examination of the newborn and child\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The external genitalia are inspected (",
"    <a class=\"graphic graphic_figure graphicRef72614 \" href=\"mobipreview.htm?24/50/25379\">",
"     figure 1",
"    </a>",
"    ). The hair distribution, skin, labia major and minora, clitoris, urethral meatus, introitus, perineal body, and anus are evaluated. In particular, the labial minora should be fully extended laterally, inspected for asymmetry, and measured from the midline to the lateral free edge (",
"    <a class=\"graphic graphic_picture graphicRef51816 \" href=\"mobipreview.htm?26/44/27330\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to management is patient counseling and self-care instruction. If symptoms persist after extensive counseling, then surgical correction can be offered. Patients should be aware that surgical correction may result in scarring and potentially lead to chronic vulvar pain and dyspareunia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, surgery is considered elective, and cosmetic results vary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, concerns regarding labial asymmetry or hypertrophy can be alleviated through reassurance that variation in size is a variant of normal anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Furthermore, functional symptoms can often be conservatively managed through counseling about personal hygiene (eg, use of mild soaps, avoiding bubble baths, use of \"natural\" sanitary pads which do not contains chemicals) and avoidance of form-fitting clothing. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Diagnosis and clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Labioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of labioplasty is resection of the hypertrophic tissue and creation of symmetrically reduced labia.",
"   </p>",
"   <p>",
"    While this procedure may be performed in adolescence, if indicated, it is our experience that the minimum age should be 15 to 16 to avoid the need for a second operation if the labia continue to grow. The emotional maturity level of the adolescent should also be evaluated when determining the appropriate age for a surgical procedure. Decisions regarding surgical treatment of preadolescent or adolescent girls require involvement of a parent or guardian. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several techniques have been described. The simplest technique, and our usual surgical procedure of choice, involves straight amputation using an anterior-posterior incision of the protuberant labial tissue and oversewing of the incised edge (",
"    <a class=\"graphic graphic_picture graphicRef83179 \" href=\"mobipreview.htm?30/38/31328\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/11\">",
"     11",
"    </a>",
"    ]. We typically use an interrupted suture of 3-0 vicryl. This technique has the fastest recovery and usually is associated with excellent results. It should be noted, however, that the labial edges may be replaced with scarred suture lines that cause chronic irritation and discomfort. Furthermore, the natural contour of the labia minora may be compromised (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Outcome of labioplasty'",
"    </a>",
"    below). Of note, if this technique is used, great care should be taken to avoid the area of the clitoris and the clitoral hood.",
"   </p>",
"   <p>",
"    Several newer techniques have been described which attempt to preserve the natural contour of the labia minora and reduce the amount of exposed scar tissue. These alternative techniques involve a wedge resection with subsequent reanastomosis. While maintaining symmetry, a V-shaped segment is carefully resected. The raw edges are reapproximated using interrupted or a running subcuticular fine absorbable suture (",
"    <a class=\"graphic graphic_picture graphicRef73368 \" href=\"mobipreview.htm?43/17/44306\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2,3,6,12\">",
"     2,3,6,12",
"    </a>",
"    ]. We typically use an interrupted suture of 3-0 vicryl. In one case series, labioplasty was performed using a Nd:YAG laser [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of labioplasty include infection, bleeding, and wound dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/14\">",
"     14",
"    </a>",
"    ]. There are few data regarding the rate of complications following labioplasty. In two large case series (n = 407 and 163), reoperation rates were 2.9 and 7 percent; indications for reoperation were wound dehiscence or dissatisfaction with appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/6,15\">",
"     6,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperatively, the patient should keep the area clean and dry, avoid strenuous activity, wear lose clothing, and protect the vulvar area from friction. An athletic support cup may be worn inside the patient's underwear to reduce the risk of friction and disruption of the suture line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/12\">",
"     12",
"    </a>",
"    ]. However, in our experience, use of a support cup postoperatively may result in a slower recovery and a higher chance of suture wound breakdown, although no long-term follow-up studies have been published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME OF LABIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labioplasty is a simple surgical procedure that can be associated with a high degree of patient satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2\">",
"     2",
"    </a>",
"    ]. In the largest labioplasty case series (n = 163), the majority of women underwent bilateral surgical correction using a V-shaped wedge resection technique. We have found the best results and least complications with the straight resection procedure. The most common motives for surgical correction were aesthetic complaints, discomfort with certain types of clothing, entry dyspareunia, and difficulty participating in athletic activities.",
"   </p>",
"   <p>",
"    It should be noted that, with any surgical procedure for labioplasty, there is a risk of suture breakdown and secondary healing.",
"   </p>",
"   <p>",
"    With the V-shaped excision technique, there are cases where there is extensive prolonged swelling, most likely from adverse effect on lymphatic drainage.",
"   </p>",
"   <p>",
"    Most women reported relief of discomfort (96 percent) and aesthetic improvement (91 percent). There were no major perioperative complications. Minor complications were temporary (median duration 28 days), including: postoperative discomfort (45 percent) and entry dyspareunia (23 percent). Eleven patients (7 percent) underwent a second procedure because of small wound dehiscences, which compromised the aesthetic result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labia minora hypertrophy is generally described as protuberant labial tissue that projects beyond the labia majora. It is usually a variant of normal anatomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no standard diagnostic criteria for labia minora hypertrophy. Clinicians generally use labial width measurement and presence of symptoms to make treatment decisions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common symptoms include irritation, chronic infection, pain and interference with sexual activity or sports. In addition, concerns about aesthetic appearance can result in considerable psychological and emotional distress. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Girls or women with absent or mild symptoms from labia minora hypertrophy can often be managed with reassurance or counseling regarding personal hygiene and avoidance of form-fitting clothing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical correction may lead to scarring, chronic vulvar pain, and dyspareunia. In addition, surgery is elective and cosmetic results vary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Labioplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is our experience that the minimum age should be 15 to 16 to avoid the need for a repeat operation if the labia continue to grow. The emotional maturity level of the adolescent should also be evaluated when determining the appropriate age for a surgical procedure. Decisions regarding surgical treatment of preadolescent or adolescent girls require involvement of a parent or guardian. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Labioplasty'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"       \"Consent in adolescent health care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In girls and women with labia minora hypertrophy who undergo labioplasty, we suggest a straight amputation with an anterior-posterior incision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A V-shaped wedge resection is also a reasonable option. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Labioplasty'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Freidrich EG. Vulvar Disease, 2nd ed, WB Saunders, Philadelphia 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/2\">",
"      Rouzier R, Louis-Sylvestre C, Paniel BJ, Haddad B. Hypertrophy of labia minora: experience with 163 reductions. Am J Obstet Gynecol 2000; 182:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/3\">",
"      Munhoz AM, Filassi JR, Ricci MD, et al. Aesthetic labia minora reduction with inferior wedge resection and superior pedicle flap reconstruction. Plast Reconstr Surg 2006; 118:1237.",
"     </a>",
"    </li>",
"    <li>",
"     Laufer MR. Structural abnormalities of the female reproductive trac. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/5\">",
"      Reddy J, Laufer MR. Hypertrophic labia minora. J Pediatr Adolesc Gynecol 2010; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/6\">",
"      Alter GJ. A new technique for aesthetic labia minora reduction. Ann Plast Surg 1998; 40:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/7\">",
"      Kato K, Kondo A, Gotoh M, et al. Hypertrophy of labia minora in myelodysplastic women. Labioplasty to ease clean intermittent catheterization. Urology 1988; 31:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/8\">",
"      Jothilakshmi PK, Salvi NR, Hayden BE, Bose-Haider B. Labial reduction in adolescent population--a case series study. J Pediatr Adolesc Gynecol 2009; 22:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/9\">",
"      Radman HM. Hypertrophy of the labia minora. Obstet Gynecol 1976; 48:78S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/10\">",
"      Gowen RM, Martin VL. Labia minora reduction in an iron-lung disabled woman. Obstet Gynecol 1988; 71:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/11\">",
"      Hodgkinson DJ, Hait G. Aesthetic vaginal labioplasty. Plast Reconstr Surg 1984; 74:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/12\">",
"      Laufer, MR, Galvin, WJ. Labia hypertrophy: a new surgical approach. Adolesc Pediatr Gynecol 1995; 8:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/13\">",
"      Pardo J, Sol&agrave; V, Ricci P, Guilloff E. Laser labioplasty of labia minora. Int J Gynaecol Obstet 2006; 93:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/14\">",
"      Liao LM, Michala L, Creighton SM. Labial surgery for well women: a review of the literature. BJOG 2010; 117:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37028/abstract/15\">",
"      Alter GJ. Aesthetic labia minora and clitoral hood reduction using extended central wedge resection. Plast Reconstr Surg 2008; 122:1780.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3291 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37028=[""].join("\n");
var outline_f36_10_37028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Labial width",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Labioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME OF LABIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3291|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/50/25379\" title=\"figure 1\">",
"      Vulvar anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3291|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/44/27330\" title=\"picture 1\">",
"      Labial hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/38/31328\" title=\"picture 2\">",
"      Labioplasty straight incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/17/44306\" title=\"picture 3\">",
"      Labioplasty wedge resection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8295?source=related_link\">",
"      Clinical manifestations and diagnosis of generalized vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/46/37609?source=related_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37029="Ephedrine (systemic): Pediatric drug information";
var content_f36_10_37029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ephedrine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?11/14/11493?source=see_link\">",
"    see \"Ephedrine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/58/6053?source=see_link\">",
"    see \"Ephedrine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10811207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F14182082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Myasthenic syndromes, congenital:",
"     </b>",
"     Limited data available: Oral: Initial: 1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses, may increase to 3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10811309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/14/11493?source=see_link\">",
"      see \"Ephedrine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asthma, bronchodilation:",
"     </b>",
"     Children &ge;12 years and Adolescents: Oral: 12.5-25 mg every 4 hours; if symptoms do not improve after 1 hour from initial dose, physician should be contacted and continuation of therapy evaluated; maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for routine management and treatment of asthma and",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm (NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypotension, anesthesia-induced:",
"     </b>",
"     Use the smallest effective dose for the shortest time;",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for use in management of septic shock (Brierley, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;12 years: I.V., SubQ: 0.2-0.3 mg/kg/dose every 4-6 hours; maximum dose: 25 mg (Taguchi, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 10-25 mg; may repeat with a second dose in 5-10 minutes of 25 mg; not to exceed 150 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     SubQ: 25-50 mg (range: 10-50 mg); may repeat with a second dose of 50 mg; not to exceed 150 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myasthenic syndromes, congenital:",
"     </b>",
"     Infants, Children, and Adolescents: Limited data available: Oral: Initial: 1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses, may increase to 3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses (Engel, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Nasal decongestion:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;2-6 years: Oral: 2-3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <b>",
"      da",
"     </b>",
"     y in 4-6 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 7-11 years: Oral: 6.25-12.5 mg every 4 hours; maximum daily dose: 75 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents: Oral: 12.5-25 mg every 3-4 hours; maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypotension, anesthesia-induced:",
"     </b>",
"     I.V.: 5-25 mg/dose slow I.V. push repeated after 5-10 minutes as needed, then every 3-4 hours (maximum: 150 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Idiopathic orthostatic hypotension:",
"     </b>",
"     Oral: 25-50 mg 3 times/",
"     <b>",
"      day",
"     </b>",
"     ; maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Not considered first-line for this indication.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8084062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 50 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8083937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10811310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: pH: 4.5-7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: May be administered by slow I.V. push",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: May be administered undiluted",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8083995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, sodium chloride 5%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, dexmedetomidine, etomidate, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pentobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10811245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light and moisture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10811210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Temporary relief of bronchial asthma symptoms (shortness of breath, tightness of chest, and wheezing) (OTC labeling: FDA approved in ages &ge;12 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for routine management and treatment of asthma (NAEPP, 2007); has also been used for nasal decongestion and congenital myasthenic syndromes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of anesthesia-induced hypotension; treatment of hypotension following induced sympathectomy or following overdosage of antihypertensive drugs [FDA approved in pediatric patients (age not specified) and adults]; has also been used for idiopathic orthostatic hypotension and bronchodilation;",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for routine management and treatment of asthma (NAEPP, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8083925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EPHEDrine may be confused with Epifrin&reg;, EPINEPHrine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8083976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, chest pain, elevation or depression of blood pressure, hypertension, palpitation, tachycardia, unusual pallor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, apprehension, CNS stimulating effects, dizziness, excitation, fear, headache hyperactivity, insomnia, irritability, nervousness, restlessness, tension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, GI upset, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Painful urination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling, tremor (more common in the elderly), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10811211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ephedrine, any component, or sympathomimetic amines; angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10811213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, prostatic hypertrophy, and/or urinary stricture. Use with extreme caution in patients taking MAO inhibitors; prolonged hypertension may result from concurrent use. Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10811212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of ephedrine as a pressor is not a substitute for replacement of blood, plasma, fluids, and electrolytes; blood volume should be corrected as fully as possible before ephedrine therapy; must not be used as sole therapy in hypovolemic patients; hypoxia, hypercapnia, and acidosis may reduce the effectiveness and increase the incidence of side effects of ephedrine. May cause hypertension which may result in intracranial hemorrhage; use should generally be avoided or used with extreme caution in situations where vasopressor therapy is contraindicated [eg, thyrotoxicosis, diabetes, hypertension (including pregnancy-related), and other cardiovascular disorders]. May induce angina symptoms and potentially fatal arrhythmias in patients with cardiac disease (eg, coronary insufficiency, ischemia heart disease) or are receiving drugs that may sensitize myocardium to adrenergic stimulation; avoid use in these patients; concomitant use with anesthetics, such as cyclopropane or halothane should be avoided; agents may sensitize heart to arrhythmic effects of other sympathomimetics. Initial parenteral administration may cause temporary decrease in urine formation due to renal vasoconstriction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ephedrine should only be used in patients who have been diagnosed with asthma by a physician. Generally, ephedrine should not be used as a bronchodilator since other beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists are less toxic; do not use in patients that have been hospitalized due to asthma or use other prescription medications to control asthma symptoms; if asthma symptoms do not improve within 1 hour after dose, patients should be instructed to call prescriber.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term use has been associated with anxiety and symptoms of paranoid schizophrenia; the FDA has issued warnings concerning ephedrine-containing nonprescription products with claims of producing effects, such as euphoria, increased sexual sensation, increased energy, and weight loss; healthcare professionals are urged to be aware of these products and counsel patients, when appropriate, about the potential adverse effects of ephedrine, such as headache, dizziness, heart irregularities, seizures, and possibly death.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8083978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8083969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Ephedrine crosses the placenta (Hughes, 1985). Ephedrine injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section (ASA, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10811311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, pulse, respiratory symptoms",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10811246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates both alpha- and beta-adrenergic receptors and also stimulates the release of norepinephrine from storage sites, resulting in bronchodilation, cardiac stimulation, and increased systolic and diastolic blood pressure; tachyphylaxis may occur",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10811248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pressor/cardiac effects: Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10811285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Minimally hepatic by oxidative deamination, demethylation, aromatic hydroxylation, and conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Dependent upon urinary pH with greatest excretion in acid pH; urine pH 5: 74% to 99% excreted unchanged; urine pH 8: 22% to 25% excreted unchanged",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10811313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/58/6053?source=see_link\">",
"      see \"Ephedrine (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid other stimulant prescriptive or OTC medications to decrease risk of serious adverse reactions. May cause dizziness, blurred vision, or restlessness; contact prescriber if nervousness, excitation, abnormal thoughts, pounding heartbeat, chest pain or palpitations, tremor, insomnia, nausea or loss of appetite, or increased sweating occur; may cause dry mouth.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10811314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because ephedrine and pseudoephedrine have been used to synthesize methamphetamine, the DEA has placed them in the category of &ldquo;Schedule Listed Products&rdquo;; restrictions are in place to reduce the potential for misuse (diversion) and abuse (eg, storage requirements, additional documentation of sale); the DEA limit for a single transaction to a single individual for drug products containing ephedrine or pseudoephedrine is 3.6 g/24 hours, 9 g/30 days, or if mail-order transaction 7.5 g/30 days.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, \"Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/10/37029/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engel AG, \"The Therapy of Congenital Myasthenic Syndromes,\"",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2007, 4(2):252-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/10/37029/abstract-text/17395135/pubmed\" id=\"17395135\" target=\"_blank\">",
"        17395135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes SC, Ward MG, Levinson G, et al, \"Placental Transfer of Ephedrine Does Not Affect Neonatal Outcome,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1985, 63(2):217-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/10/37029/abstract-text/4025872/pubmed\" id=\"4025872\" target=\"_blank\">",
"        4025872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taguchi N, Nishikawa T, Inomata S, et al, \"Hemodynamic Effects of Intravenous Ephedrine in Infants and Children Anesthetized With Halothane and Nitrous Oxide,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 82(3):568-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/10/37029/abstract-text/8623963/pubmed\" id=\"8623963\" target=\"_blank\">",
"        8623963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15973 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37029=[""].join("\n");
var outline_f36_10_37029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811207\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182082\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811309\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084062\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083937\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811310\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083995\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811245\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811210\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083925\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083976\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811211\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811213\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811212\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083978\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083969\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882193\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811311\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811246\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811248\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811285\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811313\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10811314\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15973|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/14/11493?source=related_link\">",
"      Ephedrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/58/6053?source=related_link\">",
"      Ephedrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37030="Maternal conduction disorders and bradycardia during pregnancy";
var content_f36_10_37030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maternal conduction disorders and bradycardia during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Louise Harris, MBChB",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Sing-Chien Yap, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Candice Silversides, MD, MS, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     N A Mark Estes, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37030/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3648393\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias and conduction disorders are the most common cardiac complications encountered during pregnancy in women with and without structural heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. They may manifest for the first time during pregnancy, and in other cases, pregnancy can trigger exacerbations in women with preexisting arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. Women with established arrhythmias or structural heart disease are at highest risk of developing arrhythmias during pregnancy. Due to surgical advances, there has been an increase in the number of women of childbearing age with congenital heart disease and this group of women is at particularly high risk for arrhythmias (",
"    <a class=\"graphic graphic_figure graphicRef61986 \" href=\"mobipreview.htm?8/11/8382\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/1,2,7-11\">",
"     1,2,7-11",
"    </a>",
"    ]. Because of these associations, any woman who presents with an arrhythmia should have a clinical work up (including an electrocardiogram and a transthoracic echocardiogram) for evidence of structural heart disease.",
"   </p>",
"   <p>",
"    In general, the approach to the treatment of conduction disturbances and bradycardia in pregnant women is similar to that in the nonpregnant patient. Treatment strategies during pregnancy are hampered by the lack of randomized trials in this cohort of women. Choice of therapy, for the most part, is based on limited data from case reports, observational studies, and clinical experience.",
"   </p>",
"   <p>",
"    The prevalence, clinical presentation, and management of conduction disorders and bradycardia during pregnancy will be reviewed here. Electrocardiographic characteristics of sinus bradycardia and conduction disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=see_link\">",
"     \"ECG tutorial: Rhythms and arrhythmias of the sinus node\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Issues relating to supraventricular and ventricular arrhythmias, as well as cardiac arrest during pregnancy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20840?source=see_link\">",
"     \"Management of cardiopulmonary arrest in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648407\">",
"    <span class=\"h1\">",
"     PALPITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant women with palpitations does not differ from nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 110 pregnant women with arrhythmia-related symptoms (palpitations: 87 percent; dizziness: 13 percent;",
"    <span class=\"nowrap\">",
"     syncope/presyncope:",
"    </span>",
"    6 percent) who were evaluated with 24-hour Holter ambulatory monitoring, bradycardia was identified as a cause only 1 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648533\">",
"    <span class=\"h1\">",
"     SINUS BRADYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is a rhythm in which fewer than the normal number of impulses arises from the sinoatrial (SA) node. The normal heart rate has been considered historically to range from 60 to 100",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    with sinus bradycardia being defined as a sinus rhythm with a rate below 60",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Sinus bradycardia is not common during the antepartum period. Normally, there is a pregnancy-related physiologic increase in heart rate of 10 to 20",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    above baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13\">",
"     13",
"    </a>",
"    ]. Mild sinus bradycardia may occur transiently after normal delivery and may persist for a few days in the postpartum period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13\">",
"     13",
"    </a>",
"    ]. In the absence of structural heart disease, sinus bradycardia is seldom associated with symptoms and requires no intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=see_link\">",
"     \"Sinus bradycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648540\">",
"    <span class=\"h1\">",
"     FIRST AND SECOND DEGREE AV BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific association between first and second-degree heart block and pregnancy. First-degree atrioventricular block may be seen in women with structural heart disease such as rheumatic or congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13\">",
"     13",
"    </a>",
"    ]. Transient first degree AV block may be seen in settings of increased vagal tone. It is not uncommon for sinus bradycardia with first degree AV block to occur in healthy individuals while sleeping. This is a physiologic rather than a pathologic condition. Transient AV block resulting from increased vagal tone would be expected to occur less frequently in pregnant women than nonpregnant women. The exact prevalence of first-degree AV block is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13\">",
"     13",
"    </a>",
"    ]. The site of AV delay is usually located in the atrioventricular node, above the bundle of His, and it rarely progresses to advanced heart block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second-degree AV block is sometimes seen in pregnancy. Mobitz type I (Wenckebach) AV block is more commonly encountered and generally has a benign outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Typical Mobitz Type I (Wenckebach) block occurs at the level of the atrioventricular node, and, like first degree AV block, it rarely progresses to more advanced heart block. Accordingly, a conservative clinical strategy of monitoring is appropriate.",
"   </p>",
"   <p>",
"    Mobitz type II block (usually below the AV node) may precede the development of complete infra His AV block. It is uncommon during pregnancy. AV block at a level below the His bundle is usually associated with a very slow or absent ventricular escape rhythm, and therefore commonly results in hemodynamic compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope. Because of the risk of progression of Mobitz II block to complete infra His block, a permanent pacemaker is usually recommended even in an asymptomatic patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648547\">",
"    <span class=\"h1\">",
"     COMPLETE HEART BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block may be congenital or acquired. The prevalence of new onset of complete heart block during pregnancy is unknown, but is likely quite rare. There is no obvious association between pregnancy and new onset complete heart block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/17\">",
"     17",
"    </a>",
"    ], although some experts have suggested that the atrial stretch associated with pregnancy may provoke conduction disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/18\">",
"     18",
"    </a>",
"    ]. Newly acquired complete heart block is rarely first detected during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. The development of complete heart block may be associated with prior cardiac surgery, congenital heart disease, acute myocardial infarction, cardiomyopathy, drug intoxication, metabolic disturbances, or acute infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Progressive conduction disturbances during pregnancy that resolve in the postpartum period have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because placement of a pacemaker during pregnancy requires radiation exposure, women with complete heart block contemplating pregnancy should be evaluated by a cardiologist prior to becoming pregnant so a decision can be made regarding pacemaker implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648554\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with congenital complete heart block present before pregnancy, often in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/21\">",
"     21",
"    </a>",
"    ]. Typically there is an escape rhythm with a narrow QRS complex. Many women with symptomatic congenital complete heart block will have a permanent pacemaker implanted before pregnancy. The role of prophylactic pacemaker implantation in asymptomatic women with congenital complete heart block to prevent sudden death is not known. There is an emerging body of evidence to suggest that pacemaker implantation should be carefully considered in the asymptomatic adult with congenital complete heart block, as it may prevent development of cardiomyopathy, mitral regurgitation, and lower the risk of ventricular arrhythmias.",
"   </p>",
"   <p>",
"    In one study of pregnancy outcomes in women with congenital complete heart block (n = 32), 24 women without a pacemaker gave birth to 45 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/22\">",
"     22",
"    </a>",
"    ]. Thirteen percent (3 of 24) of the pregnancies were complicated by syncope, and a pacemaker was implanted in two women. The eight women with a pacemaker before pregnancy had 14 uneventful pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648561\">",
"    <span class=\"h2\">",
"     Management during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemaker implantation is recommended for almost all patients with complete heart block who are symptomatic. For women with complete heart block first detected during pregnancy who have a stable narrow complex junctional escape rhythm, pacemaker implantation can be deferred until after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. However, women with complete heart block who exhibit a slow wide QRS complex escape rhythm (suggestive of block below the His bundle) should undergo pacemaker implantation during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women with a pacemaker who undergo cesarean delivery, the interference generated by monopolar surgical",
"    <span class=\"nowrap\">",
"     diathermy/electrocautery",
"    </span>",
"    can be sufficient to temporarily inhibit pacemaker output, or may give rise to a temporary increase in pacing rate. Therefore, the pacemaker should be programmed to avoid inappropriate inhibition or high-rate pacing. All patients with permanent pacemakers should be on continuous cardiac monitoring during labor and following delivery.",
"   </p>",
"   <p>",
"    Pacemaker implantation is recommended for all patients with complete heart block who are symptomatic, and also in patients with asymptomatic complete heart block below the bundle of HIS. Perhaps the only exception to these indications for pacemaker implantation is patients with congenital complete heart block who are completely asymptomatic and have a stable junctional escape rhythm. However, there is an emerging body of evidence to suggest that pacemaker implantation should also be carefully considered in the asymptomatic adult with congenital complete heart block, as it may prevent development of cardiomyopathy, mitral regurgitation, and lower the risk of ventricular arrhythmias. Because placement of a pacemaker during pregnancy requires radiation exposure, women with complete heart block contemplating pregnancy should be evaluated by a cardiologist prior to becoming pregnant so a decision can be made regarding pacemaker implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648568\">",
"    <span class=\"h2\">",
"     Prophylactic temporary pacing for labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Valsalva maneuver during labor can be associated with a vasovagal reaction, resulting in slowing of the heart rate and potentially syncope. Thus, some centers advocate prophylactic temporary transvenous pacing for labor and delivery in asymptomatic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/21,26,27\">",
"     21,26,27",
"    </a>",
"    ]. Other centers do not prophylactically insert pacemakers in all women with complete heart block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/18,28,29\">",
"     18,28,29",
"    </a>",
"    ]. In one small case series of six asymptomatic, nonpaced women with complete heart block, there was no significant change in heart rate before, during, or after labor and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/28\">",
"     28",
"    </a>",
"    ]. Only one woman developed hypotension secondary to postpartum hemorrhage.",
"   </p>",
"   <p>",
"    In general, the indications for temporary pacing during labor are identical to those for nonpregnant adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    .) In emergency situations, temporary transcutaneous pacing can be used. However, this is painful and generally poorly tolerated by patients. Transcutaneous pacing generally is used for a short period of time while a transvenous pacing is placed or the bradycardia resolves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3648575\">",
"    <span class=\"h2\">",
"     Pacemaker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, women with complete heart block, who develop symptomatic bradycardia, including syncope and presyncope, may need to have a pacemaker implantation during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/18,30-33\">",
"     18,30-33",
"    </a>",
"    ], but there is no consensus among experts on the best location for a pacemaker placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/25\">",
"     25",
"    </a>",
"    ]. Radiation exposure due to the use of fluoroscopy during pacemaker implantation is the most frequent concern for pregnant women and clinicians. Fetal risks of anomalies, growth restriction, or abortions are not increased with radiation exposure of less than 50 mGy (5 rads) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/34\">",
"     34",
"    </a>",
"    ]. One study estimated that the average radiation dose to the fetus was &lt;1 mGy during catheter ablation of supraventricular tachycardia (much longer fluoroscopy times compared with pacemaker implantation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/35\">",
"     35",
"    </a>",
"    ]. Other precautions can be used to minimize radiation exposure. During fluoroscopy for pacemaker implantation, the uterus is positioned outside the field of view and therefore, the fetus is exposed to internal and external scattered radiation only. It may be possible to use a lead shield to protect the uterus from external scattered radiation; however, because the dose from external scattered radiation is minimal, the use of lead shielding is left to the discretion of the operator. Modifying the exposure time, number of films obtained, beam size, and imaging area can further reduce the amount of radiation exposure. If necessary, pacemaker implantation can be safely performed with minimal radiation exposure by a skilled operator in a cath lab with pulse fluoroscopy. Although some have advocated echocardiographic guidance during the first trimester, the amount of fluoroscopy received is sufficiently low, that it is our opinion that an echocardiographic guided approach should not be advised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37030/abstract/30,31,33\">",
"     30,31,33",
"    </a>",
"    ]. With an experienced implanting clinician and appropriate fluoroscopy equipment and shielding of the fetus, temporary and permanent pacemaker leads can be safely placed during all stages of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466818880\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia can occur transiently after normal delivery and may persist for a few days in the postpartum period. (See",
"      <a class=\"local\" href=\"#H3648533\">",
"       'Sinus bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conduction disorders can be associated with structural heart disease such as rheumatic heart disease or ischemia heart disease. (See",
"      <a class=\"local\" href=\"#H3648540\">",
"       'First and second degree AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete heart block during pregnancy may be acquired or congenital. (See",
"      <a class=\"local\" href=\"#H3648547\">",
"       'Complete heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the indications for temporary and permanent pacing during pregnancy are similar to those in the general population. (See",
"      <a class=\"local\" href=\"#H3648547\">",
"       'Complete heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancies in women with pacemakers are safe. Women with pacemakers who undergo cesarean delivery may require pacemaker reprogramming to avoid interference caused by electrocautery. (See",
"      <a class=\"local\" href=\"#H3648575\">",
"       'Pacemaker therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus with regard to prophylactic temporary pacing for labor in asymptomatic women with congenital complete heart block. (See",
"      <a class=\"local\" href=\"#H3648568\">",
"       'Prophylactic temporary pacing for labor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/1\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/2\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/3\">",
"      Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/4\">",
"      Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/5\">",
"      Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/6\">",
"      Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/7\">",
"      Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/8\">",
"      Drenthen W, Pieper PG, Ploeg M, et al. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005; 26:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/9\">",
"      Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/10\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan palliation. Heart 2006; 92:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/11\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/12\">",
"      Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997; 79:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/13\">",
"      MENDELSON CL. Disorders of the heartbeat during pregnancy. Am J Obstet Gynecol 1956; 72:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/14\">",
"      COPELAND GD, STERN TN. Wenckebach periods in pregnancy and puerperium. Am Heart J 1958; 56:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/15\">",
"      Sherer DM, Nawrocki MN, Thompson HO, Woods JR Jr. Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor. Am J Perinatol 1991; 8:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/16\">",
"      Matta BF, Magee P. Wenckebach type heart block following spinal anaesthesia for caesarean section. Can J Anaesth 1992; 39:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/17\">",
"      Eddy WA, Frankenfeld RH. Congenital complete heart block in pregnancy. Am J Obstet Gynecol 1977; 128:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/18\">",
"      Thaman R, Curtis S, Faganello G, et al. Cardiac outcome of pregnancy in women with a pacemaker and women with untreated atrioventricular conduction block. Europace 2011; 13:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/19\">",
"      Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003; 67:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/20\">",
"      Suri V, Keepanasseril A, Aggarwal N, et al. Maternal complete heart block in pregnancy: analysis of four cases and review of management. J Obstet Gynaecol Res 2009; 35:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/21\">",
"      Dalvi BV, Chaudhuri A, Kulkarni HL, Kale PA. Therapeutic guidelines for congenital complete heart block presenting in pregnancy. Obstet Gynecol 1992; 79:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/22\">",
"      Micha&euml;lsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/23\">",
"      Kenmure AC, Cameron AJ. Congenital complete heart block in pregnancy. Br Heart J 1967; 29:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/24\">",
"      Avasthi K, Gupta S, Avasthi G. An unusual case of complete heart block with triplet pregnancy. Indian Heart J 2003; 55:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/25\">",
"      Jaffe R, Gruber A, Fejgin M, et al. Pregnancy with an artificial pacemaker. Obstet Gynecol Surv 1987; 42:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/26\">",
"      Sharma JB, Malhotra M, Pundir P. Successful pregnancy outcome with cardiac pacemaker after complete heart block. Int J Gynaecol Obstet 2000; 68:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/27\">",
"      Ramsewak S, Persad P, Perkins S, Narayansingh G. Twin pregnancy in a patient with complete heart block. A case report. Clin Exp Obstet Gynecol 1992; 19:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/28\">",
"      Hidaka N, Chiba Y, Kurita T, et al. Is intrapartum temporary pacing required for women with complete atrioventricular block? An analysis of seven cases. BJOG 2006; 113:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/29\">",
"      Hidaka N, Chiba Y, Fukushima K, Wake N. Pregnant women with complete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol 2011; 34:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/30\">",
"      Jordaens LJ, Vandenbogaerde JF, Van de Bruaene P, De Buyzere M. Transesophageal echocardiography for insertion of a physiological pacemaker in early pregnancy. Pacing Clin Electrophysiol 1990; 13:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/31\">",
"      Lau CP, Lee CP, Wong CK, et al. Rate responsive pacing with a minute ventilation sensing pacemaker during pregnancy and delivery. Pacing Clin Electrophysiol 1990; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/32\">",
"      Amikam S, Abramovici H, Brandes JM, et al. Pregnancy in the presence of an implanted pacemaker. Int Surg 1981; 66:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/33\">",
"      G&uuml;dal M, Kervancio��lu C, Oral D, et al. Permanent pacemaker implantation in a pregnant woman with the guidance of ECG and two-dimensional echocardiography. Pacing Clin Electrophysiol 1987; 10:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/34\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37030/abstract/35\">",
"      Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation 2001; 104:893.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15252 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37030=[""].join("\n");
var outline_f36_10_37030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H466818880\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3648393\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3648407\">",
"      PALPITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3648533\">",
"      SINUS BRADYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3648540\">",
"      FIRST AND SECOND DEGREE AV BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3648547\">",
"      COMPLETE HEART BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3648554\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3648561\">",
"      Management during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3648568\">",
"      Prophylactic temporary pacing for labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3648575\">",
"      Pacemaker therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466818880\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/15252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/15252|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/11/8382\" title=\"figure 1\">",
"      Prevalence arrhythmias pregnancy congenital heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=related_link\">",
"      ECG tutorial: Rhythms and arrhythmias of the sinus node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20840?source=related_link\">",
"      Management of cardiopulmonary arrest in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37031="Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes";
var content_f36_10_37031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     John Michael Stulak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37031/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard coronary artery bypass graft surgery (CABG) employs a midline incision through the sternum, placement of the patient on cardiopulmonary bypass, and arrest of the heart with cardioplegia. This approach allows for optimal exposure of the coronary arteries and a motionless (non-beating) heart, both of which optimize the suturing of the distal anastomoses of the bypass.",
"   </p>",
"   <p>",
"    This approach may contribute risk during certain clinical scenarios. For example, patients requiring a repeat CABG are at risk of damage to a previously placed left internal mammary bypass graft during a repeat sternotomy and patients with calcified aortas may be at increased risk of cerebral embolization with cross-clamping of the aorta during cardiopulmonary bypass.",
"   </p>",
"   <p>",
"    This topic will discuss clinical outcomes after off-pump and minimally invasive direct coronary artery bypass graft surgery (MID CABG), two approaches which have been be evaluated as potential approaches to decrease some of the risks of standard CABG. Complications of CABG using any technique, technical issues related to minimally invasive CABG, and minimally invasive approaches to valvular surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H2#H2\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Prevention of complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44296?source=see_link\">",
"     \"Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=see_link\">",
"     \"Minimally invasive aortic and mitral valve surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OFF-PUMP CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Off-pump CABG refers to CABG without the use of cardiopulmonary bypass. The major rationale for this procedure, which is also called &ldquo;beating heart surgery&rdquo;, is to avoid the morbidity associated with cardiopulmonary bypass (induction of a systemic inflammatory response by the bypass circuit) and of cross-clamping the aorta (risk of stroke or systemic embolization). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44296?source=see_link&amp;anchor=H3#H3\">",
"     \"Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues\", section on 'General principles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All surgeons performing CABG must be competent with the on-pump technique. The off-pump technique is technically more challenging and requires additional training. It has been chosen by some practitioners for high-risk patients with contraindications to conventional CABG, such as those with extensive ascending aortic atheromatous or calcific changes which might preclude safe aortic instrumentation. A potential disadvantage of off-pump surgery is the difficulty of performing distal anastomoses on a beating heart; this might lead to incomplete revascularization if exposure of the back of the heart is challenging or decreased graft patency because of suboptimal conditions during the construction of the distal anastomosis.",
"   </p>",
"   <p>",
"    The experience with off-pump CABG and MID CABG has increased dramatically since the late 1990s. An analysis of the Society of Thoracic Surgeons database in 1998 and 1999 found that some type of off-pump CABG represented 10 percent of all CABG procedures performed in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/1\">",
"     1",
"    </a>",
"    ]. By 2001, beating heart techniques accounted for approximately 25 percent of isolated CABG procedures; this figure has not changed significantly since then [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Compared to on-pump CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed by surgeons comfortable with either procedure, off- and on-pump CABG appear to deliver comparable outcomes of death, stroke, myocardial infarction, and new renal failure requiring dialysis at 30 days and one year. The rate of repeat revascularization appears to be higher with off-pump CABG.",
"   </p>",
"   <p>",
"    Although initial observational studies with off-pump CABG suggested similar or better outcomes compared with conventional on-pump CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/1,5-14\">",
"     1,5-14",
"    </a>",
"    ], conclusions were likely flawed due to multiple sources of bias. Other randomized trials, including the DOORS study, have been too small to demonstrate conclusive clinical superiority of either surgical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/15-23\">",
"     15-23",
"    </a>",
"    ]. A 2012 meta-analysis and systematic review of 86 randomized trials (excluding the CORONARY and GOPCABE studies presented below) compared the two surgical techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/24\">",
"     24",
"    </a>",
"    ]. Off-pump CABG significantly increased all-cause (long-term) mortality in all trials and in the 10 trials (nearly 5000 patients) at low risk of bias (3.7 versus 3.1 percent; relative risk 1.24; 95% CI 1.01-1.53 and 6.2 versus 4.6 percent; relative risk 1.35; 95% CI 1.07-1.70, respectively).",
"   </p>",
"   <p>",
"    Many of the limitations of early observational studies and randomized trials have been directly addressed by three large randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ROOBY trial (2009) randomly assigned 2203 relatively low-risk patients scheduled for elective or urgent CABG to either an off- or on-pump procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/15\">",
"       15",
"      </a>",
"      ]. There was no significant difference in the composite short-term primary outcome (death, reoperation, new mechanical support, cardiac arrest, coma, stroke, or renal failure before discharge or within 30 days) between the off- and on-pump groups (7.0 versus 5.6 percent; relative risk [RR] 1.26, 95% CI 0.91-1.74, respectively). However, the rate of the composite long-term (one year) primary outcome was significantly higher in the off-pump group (9.9 versus 7.4 percent, RR 2.5, 95% CI 1.01-1.76), including a significant increase in the rate of death from cardiac causes (2.7 versus 1.3 percent). The proportion of patients with fewer grafts completed than originally planned was significantly higher in the off-pump group (17.8 versus 11 percent).",
"      <br/>",
"      <br/>",
"      An angiographic follow-up study of 1370 patients enrolled in ROOBY evaluated graft patency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/25\">",
"       25",
"      </a>",
"      ]. At one year, graft patency was significantly worse in those who received off-pump CABG (82.6 versus 87.8 percent), attributable primarily to a lower overall patency in saphenous vein grafts (76.6 versus 83.8 percent). The one-year adverse cardiac event rate (death, nonfatal MI, or repeat revascularization) was significantly lower in patients with effective, compared to ineffective, revascularization (5.9 versus 16.4 percent). Effective revascularization was defined as follows: All three major coronary territories with significant disease (at randomization) were revascularized with a patent graft, which was placed in proper position relative to the native disease, and there were no new postanastomotic lesions.",
"     </li>",
"     <li>",
"      The CORONARY trial (2012) randomly assigned 4752 patients scheduled to undergo isolated CABG surgery to either an off- or on-pump procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/26\">",
"       26",
"      </a>",
"      ]. The patients represented a higher risk group than those enrolled in ROOBY and the surgeons as a group had a higher level of expertise with off-pump techniques.",
"      <br/>",
"      <br/>",
"      There was no significant difference in the rate of the primary composite outcome (death, nonfatal stroke, nonfatal myocardial infarction, or new renal failure requiring dialysis at 30 days) between off- and on-pump CABG (9.8 versus 10.3 percent, respectively; hazard ratio [HR] 0.95, 95% CI 0.79-1.14). The use of off-pump CABG significantly reduced the rates of blood-product transfusion (51 versus 63 percent), reoperation for perioperative bleeding (1.4 versus 2.4 percent), acute kidney injury (28 versus 32 percent), and respiratory complications (5.9 versus 7.5 percent). However, the rate of repeat revascularization was significantly increased in the off-pump group (0.7 versus 0.2 percent). [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      At one year, there was no significant difference in the rate of the primary composite outcome (12.1 versus 13.3 percent, respectively; HR 0.91, 95% CI 0.77-1.07) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/27\">",
"       27",
"      </a>",
"      ]. In addition, there were no significant differences in the rates of the individual components of the composite outcome or in measures of quality of life or neurocognitive function. However, there was a trend toward a higher rate of revascularization with off-pump CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The GOPCABE study (2013) randomly assigned 2539 patients 75 years of age or older to an off- or on-pump procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/28\">",
"     28",
"    </a>",
"    ]. Similar to CORONARY, the patients were higher risk than those in ROOBY.",
"    <br/>",
"    <br/>",
"    There was no significant difference in the rate of the primary composite outcome (death, stroke, myocardial infarction, repeat revascularization, or new renal failure requiring dialysis) between off- and on-pump CABG at 30 days (7.8 versus 8.2 percent, respectively; odds ratio [OR] 0.95, 95% CI 0.71-1.28) and at one year (13.1 versus 14.0 percent, respectively; odds ratio [HR] 0.93, 95% CI 0.76-1.16). At 30 days, there was no significant difference between the two approaches with regard to the individual components of the composite outcome with the exception of the rate of repeat revascularization, which occurred more frequently with off-pump CABG (OR 2.42, 95% CI 1.03-5.72). At one year, there was a trend toward a higher rate of revascularization with off-pump CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036579116\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and others believe that the following factors should be taken into account when deciding between the two approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/18,29\">",
"     18,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expertise of the surgeon in performing off-pump CABG.",
"     </li>",
"     <li>",
"      The extent of atheromatous involvement of the ascending aorta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/30-35\">",
"       30-35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Off-pump CABG'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Neurologic dysfunction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Technically challenging anatomy such as might occur in patients with small, diffusely diseased or calcified vessels or intramyocardial vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/36\">",
"       36",
"      </a>",
"      ], marked cardiomegaly, diffuse intramyocardial coronary disease, or hemodynamic instability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/37\">",
"       37",
"      </a>",
"      ]. In addition, patients with heart failure or significant mitral regurgitation are less likely to tolerate the cardiac displacement that occurs during this procedure. We prefer on-pump CABG when any of these factors are present.",
"     </li>",
"     <li>",
"      The greater need for repeat revascularization with off-pump CABG. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H23#H23\">",
"       \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Incomplete revascularization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of serious co-morbidities such as significant renal or pulmonary dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/30-35\">",
"       30-35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most surgeons consider using off-pump CABG in patients with isolated proximal left anterior descending (LAD) coronary artery disease and occasionally with LAD and proximal right coronary artery disease. It is also used as part of a hybrid revascularization approach. (See",
"    <a class=\"local\" href=\"#H1054564229\">",
"     'Hybrid revascularization procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Compared to PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between CABG (either on- or off-pump) and percutaneous coronary intervention (PCI) is dependent on a number of factors and our recommendations for decision making are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H3#H3\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'CABG versus PCI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most studies comparing CABG and PCI, CABG was performed on-pump; there are few studies comparing off-pump CABG to PCI. Three studies (two with drug-eluting and one with bare-metal stents) have directly compared these two procedures and found a lower rate of repeat revascularization with off-pump CABG; this is consistent with findings for patients with on-pump CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is a relatively common complication of cardiac surgery. Some but not all studies have found that off-pump CABG lowers the rate of postoperative atrial fibrillation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Compared to on-pump CABG'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurologic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to neurologic dysfunction, meta-analyses of randomized trials suggest that off-pump CABG significantly reduces stroke, but not neurocognitive function during follow-up. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2168?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of neurologic complications of cardiac surgery\", section on 'Minimally invasive surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H965600082\">",
"    <span class=\"h1\">",
"     MID CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term minimally invasive direct coronary artery bypass graft surgery (MID CABG), also called minimal or limited access CABG, is applied to procedures that use alternative incisions to standard median sternotomy. MID CABG is performed through a limited anterior thoracotomy and generally without cardiopulmonary bypass. In many instances, this approach typically involves only an anastomosis between the left internal mammary artery (LIMA) and left anterior descending coronary artery or some use of a composite graft off the LIMA to other coronary arteries.",
"   </p>",
"   <p>",
"    Left internal mammary artery to left anterior descending (LAD) coronary artery MID CABG with off-pump bypass is associated with angiographic patency ranges from 86 to 97 percent, a low incidence of postoperative complications (approximately 2 percent), and rapid recuperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In an observational study of 274 patients, the one year mortality was 2 percent and the reintervention rate was 2.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there is little high quality evidence to suggest that it is superior to a median sternotomy for outcomes of death, stroke, non-fatal myocardial infarction, or repeat revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that a sternal approach allows for more complete revascularization in most instances. However, MID CABG may be preferable to median sternotomy in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients for whom a long sternal incision is cosmetically problematic or for whom the shorter recovery after MID CABG is preferable.",
"     </li>",
"     <li>",
"      Patients who require reoperation, but in whom a repeat sternotomy carries risk due to an underlying bypass graft or cardiac structure adherent to the sternum, previous sternal wound infection or mediastinal radiation therapy, or calcified or diffusely atherosclerotic aorta. This approach may be limited in its access to the heart. This approach may be preferable if a bypass graft to the lateral wall of the heart needs to be revised and is thought to be feasible to perform without cardiopulmonary bypass.",
"     </li>",
"     <li>",
"      Patients in whom a hybrid approach to coronary revascularization is entertained. (See",
"      <a class=\"local\" href=\"#H1054564229\">",
"       'Hybrid revascularization procedures'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early randomized trials compared MID CABG to percutaneous coronary intervention, but the ability to apply their conclusions to current practice is limited due to factors such as the predominant use of bare metal stents (compared to drug-eluting stents), relatively short follow-up, and inconsistent use of current adjunctive medical therapies such as aggressive antiplatelet therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In two small randomized trials of patients with isolated LAD disease, MID CABG was associated with a marked reduction in the need for target vessel revascularization consequent to restenosis at six months compared to percutaneous coronary intervention with bare-metal stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. In addition, it can approach lesions that cannot be treated with percutaneous coronary intervention (PCI), such as those that have excessive length, angulation, tortuosity, or complex lesions.",
"   </p>",
"   <p>",
"    Although incisions that are alternatives to median sternotomy are thought to be less invasive, the incidence of wound complications, such as incisional hernia, dehiscence, seroma formation, and infection, with an anterior thoracotomy (MID CABG) incision is significant (9 versus 1 percent with standard median sternotomy) and may have been underreported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, a thoracotomy incision generally is a more painful incision compared with a midline sternotomy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1054564229\">",
"    <span class=\"h2\">",
"     Hybrid revascularization procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;MID CABG is used by some surgeons when an attempt is made at complete revascularization using CABG and percutaneous coronary intervention (PCI). This is often referred to as a hybrid coronary artery revascularization procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/51\">",
"     51",
"    </a>",
"    ]. The most common approach is when the left anterior descending coronary artery is revascularized with a left internal mammary artery graft using a MID CABG (usually off-pump) and one or more other vessels are revascularized with PCI. Hybrid procedures are either staged or performed at the same time in a specially designed operative suite. This approach to revascularization is in evolution and there is little published information to guide its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036580521\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for Coronary Artery Bypass Graft Surgery does not make a specific recommendation for the choice between off- and on-pump CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37031/abstract/52\">",
"     52",
"    </a>",
"    ]. It states &ldquo;&hellip;most surgeons consider either approach to be reasonable for the majority of subjects undergoing CABG&hellip;&rdquo;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036580514\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery (MID CABG) are techniques that were designed to lower the rates of some complications of on-pump CABG using a median sternotomy in patients who are thought to be at higher risk because of co-morbidities. In choosing one approach compared to another, multiple patient and practitioner characteristics need to be taken into account. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Off-pump CABG'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H965600082\">",
"       'MID CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 30-day and one-year results of off- and on-pump CABG are comparable for composite outcomes that include death, stroke, and nonfatal myocardial infarction. However, at one year, the rate of revascularization appears to be increased with off-pump CABG. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Compared to on-pump CABG'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For most patients who are referred for coronary artery bypass graft surgery, we suggest an on-pump as opposed to off-pump procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with significant atheromatous disease of the aorta or those with significant medical co-morbidities may reasonably choose off-pump CABG, after taking into account the expertise of the surgeon and outcomes at a particular institution. &nbsp;",
"     </li>",
"     <li>",
"      The term minimally invasive direct coronary artery bypass graft surgery (MID CABG) is applied to procedures that use alternatives to standard median sternotomy.",
"      <br/>",
"      <br/>",
"      For most patients undergoing CABG, we suggest a sternal approach as opposed to MID CABG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A MID CABG procedure may be a reasonable choice for cosmetic reasons or for patients in whom there is a significant risk of reoperation on the sternum, when performed by surgeons who are experts in this technique. (See",
"      <a class=\"local\" href=\"#H965600082\">",
"       'MID CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hybrid revascularization techniques are in evolution and combine the survival benefit of the LIMA to LAD graft and the less invasive nature of PCI of other disease vessels. (See",
"      <a class=\"local\" href=\"#H1054564229\">",
"       'Hybrid revascularization procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/1\">",
"      Cleveland JC Jr, Shroyer AL, Chen AY, et al. Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg 2001; 72:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/2\">",
"      Mack MJ, Duhaylongsod FG. Through the open door! Where has the ride taken us? J Thorac Cardiovasc Surg 2002; 124:655.",
"     </a>",
"    </li>",
"    <li>",
"     www.sts.org/sections/stsnationaldatabase/ (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/4\">",
"      Aldea GS, Mokadam NA, Melford R Jr, et al. Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thorac Surg 2009; 87:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/5\">",
"      Cartier R, Brann S, Dagenais F, et al. Systematic off-pump coronary artery revascularization in multivessel disease: experience of three hundred cases. J Thorac Cardiovasc Surg 2000; 119:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/6\">",
"      Kshettry VR, Flavin TF, Emery RW, et al. Does multivessel, off-pump coronary artery bypass reduce postoperative morbidity? Ann Thorac Surg 2000; 69:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/7\">",
"      Dewey TM, Magee MJ, Edgerton JR, et al. Off-pump bypass grafting is safe in patients with left main coronary disease. Ann Thorac Surg 2001; 72:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/8\">",
"      Arom KV, Flavin TF, Emery RW, et al. Safety and efficacy of off-pump coronary artery bypass grafting. Ann Thorac Surg 2000; 69:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/9\">",
"      Aldea GS, Goss JR, Boyle EM Jr, et al. Use of off-pump and on-pump CABG strategies in current clinical practice: the Clinical Outcomes Assessment Program of the state of Washington. J Card Surg 2003; 18:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/10\">",
"      Magee MJ, Jablonski KA, Stamou SC, et al. Elimination of cardiopulmonary bypass improves early survival for multivessel coronary artery bypass patients. Ann Thorac Surg 2002; 73:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/11\">",
"      Mack MJ, Pfister A, Bachand D, et al. Comparison of coronary bypass surgery with and without cardiopulmonary bypass in patients with multivessel disease. J Thorac Cardiovasc Surg 2004; 127:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/12\">",
"      Al-Ruzzeh S, Ambler G, Asimakopoulos G, et al. Off-Pump Coronary Artery Bypass (OPCAB) surgery reduces risk-stratified morbidity and mortality: a United Kingdom Multi-Center Comparative Analysis of Early Clinical Outcome. Circulation 2003; 108 Suppl 1:II1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/13\">",
"      Hannan EL, Wu C, Smith CR, et al. Off-pump versus on-pump coronary artery bypass graft surgery: differences in short-term outcomes and in long-term mortality and need for subsequent revascularization. Circulation 2007; 116:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/14\">",
"      Hu S, Zheng Z, Yuan X, et al. Increasing long-term major vascular events and resource consumption in patients receiving off-pump coronary artery bypass: a single-center prospective observational study. Circulation 2010; 121:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/15\">",
"      Shroyer AL, Grover FL, Hattler B, et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 2009; 361:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/16\">",
"      van Dijk D, Nierich AP, Jansen EW, et al. Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation 2001; 104:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/17\">",
"      Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002; 359:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/18\">",
"      Khan NE, De Souza A, Mister R, et al. A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med 2004; 350:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/19\">",
"      Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA 2004; 291:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/20\">",
"      Nathoe HM, van Dijk D, Jansen EW, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003; 348:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/21\">",
"      L&eacute;gar&eacute; JF, Buth KJ, King S, et al. Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. Circulation 2004; 109:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/22\">",
"      Widimsky P, Straka Z, Stros P, et al. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 2004; 110:3418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/23\">",
"      Houlind K, Kjeldsen BJ, Madsen SN, et al. On-pump versus off-pump coronary artery bypass surgery in elderly patients: results from the Danish on-pump versus off-pump randomization study. Circulation 2012; 125:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/24\">",
"      M&oslash;ller CH, Penninga L, Wetterslev J, et al. Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease. Cochrane Database Syst Rev 2012; 3:CD007224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/25\">",
"      Hattler B, Messenger JC, Shroyer AL, et al. Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012; 125:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/26\">",
"      Lamy A, Devereaux PJ, Prabhakaran D, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 2012; 366:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/27\">",
"      Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med 2013; 368:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/28\">",
"      Diegeler A, B&ouml;rgermann J, Kappert U, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 2013; 368:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/29\">",
"      MacGillivray TE, Vlahakes GJ. Patency and the pump--the risks and benefits of off-pump CABG. N Engl J Med 2004; 350:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/30\">",
"      Sharony R, Bizekis CS, Kanchuger M, et al. Off-pump coronary artery bypass grafting reduces mortality and stroke in patients with atheromatous aortas: a case control study. Circulation 2003; 108 Suppl 1:II15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/31\">",
"      Karthik S, Musleh G, Grayson AD, et al. Coronary surgery in patients with peripheral vascular disease: effect of avoiding cardiopulmonary bypass. Ann Thorac Surg 2004; 77:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/32\">",
"      Hirose H, Amano A, Takahashi A. Off-pump coronary artery bypass grafting for elderly patients. Ann Thorac Surg 2001; 72:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/33\">",
"      Boyd WD, Desai ND, Del Rizzo DF, et al. Off-pump surgery decreases postoperative complications and resource utilization in the elderly. Ann Thorac Surg 1999; 68:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/34\">",
"      Ascione R, Nason G, Al-Ruzzeh S, et al. Coronary revascularization with or without cardiopulmonary bypass in patients with preoperative nondialysis-dependent renal insufficiency. Ann Thorac Surg 2001; 72:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/35\">",
"      Bucerius J, Gummert JF, Walther T, et al. On-pump versus off-pump coronary artery bypass grafting: impact on postoperative renal failure requiring renal replacement therapy. Ann Thorac Surg 2004; 77:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/36\">",
"      Brown JM, Poston RS, Gammie JS, et al. Off-pump versus on-pump coronary artery bypass grafting in consecutive patients: decision-making algorithm and outcomes. Ann Thorac Surg 2006; 81:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/37\">",
"      Abu-Omar Y, Taggart DP. Off-pump coronary artery bypass grafting. Lancet 2002; 360:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/38\">",
"      Herz I, Moshkovitz Y, Hendler A, et al. Revascularization of left anterior descending artery with drug-eluting stents: comparison with off-pump surgery. Ann Thorac Surg 2005; 79:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/39\">",
"      Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003; 108:2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/40\">",
"      Yi G, Youn YN, Hong S, et al. Comparison of long-term outcome of off-pump coronary artery bypass grafting versus drug-eluting stents in triple-vessel coronary artery disease. Am J Cardiol 2012; 109:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/41\">",
"      Galloway AC, Shemin RJ, Glower DD, et al. First report of the Port Access International Registry. Ann Thorac Surg 1999; 67:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/42\">",
"      Mehran R, Dangas G, Stamou SC, et al. One-year clinical outcome after minimally invasive direct coronary artery bypass. Circulation 2000; 102:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/43\">",
"      Calafiore AM, Di Giammarco G, Teodori G, et al. Midterm results after minimally invasive coronary surgery (LAST operation). J Thorac Cardiovasc Surg 1998; 115:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/44\">",
"      Boonstra PW, Grandjean JG, Mariani MA. Reoperative coronary bypass grafting without cardiopulmonary bypass through a small thoracotomy. Ann Thorac Surg 1997; 63:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/45\">",
"      Azoury FM, Gillinov AM, Lytle BW, et al. Off-pump reoperative coronary artery bypass grafting by thoracotomy: patient selection and operative technique. Ann Thorac Surg 2001; 71:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/46\">",
"      Stamou SC, Pfister AJ, Dangas G, et al. Beating heart versus conventional single-vessel reoperative coronary artery bypass. Ann Thorac Surg 2000; 69:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/47\">",
"      Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med 2002; 347:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/48\">",
"      Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. Circulation 2005; 112:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/49\">",
"      Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol 2002; 40:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/50\">",
"      Ng PC, Chua AN, Swanson MS, et al. Anterior thoracotomy wound complications in minimally invasive direct coronary artery bypass. Ann Thorac Surg 2000; 69:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/51\">",
"      Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures. JACC Cardiovasc Interv 2008; 1:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37031/abstract/52\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1558 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37031=[""].join("\n");
var outline_f36_10_37031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1036580514\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OFF-PUMP CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Compared to on-pump CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1036579116\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Compared to PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H965600082\">",
"      MID CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1054564229\">",
"      Hybrid revascularization procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1036580521\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1036580514\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=related_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44296?source=related_link\">",
"      Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2168?source=related_link\">",
"      Prevention of neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37032="Acute respiratory failure during pregnancy and the peripartum period";
var content_f36_10_37032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute respiratory failure during pregnancy and the peripartum period",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Peter F Clardy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Christine C Reardon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37032/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 1 percent of women require admission to an intensive care unit (ICU) during pregnancy or the peripartum period (ie, the last month of gestation or the first few weeks after delivery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Among those who are admitted to an ICU, the most common indications are postpartum hemorrhage and hypertensive disorders. Acute respiratory failure is a rare complication of pregnancy.",
"   </p>",
"   <p>",
"    The clinical presentation, differential diagnosis, most common causes, and management of acute respiratory failure during pregnancy and the peripartum period are reviewed here. Other critical illnesses associated with pregnancy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34681?source=see_link\">",
"     \"Critical illness during pregnancy and the peripartum period\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute respiratory failure during pregnancy or the peripartum period generally present with respiratory distress. They are usually dyspneic and unable to speak in complete sentences. Confusion, somnolence, agitation, diaphoresis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyanosis are common.",
"   </p>",
"   <p>",
"    Most patients are breathing rapidly (tachypnea) and shallowly (small tidal volumes), while using their accessory muscles of respiration. Ausculatory findings vary according to the cause of the acute respiratory failure, but may included crackles, rhonchi,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wheezes. Consolidation may be evident, as indicated by bronchophony, egophony, or whisper pectoriloquy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management is the same regardless of the cause of the acute respiratory failure. Supplemental oxygen should be administered. The preferred method of administering the oxygen depends upon the severity of the hypoxemia. For patients with mild hypoxemia, administration via nasal cannula may be sufficient. More severe hypoxemia generally requires administration via a facemask or a nonrebreather mask. Oxygenation should be monitored continuously by pulse oximetry. A reasonable goal is to maintain the oxyhemoglobin saturation &ge;95 percent to optimize the fetal oxygen content. Adequate fetal oxygenation requires a maternal arterial oxygen tension (PaO2) &gt;70 mmHg, which corresponds to an oxyhemoglobin saturation of 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanical ventilation may be required. The decision about whether to intubate a patient should be considered in the context of pregnancy. Pregnant women have hypocapnia due to hyperventilation at baseline. Thus, the arterial carbon dioxide tension (PaCO2) tends to be lower in pregnant woman than in nonpregnant individuals with a similar degree of respiratory failure. The decision to intubate is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intubation may be difficult during pregnancy and the peripartum period due to upper airway edema and diminished airway caliber, especially late in pregnancy. The process of intubation and the initiation of mechanical ventilation are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An arterial blood analysis (ABG) and chest radiograph should be obtained after initial stabilization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ABG identifies and quantitates the severity of any ventilatory abnormalities. It also guides ventilator adjustments in mechanically ventilated patients. Ventilatory goals are different in pregnant patients. The target PaCO2 is 30 to 32 mmHg, since this is the normal level during pregnancy. Marked respiratory alkalosis should be avoided because it may decrease uterine blood flow. Maternal permissive hypercapnia may also be deleterious to the fetus because of resultant fetal respiratory acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Arterial catheterization may be helpful if frequent arterial blood gases are likely to be needed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=see_link\">",
"       \"Arterial catheterization techniques for invasive monitoring\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The chest radiograph is used to narrow the differential diagnosis of the respiratory failure and, among intubated patients, to confirm that the endotracheal tube is in the correct position. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"       \"Diagnostic imaging procedures during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory failure during pregnancy or the peripartum period may be due to a conventional respiratory insult or a pregnancy-specific disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The usual differential diagnosis includes the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary edema",
"     </li>",
"     <li>",
"      Community-acquired pneumonia",
"     </li>",
"     <li>",
"      Aspiration",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Asthma exacerbation",
"     </li>",
"     <li>",
"      Amniotic fluid embolism",
"     </li>",
"     <li>",
"      Venous air embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features, diagnosis, and treatment of the major causes of acute respiratory failure during pregnancy and the peripartum period are reviewed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pulmonary edema occurs in approximately 0.08 percent of pregnancies, according to a retrospective cohort study of nearly 63,000 consecutive deliveries in a single medical center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/12\">",
"     12",
"    </a>",
"    ]. Approximately 50 percent of the cases of pulmonary edema were attributed to tocolytic therapy or cardiac disease. The remaining cases were ascribed to either preeclampsia or iatrogenic volume overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Tocolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tocolytic beta-2 agonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    ) to inhibit preterm labor is associated with pulmonary edema. It is more common among pregnancies complicated by multiple gestations or maternal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/13\">",
"     13",
"    </a>",
"    ], as well as among women who receive multiple tocolytic agents simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link&amp;anchor=H7#H7\">",
"     \"Inhibition of acute preterm labor\", section on 'Beta-adrenergic receptor agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid overload is probably the major pathogenic factor in tocolytic-related pulmonary edema, although cardiac dysfunction and increased capillary permeability may also contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/15\">",
"     15",
"    </a>",
"    ]. Pregnant women are predisposed to fluid overload because they tend to receive a large amount of intravenous fluid in response to hypotension caused by peripheral vasodilation.",
"   </p>",
"   <p>",
"    The clinical presentation of tocolytic-related pulmonary edema is nearly identical to that of other types of pulmonary edema: dyspnea, tachypnea, tachycardia, hypoxemia, and diffuse crackles. Chest pain and a cough may also be present. The chest radiograph reveals bilateral air space disease. A review of 58 case reports and case series found that the following findings were most frequent in tocolytic-related pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basilar crackles (100 percent)",
"     </li>",
"     <li>",
"      Shortness of breath (76 percent)",
"     </li>",
"     <li>",
"      Chest pain (24 percent)",
"     </li>",
"     <li>",
"      Cough (17 percent)",
"     </li>",
"     <li>",
"      Bilateral air space disease on chest radiograph (81 percent)",
"     </li>",
"     <li>",
"      Fever (14 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of tocolytic-related pulmonary edema is made when these findings develop in a woman who is receiving tocolytic therapy with a beta-2 agonist and there is no alternative explanation for the acute respiratory failure. There are no definitive diagnostic tests.",
"   </p>",
"   <p>",
"    Most patients with tocolytic-related pulmonary edema respond well to discontinuation of the tocolytic beta-2 agonist, supplemental oxygen, fluid restriction, and diuresis. Mechanical ventilation may be necessary. Most cases resolve within 12 to 24 hours. Persistence of symptoms beyond this time period should prompt reconsideration of the diagnosis. Mortality is uncommon.",
"   </p>",
"   <p>",
"    Alternative tocolytics that can be used after discontinuation of the beta-2 agonist are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary edema has occurred with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    tocolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/16\">",
"     16",
"    </a>",
"    ]. It appears to be associated with high magnesium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous fluid infusion rate, as well as a large positive fluid balance. Thus, it is uncertain whether the etiology is the magnesium itself or volume overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cardiogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance data from the United States National Hospital Discharge Survey (2004 to 2006) found the rate of cardiogenic pulmonary edema was 23 and 11 per 1,000 deliveries during delivery and the postpartum period, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/17\">",
"     17",
"    </a>",
"    ]. Cardiogenic pulmonary edema can be a consequence of preexisting or new cardiac disease. This was illustrated by a case series of 51 women who developed acute pulmonary edema during pregnancy or postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/12\">",
"     12",
"    </a>",
"    ]. The pulmonary edema was attributed to heart disease in 13 patients (26 percent). Among these patients, six developed pulmonary edema prior to being diagnosed with valvular or myocardial dysfunction, while seven had known heart disease (aortic regurgitation, aortic stenosis, idiopathic subaortic stenosis, dilated cardiomyopathy).",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and management of heart disease during pregnancy and the peripartum period are reviewed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Preeclampsia or eclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema is an uncommon complication of severe preeclampsia and eclampsia. In a case series that included 1276 patients with severe preeclampsia or eclampsia, only 3 percent developed pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/19\">",
"     19",
"    </a>",
"    ]. Among those with pulmonary edema, 70 percent developed the pulmonary edema postpartum (mean of 71 hours after delivery) and 11 percent died. Patients who were older or multigravid were at the greatest risk for pulmonary edema. The pulmonary edema was often accompanied by dysfunction of another organ system, such as disseminated intravascular coagulation, acute renal failure, hypertensive crisis, cardiopulmonary arrest, or cerebral edema.",
"   </p>",
"   <p>",
"    Pulmonary edema associated with preeclampsia and eclampsia is multifactorial. Fluid overload, decreased plasma oncotic pressure, increased capillary permeability, and increased pulmonary capillary hydrostatic pressures all appear to play a role. The increased hydrostatic pressure is probably due to arterial vasospasm causing elevated cardiac afterload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of severe preeclampsia- or eclampsia-related pulmonary edema is nearly identical to that of other types of pulmonary edema: dyspnea, tachypnea, tachycardia, hypoxemia, and diffuse crackles. Chest pain and a cough may also be present. The chest radiograph reveals bilateral air space disease.",
"   </p>",
"   <p>",
"    The diagnosis is made when these findings develop in a woman who has severe preeclampsia or eclampsia and there is no alternative explanation for the acute respiratory failure. There is no definitive diagnostic test. Recognition of both preeclampsia and eclampsia is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=see_link\">",
"     \"Eclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of severe preeclampsia- or eclampsia-related pulmonary edema includes treatment of the severe preeclampsia or eclampsia, supplemental oxygen, and fluid restriction. Diuresis is indicated if there is fluid overload. However, clinicians must be careful to avoid compromising cardiac output and placental perfusion because many such patients already have reduced cardiac preload due to intravascular depletion. Mechanical ventilation may be necessary. The treatment of preeclampsia and eclampsia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=see_link\">",
"     \"Eclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia is a relatively common cause of acute respiratory failure in pregnant patients. The most common pathogens are the same as those found in nonpregnant patients: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella, Chlamydia pneumoniae, and influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. However, the reduction in cell-mediated immunity that is associated with pregnancy (especially during the third trimester) also places women at increased risk for severe pneumonia and disseminated disease from atypical pathogens, such as herpesvirus, varicella, and coccidioidomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of community-acquired pneumonia are the same for pregnant and nonpregnant patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features include fever, a cough productive of mucopurulent sputum, dyspnea, tachycardia, and tachypnea. Many patients also have hypoxemia, chills, rigors, pleuritic chest pain, gastrointestinal symptoms (nausea, vomiting, diarrhea), and mental status changes. Auscultation may reveal focal crackles, rhonchi,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of consolidation (eg, bronchophony, egophony, whisper pectoriloquy). Chest radiographs generally demonstrate focal air space disease. Gram stain of the sputum may reveal abundant polymorphonuclear leukocytes, while a culture of the sputum may grow the pathogen. The major blood test abnormality is leukocytosis with a leftward shift.",
"     </li>",
"     <li>",
"      Diagnosis requires a chest radiograph that reveals focal or multifocal airspace disease, as well as supportive clinical and microbiological features.",
"     </li>",
"     <li>",
"      Antibiotic therapy is necessary to treat community-acquired pneumonia. It is generally initiated empirically and then tailored to the microbiological results. Adjunctive therapies may include supplemental oxygen and suctioning. Mechanical ventilation may be necessary.",
"     </li>",
"     <li>",
"      CDC guidelines recommend that pregnant women (up until 2 weeks post-partum) receive treatment for influenza A if they have had a documented exposure to the influenza virus, or if they present with symptoms that are consistent with influenza infection and they are within the first 48 hours of illness. During the H1N1 pandemic,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      (75 mg twice a day for 5 days) was the recommended therapy, ideally begun within the first 48 hours. Therapy should not be delayed while awaiting confirmation of the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/23,27\">",
"       23,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of community-acquired pneumonia are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Asthma exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four to eight percent of pregnant women in the United States have asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/28\">",
"     28",
"    </a>",
"    ]. Among these women, 20 to 36 percent have an exacerbation during their pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asthma exacerbations are not uniformly distributed over the course of pregnancy. Two observational studies found that exacerbations were most frequently prior to week 24 of pregnancy, particularly during the preceding seven to ten weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19159?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiology and clinical course of asthma in pregnancy\", section on 'Effects of pregnancy on asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women who have frequent or severe asthma exacerbations are more likely to have fetal complications (",
"    <a class=\"graphic graphic_table graphicRef59809 \" href=\"mobipreview.htm?19/27/19899\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These include growth restriction, preterm delivery, low birth weight, and perinatal mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19159?source=see_link&amp;anchor=H10#H10\">",
"     \"Physiology and clinical course of asthma in pregnancy\", section on 'Effects of asthma on pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features of an asthma exacerbation include dyspnea, tachypnea, tachycardia, and wheezing. Many patients will have noticed a decrease in their peak flow rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in the use of their as-needed short-acting bronchodilator during the days prior to presentation. Pulsus paradoxus (ie, a fall in systolic blood pressure by at least 12 mmHg during inspiration), use of the accessory muscles of respiration, diaphoresis, and the inability to lie supine due to breathlessness are indicative of severe airflow obstruction. Most patients are hypocapnic due to an increased respiratory drive; thus, eucapnia or hypercapnia suggest impending respiratory failure. Marked hypoxemia is unusual and chest radiographs are generally unrevealing.",
"   </p>",
"   <p>",
"    Diagnosis of an asthma exacerbation is based upon the identification of compatible clinical features in a patient who has a history of asthma and no alternative explanation for their symptoms and signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy to reverse airway bronchospasm and inflammation should be instituted immediately following stabilization of the patient (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Initial management'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled short-acting beta agonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ) and short-acting anticholinergic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      ) may be given during pregnancy. For patients who are refractory to inhaled short-acting beta agonists, subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      sulfate or epinephrine may be considered as a rescue therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic steroids should be given if the symptoms and signs do not improve quickly following the initiation of inhaled bronchodilator therapy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      are the favored formulations because their active metabolites do not cross the placenta well. Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      may also be used. Prednisone, methylprednisolone, or prednisolone may be dosed 120 to 180",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in 3 or 4 divided doses for 48 hours. Then the dosing is 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      until the peak expiratory flow reaches 70 percent of predicted or of the patient's best [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    is considered an alternative, but not preferred, agent for severe asthma exacerbations in pregnant women. Intravenous theophylline has not been shown to improve clinical outcomes and careful monitoring is necessary to reduce the risk of fetal theophylline toxicity. The theophylline level should be kept between 5 and 12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    and inhalational anesthetics have bronchodilating effects and have been used to treat nonpregnant patients with refractory or life-threatening asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, these agents should be reserved for life-threatening asthma because neither has been studied as a treatment for asthma in pregnancy. There have been case reports about pregnant women with refractory asthma exacerbations who improved after emergent delivery of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/37\">",
"     37",
"    </a>",
"    ]. This must be an individualized decision based upon the gestational age of the fetus, severity of the mother's condition, and opinions of the medical and obstetric caregivers.",
"   </p>",
"   <p>",
"    The management of stable asthma during pregnancy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29226?source=see_link\">",
"     \"Management of asthma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of gastric contents is most common during labor or soon after delivery. This is probably because the effects of sedation, analgesia, increased intraabdominal pressure, and recumbency are added to preexisting factors that predispose pregnant women to aspirate. These factors include increased intraabdominal pressure, relaxation of the lower esophageal sphincter, and delayed gastric emptying. Aspiration may also be a complication of general anesthesia and intubation during an emergent cesarean delivery.",
"   </p>",
"   <p>",
"    Aspiration may induce chemical pneumonitis, airway obstruction, or acute bronchospasm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemical pneumonitis can be difficult to distinguish from pneumonia because the clinical manifestations are similar. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pneumonia'",
"      </a>",
"      above.) Features that favor aspiration over pneumonia include an abrupt onset of symptoms and signs, a cough productive of material that resembles gastric contents, diffuse crackles, and chest radiograph infiltrates that are multifocal and predominate in the dependent portions of the lung. In addition, fevers tend to be low-grade. The diagnosis of pneumonitis is made when compatible symptoms and signs occur within the correct clinical context and there is no better explanation for the clinical findings. Treatment is supportive. This may include supplemental oxygen, suctioning, and, if necessary, ventilatory assistance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H6#H6\">",
"       \"Aspiration pneumonia in adults\", section on 'Chemical pneumonitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Airway obstruction typically presents with dyspnea and impaired ventilation and oxygenation. Physical findings vary depending upon the site of obstruction. Laryngeal, subglottic, or tracheal obstruction may cause stridor, while obstruction distal to the carina may induce asymmetric wheezing. These clinical findings are generally unresponsive to bronchodilators. The diagnosis is made by direct bronchoscopic visualization of the obstruction. Treatment is bronchoscopic removal of the obstructing foreign body. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute bronchospasm due to aspiration is difficult to distinguish from an asthma exacerbation because the symptoms and signs may be identical. Features that favor acute bronchospasm due to aspiration over an asthma exacerbation include an acute onset (ie, no prodrome) and coexisting evidence of aspiration (eg, witnessed aspiration, multifocal infiltrates in the dependent areas of the lung). The diagnosis is made when compatible symptoms and signs occur within the correct clinical context and there is no better explanation for the clinical findings. The treatment is the same as that for an asthma exacerbation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Asthma exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients who have aspirated progress to aspiration pneumonia or acute respiratory distress syndrome (ARDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/11\">",
"     11",
"    </a>",
"    ]. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acute pulmonary embolism (PE) is increased five- to six-times during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/38\">",
"     38",
"    </a>",
"    ]. This appears to be a consequence of several factors, including changes in the clotting factors and an increased likelihood of venous stasis. Predisposing factors include obesity, an older age, a personal or family history of thromboembolic disease, inherited thrombophilia, anti-phospholipid syndrome, trauma, cesarean delivery, and immobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of acute PE in women who are pregnant or peripartum are similar to those in nonpregnant individuals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features include dyspnea, pleuritic chest pain, cough, leg pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling, tachypnea, tachycardia, and hypoxemia. Circulatory collapse can occur, but it is uncommon.",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by imaging. Computed tomography pulmonary angiography (CT-PA) and low-dose ventilation perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      scanning are appropriate imaging modalities, but conventional pulmonary angiography should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"       \"Diagnostic imaging procedures during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticoagulation is the mainstay therapy. Adjunctive therapies include supplemental oxygen and, if necessary, ventilatory assistance. Thrombolysis has been performed in the setting of circulatory collapse, but the risk of bleeding and its sequelae are high. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of acute PE in pregnant and peripartum women are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Amniotic fluid embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid embolism is a rare but catastrophic illness of pregnancy and the peripartum period. It is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous air embolism is an uncommon complication of pregnancy. It usually occurs during the peripartum period as a result of caesarean delivery, uterine manipulation, or central venous catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37032/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Venous air embolism is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ONGOING MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient has been stabilized and the etiology of the acute respiratory failure has been determined, therapy is directed at the specific cause. Treatment of the most common causes of acute respiratory failure was described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiologies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care refers to interventions that sustain life and prevent complications, but do not treat the underlying cause of the critical illness. It includes oxygenation and ventilation (ie, supplemental oxygen or mechanical ventilation), sedation, pain control, hemodynamic support (ie, vasopressors), monitoring, volume management (ie, intravenous fluids or diuretics), nutritional support, stress ulcer prophylaxis, and venous thromboembolism prophylaxis. The supportive care of women who are pregnant or peripartum is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34681?source=see_link&amp;anchor=H11#H11\">",
"     \"Critical illness during pregnancy and the peripartum period\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Few women require admission to an intensive care unit (ICU) during pregnancy or the peripartum period (ie, the last month of gestation or the first few weeks after delivery). Among those who are admitted to the ICU, the most common indications are postpartum hemorrhage and hypertensive disorders. Acute respiratory failure is a rare complication of pregnancy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute respiratory failure generally present with respiratory distress. Initial management is the same regardless of the cause. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute respiratory failure during pregnancy or the peripartum period may be due to a conventional respiratory insult or a pregnancy-specific disorder. The usual differential diagnosis includes pulmonary edema, community-acquired pneumonia, aspiration, pulmonary embolism, asthma exacerbation, amniotic fluid embolism, and venous air embolism. Pulmonary edema is most often due to the treatment of preterm labor, heart failure, severe preeclampsia, or eclampsia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the patient has been stabilized and the cause of the acute respiratory failure has been determined, ongoing management includes supportive care and treatment of the etiology. Supportive care includes oxygenation and ventilation (ie, supplemental oxygen or mechanical ventilation), sedation, pain control, hemodynamic support (ie, vasopressors), monitoring, volume management (ie, intravenous fluids or diuretics), nutritional support, stress ulcer prophylaxis, and venous thromboembolism prophylaxis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ongoing management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/1\">",
"      Selo-Ojeme DO, Omosaiye M, Battacharjee P, Kadir RA. Risk factors for obstetric admissions to the intensive care unit in a tertiary hospital: a case-control study. Arch Gynecol Obstet 2005; 272:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/2\">",
"      Mirghani HM, Hamed M, Ezimokhai M, Weerasinghe DS. Pregnancy-related admissions to the intensive care unit. Int J Obstet Anesth 2004; 13:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/3\">",
"      Demirkiran O, Dikmen Y, Utku T, Urkmez S. Critically ill obstetric patients in the intensive care unit. Int J Obstet Anesth 2003; 12:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/4\">",
"      Leung NY, Lau AC, Chan KK, Yan WW. Clinical characteristics and outcomes of obstetric patients admitted to the Intensive Care Unit: a 10-year retrospective review. Hong Kong Med J 2010; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/5\">",
"      Vasquez DN, Estenssoro E, Canales HS, et al. Clinical characteristics and outcomes of obstetric patients requiring ICU admission. Chest 2007; 131:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/6\">",
"      Pollock W, Rose L, Dennis CL. Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Med 2010; 36:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/7\">",
"      Cole DE, Taylor TL, McCullough DM, et al. Acute respiratory distress syndrome in pregnancy. Crit Care Med 2005; 33:S269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/8\">",
"      Grum, CM, Morganroth, ML. Initiating mechanical ventilation. J Intensive Care Med 1988; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     Meschia G. Placental respiratory gas exchange and fetal oxygenation. In: Maternal-Fetal Medicine, Creasy RK, Resnik R (Eds), WB Saunders, Philadelphia 1999. p.260.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/10\">",
"      Kilpatrick SJ, Matthay MA. Obstetric patients requiring critical care. A five-year review. Chest 1992; 101:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/11\">",
"      Mighty HE. Acute respiratory failure in pregnancy. Clin Obstet Gynecol 2010; 53:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/12\">",
"      Sciscione AC, Ivester T, Largoza M, et al. Acute pulmonary edema in pregnancy. Obstet Gynecol 2003; 101:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/13\">",
"      Hatjis CG, Swain M. Systemic tocolysis for premature labor is associated with an increased incidence of pulmonary edema in the presence of maternal infection. Am J Obstet Gynecol 1988; 159:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/14\">",
"      Lamont RF. The pathophysiology of pulmonary oedema with the use of beta-agonists. BJOG 2000; 107:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/15\">",
"      Pisani RJ, Rosenow EC 3rd. Pulmonary edema associated with tocolytic therapy. Ann Intern Med 1989; 110:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/16\">",
"      Samol JM, Lambers DS. Magnesium sulfate tocolysis and pulmonary edema: the drug or the vehicle? Am J Obstet Gynecol 2005; 192:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/17\">",
"      Kuklina EV, Callaghan WM. Cardiomyopathy and other myocardial disorders among hospitalizations for pregnancy in the United States: 2004-2006. Obstet Gynecol 2010; 115:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/18\">",
"      Tidswell M. Peripartum cardiomyopathy. Crit Care Clin 2004; 20:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/19\">",
"      Sibai BM, Mabie BC, Harvey CJ, Gonzalez AR. Pulmonary edema in severe preeclampsia-eclampsia: analysis of thirty-seven consecutive cases. Am J Obstet Gynecol 1987; 156:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/20\">",
"      Benedetti TJ, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 1985; 152:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/21\">",
"      Bauer ST, Cleary KL. Cardiopulmonary complications of pre-eclampsia. Semin Perinatol 2009; 33:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/22\">",
"      Sheffield JS, Cunningham FG. Community-acquired pneumonia in pregnancy. Obstet Gynecol 2009; 114:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/23\">",
"      Graves CR. Pneumonia in pregnancy. Clin Obstet Gynecol 2010; 53:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/24\">",
"      Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit Care Med 2010; 38:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/25\">",
"      Wack EE, Ampel NM, Galgiani JN, Bronnimann DA. Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. Chest 1988; 94:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/26\">",
"      Harger JH, Ernest JM, Thurnau GR, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002; 185:422.",
"     </a>",
"    </li>",
"    <li>",
"     CDC: Updated Interim  Recommendations for Obstetric Health Providers Related to Use of  Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season. www.cdc.gov (Accessed on January 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/28\">",
"      Kwon HL, Belanger K, Bracken MB. Effect of pregnancy and stage of pregnancy on asthma severity: a systematic review. Am J Obstet Gynecol 2004; 190:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/29\">",
"      Schatz M, Dombrowski MP, Wise R, et al. Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 2003; 112:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/30\">",
"      Murphy VE, Gibson P, Talbot PI, Clifton VL. Severe asthma exacerbations during pregnancy. Obstet Gynecol 2005; 106:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/31\">",
"      Stenius-Aarniala BS, Hedman J, Teramo KA. Acute asthma during pregnancy. Thorax 1996; 51:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/32\">",
"      Enriquez R, Griffin MR, Carroll KN, et al. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. J Allergy Clin Immunol 2007; 120:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/33\">",
"      K&auml;ll&eacute;n B, Rydhstroem H, Aberg A. Asthma during pregnancy--a population based study. Eur J Epidemiol 2000; 16:167.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program. Managing asthma during pregnancy: Recommendations for pharmacological treatment, Update 2004. Bethesda MD, National Institutes of Health, National Heart, Lung and Blood Institute, 2004, Publication 04-5246.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/35\">",
"      Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002; 122:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/36\">",
"      Johnston RG, Noseworthy TW, Friesen EG, et al. Isoflurane therapy for status asthmaticus in children and adults. Chest 1990; 97:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/37\">",
"      Hanania NA, Belfort MA. Acute asthma in pregnancy. Crit Care Med 2005; 33:S319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/38\">",
"      Brown HL, Hiett AK. Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, complications, and management. Clin Obstet Gynecol 2010; 53:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/39\">",
"      Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/40\">",
"      Bandi VD, Munnur U, Matthay MA. Acute lung injury and acute respiratory distress syndrome in pregnancy. Crit Care Clin 2004; 20:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37032/abstract/41\">",
"      Kostash MA, Mensink F. Lethal air embolism during cesarean delivery for placenta previa. Anesthesiology 2002; 96:753.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1599 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37032=[""].join("\n");
var outline_f36_10_37032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Tocolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cardiogenic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Preeclampsia or eclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Asthma exacerbation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Amniotic fluid embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ONGOING MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/27/19899\" title=\"table 1\">",
"      Eur study preg result asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34681?source=related_link\">",
"      Critical illness during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19159?source=related_link\">",
"      Physiology and clinical course of asthma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37033="Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging";
var content_f36_10_37033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Douglas Morgan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37033/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early gastric cancer (EGC) is defined as invasive gastric cancer that invades no more deeply than the submucosa, irrespective of lymph node metastasis (T1, any N). While EGC is of particular importance for patient care in Eastern Asia, its significance extends to other disciplines and patient populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Globally, gastric adenocarcinoma, with nearly one million incident cases annually, is the second leading cause of global cancer mortality and the leading cause of infection-associated cancer death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. EGC accounts for 15 to 57 percent of incident gastric cancer, depending upon geographic location. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      EGC has driven the development of novel imaging technologies for early neoplasia detection, such as narrow-band imaging and autofluorescence imaging. These technologies are now being used throughout the gastrointestinal tract.",
"     </li>",
"     <li>",
"      The need for better approaches to the treatment of EGC has led to the development of advanced endoscopic resection techniques, such as endoscopic mucosal resection and endoscopic submucosal dissection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935984#H757935984\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic mucosal resection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935998#H757935998\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic submucosal dissection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New surveillance guidelines are in evolution for gastric intestinal metaplasia, which may increase the frequency of detection of EGC in the western populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6983?source=see_link\">",
"       \"Screening and prevention of gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intestinal-type gastric adenocarcinoma, the major subtype, progresses through a series of histopathologic stages, from normal mucosa, to chronic gastritis, atrophic gastritis, intestinal metaplasia, and finally dysplasia and adenocarcinoma. The underlying cause of early pan-gastric mucosal inflammation and of chronic gastritis is",
"    <em>",
"     Helicobacter Pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) infection, with modulation by the host response, diet, and other environmental factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations, diagnosis, and staging of early gastric cancer. The treatment and prognosis of patients with early gastric cancer and the management of patients with advanced gastric cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19333?source=see_link\">",
"     \"Local palliation for advanced gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H142529192\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of early gastric cancer (EGC) originated in Japan in 1962; at that time, an EGC was defined as a neoplasm that could be successfully treated with surgery. EGC is now defined more specifically as an adenocarcinoma that is restricted to the mucosa or submucosa, irrespective of lymph node metastasis (T1, any N) (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"mobipreview.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/7\">",
"     7",
"    </a>",
"    ].These cancers have a much better prognosis (approximately 90 percent five-year survival rate) than do more advanced stages of gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Importantly, this definition, which has been adopted by the Japanese National Cancer Centre (JNCC), the Japan Gastric Cancer Association (JGCA), and other international groups, acknowledges that there is a small percentage of patients with EGC who have lymph node involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/7\">",
"     7",
"    </a>",
"    ]. That these cancers should still be considered EGC, even if they have nodal metastases, is supported by decades of investigation and data from screening programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, nodal metastases can affect treatment in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have proven nodal metastases, those whose pretreatment local staging evaluation indicates a high likelihood of nodal metastases, and patients with T1 disease who are at high risk for nodal metastases (because of tumor size, configuration, or depth of invasion) are not appropriate candidates for endoscopic resection. Gastrectomy, which removes the regional nodes, is the appropriate treatment strategy for such patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935970#H757935970\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with node-positive resected EGC are candidates for adjuvant therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757936033#H757936033\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Adjuvant therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer demonstrates marked geographic variability, both regionally and within countries. High-incidence areas include Latin America, Eastern Asia, and parts of Europe and the Middle East [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, the overall incidence rates are modest, but are increased in some ethnic and racial groups, such as Hispanics and African-Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. For unclear reasons, a rising incidence of gastric cancer has been recently observed among young adults in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of early gastric cancer (EGC), as well as the proportion of gastric adenocarcinomas that are EGCs, vary depending on the population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Japan and Eastern Asia, up to one-half of resections for gastric adenocarcinoma represent EGC. In Japan, the proportion rose from 15 to as high as 57 percent with the introduction of screening programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Korea, 25 to 30 percent of gastric adenocarcinomas are EGCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Western countries, EGCs account for 15 to 21 percent of gastric adenocarcinomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/14,17-19\">",
"       14,17-19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several proposed explanations for the higher incidence of EGC in Asian versus Western countries. The 5- to 10-fold higher incidence rates of gastric cancer in Eastern Asia contribute to this phenomenon. In addition, screening programs have been in place in Japan for several decades, and more recently in other parts of Eastern Asia, facilitating early detection. Lastly, there is a well-described difference in the interpretation of gastric histology in Eastern versus Western centers. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Histologic classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gastric cancer screening in Japan began in the 1960s, and continues as gastric cancer is the leading cause of cancer mortality in that country. Photofluorography has been the dominant method recommended for screening in Japanese national guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/20\">",
"     20",
"    </a>",
"    ]. Photofluorography is a double contrast radiographic examination in which patients swallow effervescent granules and then drink 200 to 300 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    . Several plain radiographs are obtained of the stomach from different positions. Patients with abnormalities detected are then referred for additional evaluation.",
"   </p>",
"   <p>",
"    There has been a transition to magnification chromoendoscopy with indigo-carmine spray in experienced centers in eastern Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, there is variation in screening practices by country and region, with the use of endoscopy,",
"    <em>",
"     H. pylori",
"    </em>",
"    serology, and serum pepsinogen testing to detect gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There do not appear to be significant differences in the demographic features of patients with EGC between Asian and Western countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The sex and age distributions of EGC are similar in Japan, Europe, and America. The average age at diagnosis is approximately 60 years, and men are more commonly affected than women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59427507\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancers can be classified in a number of ways, according to both histologic and macroscopic findings. In addition, molecular markers may in the future help better define the classification of these tumors, which could influence treatment choices and provide better understanding of a patient&rsquo;s prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Histologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, differences in gastric histologic interpretation between Japanese and Western pathologists contributes to the higher proportion of early gastric cancers (EGCs) among Japanese patients. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.) The disagreement centers on the characterization of high-grade dysplasia and intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/24\">",
"     24",
"    </a>",
"    ]. Western pathologists have typically required invasion of the lamina propria for the diagnosis of cancer, whereas Japanese pathologists have based the diagnosis on cytologic and architectural changes alone, without requiring invasion of the lamina propria. As a result, lesions classified as high-grade dysplasia by Western pathologists may be classified as intramucosal carcinoma by Japanese pathologists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link&amp;anchor=H646035135#H646035135\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Asian versus Western nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of the discrepancy is illustrated by one study, in which four Japanese and four Western pathologists examined 17 gastric biopsies and 18 endoscopic mucosal resection (EMR) specimens from 17 Japanese patients, with findings ranging from reactive atypia to early gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/25\">",
"     25",
"    </a>",
"    ]. There was overall histologic agreement in only 11 of 35 cases (31 percent).",
"   </p>",
"   <p>",
"    However, these differences in classification are usually not clinically meaningful because of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe dysplasia or EGC are usually managed with endoscopic resection, since both diagnoses are associated with a low risk of lymph node metastases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935998#H757935998\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic submucosal dissection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935984#H757935984\">",
"       \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic mucosal resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Invasion of the lamina propria, which is the threshold for diagnosing cancer among Western pathologists, may be difficult to identify on histology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an attempt to close the gap between the Japanese and Western views and reporting schemes, consensus groups have formulated the Vienna classification of gastrointestinal epithelial neoplasia and the Padova international classification of dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. The Vienna classification recognizes the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category 1: Negative for",
"      <span class=\"nowrap\">",
"       neoplasia/dysplasia",
"      </span>",
"     </li>",
"     <li>",
"      Category 2: Indefinite for",
"      <span class=\"nowrap\">",
"       neoplasia/dysplasia",
"      </span>",
"     </li>",
"     <li>",
"      Category 3: Noninvasive low-grade neoplasia (low-grade",
"      <span class=\"nowrap\">",
"       adenoma/dysplasia)",
"      </span>",
"     </li>",
"     <li>",
"      Category 4: Noninvasive high-grade neoplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      4.1: High-grade",
"      <span class=\"nowrap\">",
"       adenoma/dysplasia",
"      </span>",
"     </li>",
"     <li>",
"      4.2: Noninvasive carcinoma (carcinoma in situ)",
"     </li>",
"     <li>",
"      4.3: Suspicion of invasive carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category 5: Invasive neoplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      5.1: Intramucosal carcinoma (invasion into the lamina propria or muscularis mucosae)",
"     </li>",
"     <li>",
"      5.2: Submucosal carcinoma or beyond",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independently, the World Health Organization (WHO) proposed a classification of intraepithelial gastric neoplasias using different terms (negative for dysplasia, indefinite for dysplasia, low-grade and high-grade dysplasia, and carcinoma [invasion into the lamina propria or beyond]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these classification systems, the terminology of adenoma (raised lesions) and dysplasia (flat lesions) remains widely used in Western literature and in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711100\">",
"    <span class=\"h3\">",
"     Lauren classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologically, gastric cancers are classified as intestinal (well-differentiated) or diffuse (undifferentiated) based upon the Lauren classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These two types of gastric cancer have distinct morphologic appearances, epidemiology, pathogenesis, and genetic profiles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Intestinal versus diffuse types'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Macroscopic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various macroscopic classification systems have been developed for gastric adenocarcinoma. One of the more common is the Borrmann system, with classifications of types I-IV for polypoid, fungating, ulcerated, and diffusely infiltrating tumors, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711133\">",
"    <span class=\"h3\">",
"     Early gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification systems have also been developed specifically for early gastrointestinal cancers. While used in Eastern Asia, they are rarely used in the United States and Europe. In particular, the Japanese Macroscopic Classification of Superficial Gastric Carcinoma is widely used in Eastern Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/30\">",
"     30",
"    </a>",
"    ]. The system is based upon visual and endosonographic features and was developed in an attempt to codify the indications and outcomes related to endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The system recognizes four types of early endoluminal cancers (",
"    <a class=\"graphic graphic_table graphicRef71003 \" href=\"mobipreview.htm?18/35/19003\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82731 \" href=\"mobipreview.htm?2/59/2994\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I lesions are polypoid or protuberant and are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ip &ndash; pedunculated",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ips/sp",
"      </span>",
"      &ndash; subpedunculated",
"     </li>",
"     <li>",
"      Is &ndash; sessile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type II lesions are flat and are further subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IIa &ndash; superficial elevated",
"     </li>",
"     <li>",
"      IIb &ndash; flat",
"     </li>",
"     <li>",
"      IIc &ndash; flat depressed",
"     </li>",
"     <li>",
"      IIc+IIa lesions &ndash; elevated area within a depressed lesion",
"     </li>",
"     <li>",
"      IIa+IIc lesions &ndash; depressed area within an elevated lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type III lesions are ulcerated",
"     </li>",
"     <li>",
"      Type IV lesions are lateral spreading",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A newer classification system, the Paris system, was proposed in 2002 and is similar to the Japanese classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/32\">",
"     32",
"    </a>",
"    ]. Superficial lesions (type 0) are classified as polypoid, nonpolypoid, or excavated (",
"    <a class=\"graphic graphic_table graphicRef50239 \" href=\"mobipreview.htm?12/56/13195\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61277 \" href=\"mobipreview.htm?43/19/44348\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-I lesions are polypoid are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 0-Ip &ndash; protruded, pedunculated",
"     </li>",
"     <li>",
"      Type 0-Is &ndash; protruded, sessile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-II lesions are nonpolypoid and are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 0-IIa &ndash; slightly elevated",
"     </li>",
"     <li>",
"      Type 0-IIb &ndash; flat",
"     </li>",
"     <li>",
"      Type 0-IIc &ndash; slightly depressed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-III lesions are excavated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Paris Workshop confirmed the importance of the Japanese classification for gastric cancer based upon its correlation with risk for nodal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2082926\">",
"    <span class=\"h2\">",
"     Molecular classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of molecular markers are associated with disease progression and recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/33-39\">",
"     33-39",
"    </a>",
"    ]. The improved understanding of the genetic alterations associated with EGC may in the future help better define the classification of these tumors, their optimal treatment, and prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two general principles have emerged:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic pathways differ between intestinal-type and diffuse-type tumors. (See",
"      <a class=\"local\" href=\"#H711100\">",
"       'Lauren classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Models of molecular pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Molecular pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With intestinal type tumors, some genetic changes occur early in the preneoplastic period, whereas others occur late or with advanced cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathology and molecular pathogenesis of gastric cancer\", section on 'Models of molecular pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Novel markers may be used for molecular categorization of intestinal and diffuse gastric cancers, and more proximal gastric cancers that are located at the esophagogastric junction and gastric cardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. It is hoped that these classifications may help to identify new molecular targets for treatment of each specific entity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms of early gastric cancer (EGC) are nonspecific. Patients may be asymptomatic or they may present with dyspepsia, mild epigastric pain, nausea, or anorexia. Because of active screening programs in Eastern Asia, many patients are now detected while asymptomatic. A prodrome of vague upper gastrointestinal symptoms may be present for 6 to 12 months prior to the diagnosis of EGC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/42\">",
"     42",
"    </a>",
"    ] and occurs in up to 90 to 95 percent of patients who are not detected through screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/17\">",
"     17",
"    </a>",
"    ]. Ulcerated lesions have a longer prodrome of symptoms than protuberant lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/23\">",
"     23",
"    </a>",
"    ]. Given the high prevalence of dyspepsia in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/43\">",
"     43",
"    </a>",
"    ], many EGCs may be diagnosed incidentally.",
"   </p>",
"   <p>",
"    Warning (or alarm) signs or symptoms suggestive of invasive disease in patients with EGC, such as anemia or weight loss, occur in 5 to 15 percent and 4 to 40 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/17\">",
"     17",
"    </a>",
"    ]. By comparison, weight loss occurs in more than 60 percent of those with advanced gastric adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nonspecific nature of symptoms in EGC complicates optimal disease management strategies for patients presenting with dyspepsia. While the prevalence of gastric carcinoma among patients presenting with dyspepsia is low in the United States and other Western countries, there are no reliable clinical or laboratory features to distinguish patients with benign causes of dyspepsia from those with more serious underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy with systematic non-targeted biopsies and targeted biopsies of suspicious lesions is the diagnostic procedure of choice for early gastric cancer (EGC). It is more sensitive and specific for the detection of EGC than air contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61767 \" href=\"mobipreview.htm?12/7/12400\">",
"     image 1",
"    </a>",
"    ). The sensitivity of barium studies was only 14 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/45\">",
"     45",
"    </a>",
"    ]; in another series, all 15 patients with surgically proven EGC had a negative barium study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported accuracy of white-light endoscopy for the detection of EGC ranges from 90 to 96 percent, although some studies have found lower values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/46\">",
"     46",
"    </a>",
"    ]. On endoscopy, an EGC may appear as a subtle polypoid protrusion, a superficial plaque, mucosal discoloration, a depression, or an ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/47\">",
"     47",
"    </a>",
"    ]. Detection of small or subtle lesions can be difficult and may be missed even by experienced endoscopists. Careful inspection of the entire gastric mucosa with biopsy of any suspicious lesion is essential. The Japanese experience underscores the practice of meticulous upper endoscopy, wherein the patient is prepared with a defoaming agent combined with a mucolytic agent to improve visibility, there is a careful, systematic inspection of the stomach under adequate air insufflation, and there is extensive photodocumentation (&gt;25 images) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric topographic biopsy mapping should be considered in high-risk patients and populations. In Western regions, this approach is reasonable for patients with known intestinal metaplasia (IM), for immigrants from high-incidence areas, and for patients with clinical or endoscopic parameters warranting vigilance. Standard endoscopic biopsy mapping includes a minimum of two non-targeted biopsies each from the antrum and corpus (both lesser and greater curvatures) and possibly the incisura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/4,5,49,50\">",
"     4,5,49,50",
"    </a>",
"    ]. Additional biopsies may be warranted from the prepyloric region, fundus, and cardia. Atypical areas of gastric mucosa are also sampled. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6983?source=see_link\">",
"     \"Screening and prevention of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the presence of a gastric ulcer, the site and the number of biopsy specimens are important. The sensitivity for detecting a gastric cancer increases with more biopsies, but the optimal number of biopsies is debatable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of peptic ulcer disease\", section on 'Differentiation of benign gastric ulcers from cancer at endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of follow-up endoscopy for gastric ulcers not showing gastric cancer on the initial endoscopy with biopsies is in evolution and depends upon the adequacy of biopsies obtained during the initial endoscopy, the appearance of the ulcer, and patient characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Follow-up after initial therapy for peptic ulcer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric cancer screening programs in Eastern Asia have driven the development of novel endoscopic imaging technologies with applications throughout the gastrointestinal tract. Improved detection of abnormal lesions may be possible with chromoendoscopy, magnification endoscopy, narrow band imaging, and autofluorescence imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. Magnification chromoendoscopy is now the standard in many referral centers in Eastern Asia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13750?source=see_link&amp;anchor=H8#H8\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\", section on 'Autofluorescence endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2083142\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer is staged using the TNM classification system of the American Joint Committee on Cancer (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"mobipreview.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/57\">",
"     57",
"    </a>",
"    ]. Early gastric cancers (EGCs) are T1 lesions, irrespective of nodal status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Staging systems'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711582\">",
"    <span class=\"h2\">",
"     Lymph node metastases in EGC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of lymph node metastases in clinically staged T1 EGC is 0 to 15 percent (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"mobipreview.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. Although lymph node metastases do not affect the designation of a T1 tumor as an EGC, they have implications for therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumor characteristics affect the probability of lymph node metastases and have helped refine guidelines for which patients are appropriate candidates for endoscopic resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935977#H757935977\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors associated with lymph node metastases include larger tumor size, ulceration, diffuse (undifferentiated) or mixed",
"    <span class=\"nowrap\">",
"     (intestinal/undifferentiated)",
"    </span>",
"    type histology, depth of invasion, and submucosal or lymphovascular invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/60,62-66\">",
"     60,62-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Italian study evaluated 652 cases of resected EGC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/60\">",
"       60",
"      </a>",
"      ]. The incidence of lymph node metastases was 14.1 percent overall, and was higher for submucosal cancer compared with mucosal cancer (24 versus 5 percent). Smaller cancers were significantly less likely to be associated with positive nodes (9 versus 20 and 30 percent for tumors &lt;2 cm, 2 to 4 cm, and &gt;4 cm, respectively).",
"     </li>",
"     <li>",
"      In a retrospective study from Japan with 5265 patients, among patients with well-differentiated mucosal tumors, there were no lymph node metastases in patients with tumors less than 3 cm in size (regardless of ulceration) or in patients with tumors that were not ulcerated (regardless of size) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/62\">",
"       62",
"      </a>",
"      ]. In patients with submucosal tumors, there were no lymph node metastases in patients with well-differentiated tumors that were less than 3 cm in size and that lacked lymphovascular invasion, provided that the tumors invaded less than 0.5 mm in to the submucosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that the patients with EGC who are most appropriate for endoscopic resection are those with small (&lt;2 cm), nonulcerated, mucosal cancers, and possibly those with submucosal tumors that are small (&lt;2 to 3 cm), well-differentiated, and lack lymphovascular invasion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935970#H757935970\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711436\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on endoscopy can predict tumor stage. In one study of 2105 patients, endoscopic findings were 78 percent accurate for predicting the depth of invasion of EGC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/67\">",
"     67",
"    </a>",
"    ]. Findings associated with mucosal disease included smooth surface protrusion or depression, slight marginal elevation, and smooth tapering of converging folds. Findings suggestive of submucosal disease included an irregular surface, marked marginal elevation, and clubbing, abrupt cutting, or fusion of converging folds. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Staging and preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, staging may be more accurately accomplished using a combination of endoscopic resection and endoscopic ultrasonography (EUS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H142530392\">",
"    <span class=\"h3\">",
"     Endoscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection is considered both a staging procedure and a treatment for EGC. En bloc resection permits T staging of the tumor and does not preclude subsequent gastrectomy if the resection is incomplete or if there are unfavorable histologic findings. The presence of unfavorable histologic findings suggests a higher incidence of lymph node metastases, and therefore, indicates that an operative approach to treatment is preferred. In referral centers in Eastern Asia and elsewhere, strict criteria are used to determine the appropriateness of endoscopic resection for EGC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'Gastric cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=see_link&amp;anchor=H757935977#H757935977\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS is thought to be the most reliable nonsurgical method available for evaluating the depth of invasion of gastric cancer, particularly for T1 lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/68\">",
"     68",
"    </a>",
"    ]. By imaging the gastric wall and its layers, the degree of invasion can be identified more accurately than by computed tomographic (CT) scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 955 patients with suspected EGC, EUS staging accuracy was compared with surgical or endoscopic resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/71\">",
"     71",
"    </a>",
"    ]. EUS correctly identified the T stage in 644 patients (67 percent). The accuracy of miniprobe EUS was significantly higher than radial EUS (80 versus 60 percent).",
"   </p>",
"   <p>",
"    Regional lymph node involvement may also be detected by EUS. The definition of regional versus extraregional nodes for gastric cancer depends on location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/57\">",
"     57",
"    </a>",
"    ]. Regional nodes for tumors located along the greater curvature include greater curvature, greater omental, gastroduodenal, gastroepiploic, pre-pyloric antrum, and pancreaticoduodenal nodes; for tumors along the lesser curvature, they include lesser curvature, lesser omental, left gastric, cardioesophageal, common hepatic, celiac, and hepatoduodenal nodes; for both sites, nodes in the pancreatic and splenic area (pancreaticolienal, peripancreatic, splenic) are considered regional nodes. Involvement of other intra-abdominal nodal groups (ie, hepatoduodenal, retropancreatic, portal, mesenteric, and paraaortic) is classified as distant metastases.",
"   </p>",
"   <p>",
"    Although EUS may detect enlargement of regional nodes, the differentiation between benign (reactive) perigastric inflammation and nodal metastasis can be difficult. EUS-guided fine-needle aspiration of suspicious nodes and regional areas adds to the accuracy of nodal staging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Endoscopic ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS has become a valuable tool for the selection of patients with EGC who are suitable for endoscopic resection. However, certain features may lead to incorrect staging. In one study, EUS was 72 percent accurate for T staging (19 percent were overstaged and 9 percent were understaged) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/72\">",
"     72",
"    </a>",
"    ]. Tumors larger than 3 cm and those located in the mid-stomach were at risk for being overstaged, whereas poorly-differentiated tumors were at risk for being understaged. For this reason, in many areas of Japan and other parts of Asia, endoscopic resection rather than EUS is considered the primary staging procedure for EGC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/73\">",
"     73",
"    </a>",
"    ]. By contrast, in Western countries, EUS is generally recommended for all patients without evidence of metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711495\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other staging procedures, such as CT and positron emission tomography with fluorodeoxyglucose (FDG-PET) may also be used selectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37033/abstract/74\">",
"     74",
"    </a>",
"    ]. These procedures are used more commonly in Western referral centers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Abdominopelvic CT scan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'PET scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/28/32195?source=see_link\">",
"       \"Patient information: Stomach cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early gastric cancer (EGC) is defined as adenocarcinoma limited to the gastric mucosa or submucosa, regardless of involvement of the regional lymph nodes (T1, any N). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EGC is an important subset of gastric adenocarcinoma. In addition, EGC has triggered the development of novel imaging technologies and endoscopic resection modalities now in use in other areas of the gastrointestinal tract.",
"     </li>",
"     <li>",
"      The presenting symptoms of EGC are nonspecific. Patients may be asymptomatic or they may present with dyspepsia, mild epigastric pain, nausea, or anorexia. (See",
"      <a class=\"local\" href=\"#H59427507\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy, usually with gastric mucosal topographic biopsy mapping, is the diagnostic procedure of choice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staging of EGC may be accomplished using a combination of endoscopic resection and endoscopic ultrasound (EUS), although in clinical practice, the use of EUS is variable. (See",
"      <a class=\"local\" href=\"#H2083142\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/2\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/3\">",
"      Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/4\">",
"      Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010; 105:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/5\">",
"      Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/6\">",
"      Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/7\">",
"      Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol 2006; 22:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/8\">",
"      Alfaro EE, Lauwers GY. Early gastric neoplasia: diagnosis and implications. Adv Anat Pathol 2011; 18:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/9\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012; 62:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/10\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/11\">",
"      Anderson WF, Camargo MC, Fraumeni JF Jr, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010; 303:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/12\">",
"      Shimizu S, Tada M, Kawai K. Early gastric cancer: its surveillance and natural course. Endoscopy 1995; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/13\">",
"      Maehara Y, Orita H, Okuyama T, et al. Predictors of lymph node metastasis in early gastric cancer. Br J Surg 1992; 79:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/14\">",
"      Noguchi Y, Yoshikawa T, Tsuburaya A, et al. Is gastric carcinoma different between Japan and the United States? Cancer 2000; 89:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/15\">",
"      Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer 2002; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/16\">",
"      Kang HJ, Kim DH, Jeon TY, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010; 72:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/17\">",
"      Everett SM, Axon AT. Early gastric cancer in Europe. Gut 1997; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/18\">",
"      Eckardt VF, Giessler W, Kanzler G, et al. Clinical and morphological characteristics of early gastric cancer. A case-control study. Gastroenterology 1990; 98:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/19\">",
"      Everett SM, Axon AT. Early gastric cancer: disease or pseudo-disease? Lancet 1998; 351:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/20\">",
"      Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/21\">",
"      Pittayanon R, Rerknimitr R. Role of digital chromoendoscopy and confocal laser endomicroscopy for gastric intestinal metaplasia and cancer surveillance. World J Gastrointest Endosc 2012; 4:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/22\">",
"      Biasco G, Paganelli GM, Azzaroni D, et al. Early gastric cancer in Italy. Clinical and pathological observations on 80 cases. Dig Dis Sci 1987; 32:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/23\">",
"      Evans DM, Craven JL, Murphy F, Cleary BK. Comparison of \"early gastric cancer\" in Britain and Japan. Gut 1978; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/24\">",
"      Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/25\">",
"      Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997; 349:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/26\">",
"      Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     Fenoglio-Preiser C, Carneiro F, Correa P, et al. Tumours of the stomach. In: Pathology and Genetics of Tumours of the Digestive System, Hamilton R, Aalthonen L (Eds), International Agency for Research on Cancer, Lyon 2000. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/28\">",
"      LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand 1965; 64:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/29\">",
"      Laur&eacute;n PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 1993; 71:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/30\">",
"      . Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer 1998; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/31\">",
"      The general rules for The gastric cancer study in surgery. Jpn J Surg 1973; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/32\">",
"      The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/33\">",
"      Gong C, Mera R, Bravo JC, et al. KRAS mutations predict progression of preneoplastic gastric lesions. Cancer Epidemiol Biomarkers Prev 1999; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/34\">",
"      Sugai T, Nakamura S, Uesugi N, et al. Role of DNA aneuploidy, overexpression of p53 gene product, and cellular proliferation in the progression of gastric cancer. Cytometry 1999; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/35\">",
"      Shiao YH, Bovo D, Guido M, et al. Microsatellite instability and/or loss of heterozygosity in young gastric cancer patients in Italy. Int J Cancer 1999; 82:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/36\">",
"      Xiangming C, Hokita S, Natsugoe S, et al. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 1999; 57:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/37\">",
"      Kim JJ, Baek MJ, Kim L, et al. Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability. Lab Invest 1999; 79:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/38\">",
"      Yamamoto H, Perez-Piteira J, Yoshida T, et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999; 116:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/39\">",
"      Hasuo T, Semba S, Li D, et al. Assessment of microsatellite instability status for the prediction of metachronous recurrence after initial endoscopic submucosal dissection for early gastric cancer. Br J Cancer 2007; 96:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/40\">",
"      Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/41\">",
"      Tang W, Morgan DR, Meyers MO, et al. Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer 2012; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/42\">",
"      Craanen ME, Dekker W, Ferwerda J, et al. Early gastric cancer: a clinicopathologic study. J Clin Gastroenterol 1991; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. In: Rome III: The Functional Gastrointestinal Disorders, 3rd ed, Drossman DA, Corazziari E, Delvaux M, et al (Eds), Degnon Associates, Inc, McLean, Virginia 2006. p.419.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/44\">",
"      Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/45\">",
"      Longo WE, Zucker KA, Zdon MJ, Modlin IM. Detection of early gastric cancer in an aggressive endoscopy unit. Am Surg 1989; 55:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/46\">",
"      Ballantyne KC, Morris DL, Jones JA, et al. Accuracy of identification of early gastric cancer. Br J Surg 1987; 74:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/47\">",
"      Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981; 11:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/48\">",
"      Ang TL, Khor CJ, Gotoda T. Diagnosis and endoscopic resection of early gastric cancer. Singapore Med J 2010; 51:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/49\">",
"      de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010; 15:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/50\">",
"      Yantiss RK, Odze RD. Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract. Am J Gastroenterol 2009; 104:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/51\">",
"      Kuznetsov K, Lambert R, Rey JF. Narrow-band imaging: potential and limitations. Endoscopy 2006; 38:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/52\">",
"      Muto M, Katada C, Sano Y, Yoshida S. Narrow band imaging: a new diagnostic approach to visualize angiogenesis in superficial neoplasia. Clin Gastroenterol Hepatol 2005; 3:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/53\">",
"      Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/54\">",
"      Tada K, Oda I, Yokoi C, et al. Pilot study on clinical effectiveness of autofluorescence imaging for early gastric cancer diagnosis by less experienced endoscopists. Diagn Ther Endosc 2011; 2011:419136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/55\">",
"      Ezoe Y, Muto M, Uedo N, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011; 141:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/56\">",
"      Li HY, Dai J, Xue HB, et al. Application of magnifying endoscopy with narrow-band imaging in diagnosing gastric lesions: a prospective study. Gastrointest Endosc 2012; 76:1124.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/58\">",
"      Seto Y, Nagawa H, Muto T. Impact of lymph node metastasis on survival with early gastric cancer. World J Surg 1997; 21:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/59\">",
"      Folli S, Dente M, Dell'Amore D, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg 1995; 82:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/60\">",
"      Roviello F, Rossi S, Marrelli D, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006; 94:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/61\">",
"      Nakamura K, Morisaki T, Sugitani A, et al. An early gastric carcinoma treatment strategy based on analysis of lymph node metastasis. Cancer 1999; 85:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/62\">",
"      Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/63\">",
"      Nasu J, Nishina T, Hirasaki S, et al. Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers. J Clin Gastroenterol 2006; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/64\">",
"      Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/65\">",
"      An JY, Baik YH, Choi MG, et al. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg 2007; 246:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/66\">",
"      Lee IS, Yook JH, Park YS, et al. Suitability of endoscopic submucosal dissection for treatment of submucosal gastric cancers. Br J Surg 2013; 100:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/67\">",
"      Choi J, Kim SG, Im JP, et al. Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc 2011; 73:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/68\">",
"      Yoshida S, Tanaka S, Kunihiro K, et al. Diagnostic ability of high-frequency ultrasound probe sonography in staging early gastric cancer, especially for submucosal invasion. Abdom Imaging 2005; 30:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/69\">",
"      Yanai H, Fujimura H, Suzumi M, et al. Delineation of the gastric muscularis mucosae and assessment of depth of invasion of early gastric cancer using a 20-megahertz endoscopic ultrasound probe. Gastrointest Endosc 1993; 39:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/70\">",
"      Yanai H, Tada M, Karita M, Okita K. Diagnostic utility of 20-megahertz linear endoscopic ultrasonography in early gastric cancer. Gastrointest Endosc 1996; 44:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/71\">",
"      Choi J, Kim SG, Im JP, et al. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. Endoscopy 2010; 42:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/72\">",
"      Kim JH, Song KS, Youn YH, et al. Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer. Gastrointest Endosc 2007; 66:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37033/abstract/73\">",
"      Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41:929.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (Accessed on September 27, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2520 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37033=[""].join("\n");
var outline_f36_10_37033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H142529192\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59427507\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Histologic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711100\">",
"      - Lauren classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Macroscopic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711133\">",
"      - Early gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2082926\">",
"      Molecular classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2083142\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711582\">",
"      Lymph node metastases in EGC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711436\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H142530392\">",
"      - Endoscopic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711495\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2520|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/7/12400\" title=\"diagnostic image 1\">",
"      Early gastric cancer UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2520|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/59/2994\" title=\"figure 1\">",
"      JSGE classification of early endoluminal cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/19/44348\" title=\"figure 2\">",
"      Subclasses of Type 0 superficial tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/6/11374\" title=\"table 1\">",
"      2010 TNM staging stomach CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/35/19003\" title=\"table 2\">",
"      JSGE classification of endoluminal cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13195\" title=\"table 3\">",
"      Paris classification system of superficial lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=related_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/46/4842?source=related_link\">",
"      Early gastric cancer: Treatment, natural history, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19333?source=related_link\">",
"      Local palliation for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/28/32195?source=related_link\">",
"      Patient information: Stomach cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37034="Screening for colorectal cancer: Strategies in patients at average risk";
var content_f36_10_37034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for colorectal cancer: Strategies in patients at average risk",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/10/37034/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/10/37034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a common and lethal disease; removal of premalignant adenomas can prevent the cancer and removal of localized cancer may prevent CRC-related death. CRC is infrequent before age 40; the incidence rises progressively thereafter to",
"    <span class=\"nowrap\">",
"     3.7/1000",
"    </span>",
"    per year by age 80 (",
"    <a class=\"graphic graphic_figure graphicRef59440 \" href=\"mobipreview.htm?36/17/37151\">",
"     figure 1",
"    </a>",
"    ). The lifetime incidence for patients at average risk is 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/1\">",
"     1",
"    </a>",
"    ], with 90 percent of cases occurring after age 50.",
"   </p>",
"   <p>",
"    Worldwide, CRC is the second most commonly diagnosed cancer in women and third most common in men, accounting for over 600,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States (US), CRC is the second leading cause of cancer death and accounts for approximately 9 percent of cancer deaths overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately one in three people who develop CRC die of this disease.",
"   </p>",
"   <p>",
"    Both the incidence of and mortality rates from CRC have been declining in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The onset of the decline somewhat predates widespread screening. One microsimulation model, MISCAN-Colon, imputes the impact of CRC risk factors, protective factors, and screening on CRC incidence and these factors plus treatment on CRC mortality. Based on US data after 1987, the model suggests that screening may account for 53 percent of the observed reduction in CRC mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening rates for CRC, although rising in the US over the past few years, are generally below national targets, despite evidence that screening reduces colon cancer mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/7\">",
"     7",
"    </a>",
"    ]. Between 2002 and 2010, the percentage of adults (50 to 75 years old) in the United States who had received adequate screening for colorectal cancer increased from 52.3 to 65.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/4\">",
"     4",
"    </a>",
"    ]. Screening rates are higher in adults who are insured, better educated, non-Hispanic, or have a usual source of medical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately one half of the cases of colorectal cancer diagnosed in the United States between 2004 and 2006 were late stage, particularly in older adults and in black men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic addresses the rationale and modalities recommended for CRC screening in patients who are at average risk for the disease. Screening recommendations for patients at increased risk, as well as surveillance for colorectal cancer in patients with colon polyps, are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link&amp;anchor=H21758702#H21758702\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\", section on 'Surveillance in carriers and family members'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=see_link&amp;anchor=H21759653#H21759653\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Screening and surveillance'",
"    </a>",
"    .) Additionally, characteristics of specific tests used for screening for colorectal cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adenoma-carcinoma sequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most colorectal cancers (CRCs) arise from adenomas, many of which are polyps that progress from small to large (&gt;1 cm) polyps, and then to dysplasia and cancer. Neoplastic changes likely result from both inherited and acquired genetic defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progression from adenoma to carcinoma, when it occurs, apparently takes at least 10 years on average [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/11\">",
"     11",
"    </a>",
"    ], although polyps are ordinarily removed when found so this estimate is imprecise. Polyps and cancers are distributed approximately evenly throughout the colon and rectum but tend to be more proximal in women and with increasing age.",
"   </p>",
"   <p>",
"    Some colon cancers arise from non-polypoid adenomas that are flat or depressed and account for 22 to 36 percent of identified adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Flat and depressed lesions are difficult to detect and are recognizable only by subtle distortion of the mucosal pattern and special stains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/13\">",
"     13",
"    </a>",
"    ]. Large flat adenomas may be more likely to contain dysplastic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/13\">",
"     13",
"    </a>",
"    ] or cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/12\">",
"     12",
"    </a>",
"    ] than polypoid ones of comparable size.",
"   </p>",
"   <p>",
"    Most colorectal polyps are either adenomatous or hyperplastic. These cannot be distinguished reliably by gross appearance; biopsy is required for diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef66254 \" href=\"mobipreview.htm?29/58/30628\">",
"     picture 1",
"    </a>",
"    ). Hyperplastic polyps usually do not progress to cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-thirds of polyps are adenomas. Adenomas are found in about 25 percent of men and 15 percent of women, and the prevalence increases with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/15\">",
"       15",
"      </a>",
"      ]. Hyperplastic polyps account for most of the remaining polyps and are typically small and distal. They are generally not premalignant, although there are rare reports of cancers arising from isolated hyperplastic polyps. Patients with small rectal hyperplastic polyps are considered to have normal colonoscopies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/16\">",
"       16",
"      </a>",
"      ]. A rare syndrome, hyperplastic polyposis, is associated with a large number of hyperplastic polyps and an increased risk of CRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of CRC increases with adenoma size, number, and histology (eg, villous adenomas greater risk than tubular adenomas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The finding of one adenomatous polyp suggests a propensity to form polyps, especially if it is large, and the patient should be evaluated for other lesions in the colon and rectum. The number and types of lesions found will determine the appropriate interval for subsequent surveillance colonoscopy.",
"   </p>",
"   <p>",
"    Removal of adenomatous polyps prevents cancer. The National Polyp Study Work Group followed 1418 patients in whom colonoscopic examination led to the removal of one or more polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/20\">",
"     20",
"    </a>",
"    ]. During a mean follow-up of six years, the incidence of colon cancer was 88 to 90 percent lower than in patients reported in other studies who had polyps that were not removed and 76 percent lower than in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6271688\">",
"    <span class=\"h2\">",
"     Right-sided versus left-sided lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gradual shift toward right-sided or proximal colon cancers has been observed both in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/21-23\">",
"     21-23",
"    </a>",
"    ] and internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], with the greatest relative increase in incidence in the cecum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This change in the anatomic distribution of CRCs may be partly due to improvements in diagnosis and treatment, and increased screening by flexible sigmoidoscopy with removal of adenomatous polyps in the descending colon, but there also appears to be a true increase in the incidence of ascending colon and cecal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Colonoscopy also may be more effective in preventing left-sided than right-sided CRCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], which could contribute to a shift in distribution of cancers in the colon.",
"   </p>",
"   <p>",
"    It is also likely that the biology may also differ between CRCs of the right and left colon. For example, serrated adenomas, which are flatter and more difficult to visualize endoscopically, and which characteristically carry BRAF V600E mutations and give rise to microsatellite unstable CRCs, are more common in the right colon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing colorectal cancer (CRC) is largely acquired, although genetic factors also play a role. Identified risk factors include family history, age, geographic area, race, gender, dietary habits, and smoking (",
"    <a class=\"graphic graphic_table graphicRef72216 \" href=\"mobipreview.htm?32/19/33083\">",
"     table 1",
"    </a>",
"    ). Currently, risk factors other than age and family history are not taken into account in most screening recommendations. The impact of other individual factors is too small to be used as a determinant of screening, although combinations of risk factors might be [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some findings related to risk factors are presented below. A detailed discussion of risk factors for CRC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link\">",
"     \"Cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of CRC varies about 15-fold across regions of the world, and people who move from low- to high-risk regions acquire higher rates during their lifetime [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States, both incidence and mortality from CRC are higher in black people compared with white people [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/33\">",
"       33",
"      </a>",
"      ]. This may relate to differences in screening rates, environmental factors, or tumor biology. In a study of patients who had screening colonoscopy, the risk of finding polyps (&gt;9 mm) was greater in black patients compared to white patients (7.7 versus 6.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/34\">",
"       34",
"      </a>",
"      ]. For patients over 60 years, proximal lesions were more common in black patients than white patients.",
"     </li>",
"     <li>",
"      A study of a large, relatively unscreened population in Germany showed the prevalence of CRC increased with age, was higher at any given age in men than women, and was higher in later birth cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/35\">",
"       35",
"      </a>",
"      ]. This suggests an increasing incidence of CRC over calendar time, after taking age into account. Two studies found the relative risk (RR) of finding an advanced adenoma by colonoscopy screening in men compared with women to be 1.83 (95% CI 1.69 -1.97) and 1.91 (1.42-2.56) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Among people with a negative family history and negative guaiac test, advanced neoplasia was found in 8.6 percent of men and 4.5 percent of women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several dietary and behavioral risk factors have been suggested by observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. A meta-analysis of observational studies concluded that smokers, compared to never smokers, had an increased risk for CRC of approximately 20 percent (RR 1.18, 95% CI 1.11-1.25) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current screening guidelines are not stratified by sex or by age between onset of screening (50 years old in average risk individuals) and age at stopping (70 to 80 years old), even though an individual&rsquo;s risk of colorectal cancer rises rapidly during that time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection of increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before deciding how best to screen and when to initiate screening, clinicians should determine the individual patient's level of risk. A decision tool to determine risk for CRC, applicable only to non-Hispanic whites, has been developed by the National Cancer Institute and incorporates data relevant to age, diet, exercise, medication use, and colonoscopy results as well as family history in first-degree relatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, most current guidelines take into account only personal and family history of polyps and cancer when recommending a screening program.",
"   </p>",
"   <p>",
"    A few questions will help determine if the patient may be at increased risk for colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have you ever had colorectal cancer or an adenomatous polyp?",
"     </li>",
"     <li>",
"      Have you had inflammatory bowel disease (ulcerative colitis or Crohn's disease)? Have you received abdominal radiation in for childhood cancer?",
"     </li>",
"     <li>",
"      Have any family members had colorectal cancer or an adenomatous polyp?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If so, how many, were they first-degree relatives (parent, sibling, or child), and at what age was the cancer or polyp first diagnosed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient is considered at average risk if all answers to the initial questions are \"no.\" Patients answering \"yes\" to any of these questions may be at increased risk and need to be evaluated further. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8750286\">",
"     'Other risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest asking these questions by age 20 and every five years thereafter, although there are no published guidelines specifying this age or frequency. One study from a US national population-based cancer registry found that the number of patients who would meet criteria for high-risk screening based on family history significantly increased from age 30 (2.1 percent) to age 50 (7.1 percent), supporting the need to update the family history at least every 5 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/44\">",
"     44",
"    </a>",
"    ]. Most high-risk patients should begin CRC screening at an earlier age than those at average risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors that affect screening recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Strong genetic risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lynch Syndrome (Hereditary nonpolyposis colon cancer) &mdash; Lynch syndrome (hereditary nonpolyposis colorectal cancer or HNPCC) is a familial form of CRC caused by mutations in DNA mismatch repair genes, accounts for approximately 2 to 3 percent of colorectal cancer. The Lynch Syndrome also increases risk for cancers other than colorectal, including endometrial, stomach, ovarian, pancreas, ureters and kidney, biliary tract, and brain (usually glioblastoma). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The diagnosis should be considered in people with more than one family member with CRC or other Lynch Syndrome-related cancers of small bowel, ovary, and endometrium occurring at a young age, commonly in the 30s and 40s.",
"     </li>",
"     <li>",
"      Familial adenomatous polyposis &mdash; Familial adenomatous polyposis (FAP) is inherited as an autosomal dominant gene and accounts for about one percent of colorectal cancers. Hundreds to thousands of polyps occur throughout the colon beginning in adolescence (",
"      <a class=\"graphic graphic_picture graphicRef59413 \" href=\"mobipreview.htm?8/19/8504\">",
"       picture 2",
"      </a>",
"      ). Tumors develop beginning in the 20s, and nearly 100 percent of people develop CRC, usually before age 50 . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"       \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other significant risks",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior colorectal cancer or polyps &mdash; A prior history of CRC increases the risk of another primary (metachronous) cancer. In the best available study, the CRC rate in patients who had a history of CRC was 1.4 times the rate in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/45\">",
"       45",
"      </a>",
"      ]. A history of adenomatous colorectal polyps also increases the risk of CRC, especially if the polyps are multiple, large, or have villous architecture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease &mdash; The association between colonic inflammatory bowel disease (ulcerative colitis or Crohn's disease) and increased risk of CRC is well documented for extensive (pancolitis) and longstanding disease. Cancers develop in areas of dysplasia, rather than from polyps. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history &mdash; A family history of CRC is present in about 10 percent of adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/47,48\">",
"       47,48",
"      </a>",
"      ] and about 25 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/49\">",
"       49",
"      </a>",
"      ]. The increase in lifetime risk related to family history ranges from about two- to sixfold. Results of a systematic review, providing the most precise estimates of these risks, are shown in a figure (",
"      <a class=\"graphic graphic_figure graphicRef59834 \" href=\"mobipreview.htm?39/63/40957\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/50\">",
"       50",
"      </a>",
"      ]. A family history of adenomatous polyps before age 60 years has been reported to increase risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/51,52\">",
"       51,52",
"      </a>",
"      ], but the effect is small and could be the result of referral bias. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Race &mdash; Black persons, compared to other racial and ethnic groups, have the highest incidence of CRC, and the CRC mortality rate is nearly double that for other minority groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/53\">",
"       53",
"      </a>",
"      ]. While guidelines from the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy recommend initiating screening in African Americans beginning at age 45 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/54,55\">",
"       54,55",
"      </a>",
"      ], and the American College of Physicians at age 40 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/56\">",
"       56",
"      </a>",
"      ], other US national guidelines do not propose earlier screening based only on racial background [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gender &mdash; Comparing data from screening colonoscopies in men and women, the prevalences of advanced adenoma (8.0 versus 4.3 percent) and colorectal cancer (1.4 versus 0.6 percent) are higher in men, and adenomas are found at an earlier age in men than women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/15,59-61\">",
"       15,59-61",
"      </a>",
"      ]. In one cohort study of 44,350 participants, the number needed to screen for the detection of advanced adenoma was the same for men aged 45 to 49 years and for women aged 55 to 59 years (26.1 and 26.0, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/15\">",
"       15",
"      </a>",
"      ]. Although guidelines have not recommended initiating screening at different ages by gender, this consideration has been suggested by several papers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/15,62,63\">",
"       15,62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal radiation &mdash; Adult survivors of childhood malignancy who received abdominal radiation are at increased risk of subsequent gastrointestinal neoplasms, the majority colorectal cancer. In two studies, the incidence of colorectal cancer in individuals who received abdominal radiation for childhood cancer was approximately 11 times the incidence in people not exposed to childhood radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/64,65\">",
"       64,65",
"      </a>",
"      ], and colorectal cancer occurred at a relative early age (&lt;50 years old) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/64\">",
"       64",
"      </a>",
"      ]. Guidelines from the Children&rsquo;s Oncology Group recommend colonoscopy every five years for survivors of childhood cancer who received 30 Gy or more of abdominal radiation, with screening beginning 10 years after radiation or at age 35 years, whichever is later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8750286\">",
"    <span class=\"h2\">",
"     Other risks",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gardner syndrome (CRC with benign extracolonic tumors) and Turcot syndrome (CRC with brain tumors) are less-common inherited syndromes. These syndromes appear to result from expression of the same genetic defects that cause FAP (Gardner) or HNPCC (Turcot). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"       \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"       \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most hamartomatous polyps have little malignant potential, but patients with hamartomatous polyps in the colon may be at a slightly increased risk for colon cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=see_link\">",
"       \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link&amp;anchor=H15416963#H15416963\">",
"       \"Approach to the patient with colonic polyps\", section on 'Hamartomatous polyps'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men who have undergone radiotherapy for prostate cancer appear to be at increased risk for rectal cancer; the hazard ratio (HR) was 1.7 in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-infected male patients over 50 years may have a higher prevalence of colon neoplasms compared to the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional risk factors include acromegaly, renal transplantation, diabetes, androgen deprivation, alcohol, and obesity. These are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H265276647#H265276647\">",
"       \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Factors that may influence screening recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H90630250#H90630250\">",
"       \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Risk factors that do not alter screening recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TESTS USED FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple tests are available as options for colorectal cancer (CRC) screening. While stool-based tests improve disease prognosis by detecting early stage treatable cancers (and sometimes advanced adenomas), endoscopic or radiologic tests that visualize the bowel mucosa have the potential to also prevent cancer by detecting polyps that can be removed prior to malignant transformation. Characteristics and effectiveness of available colorectal cancer screening tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tests available for screening are as follows:",
"   </p>",
"   <p>",
"    Stool-based tests",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Guaiac-based fecal occult blood test (gFOBT)",
"     </li>",
"     <li>",
"      Immunochemical-based fecal occult blood test (iFOBT), also known as fecal immunochemical test (FIT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopic and radiologic examinations",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexible sigmoidoscopy (FS or FSIG)",
"     </li>",
"     <li>",
"      Optical colonoscopy",
"     </li>",
"     <li>",
"      Double-contrast",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema (DCBE)",
"     </li>",
"     <li>",
"      CT colonography (CTC, formerly referred to as \"virtual colonoscopy\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening with gFOBT has been demonstrated to reduce mortality from colorectal cancer in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. In the earliest trial, with rehydrated specimens and colonoscopy follow-up for positive results, mortality was reduced by 33 percent after annual screening and 13 years follow-up and by 21 percent after biennial screening with 18 years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/69\">",
"     69",
"    </a>",
"    ]. Other trials report a 15 to 18 percent mortality reduction for screening with nonrehydrated gFOBT samples every two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/70-73\">",
"     70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have also shown that screening with flexible sigmoidoscopy decreases the incidence of CRC and overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. In the larger trial involving 170,432 participants between the ages of 55 and 64 years, one time screening with sigmoidoscopy, compared to no screening, led to a 23 percent decrease in the incidence of CRC and a 31 percent decrease in overall mortality at 11 year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/74\">",
"     74",
"    </a>",
"    ]. A reduction in CRC mortality began around three years after screening sigmoidoscopy and persisted through 11 years of follow-up.",
"   </p>",
"   <p>",
"    The effectiveness of other tests and procedures for prevention of CRC deaths has not been demonstrated in randomized trials, although it is inferred because other screening modalities have greater sensitivity for advanced adenomas and early CRC than gFOBT and evaluate a longer segment of bowel than sigmoidoscopy.",
"   </p>",
"   <p>",
"    Fecal occult blood tests, flexible sigmoidoscopy, double-contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, and colonoscopy with direct visualization (optical colonoscopy) have been recommended as screening options for many years. A US task force representing multiple specialty societies developed consensus guidelines in 2008 that endorse two additional screening options: computed tomographic colonography (CTC) and a panel test for stool DNA (sDNA) (",
"    <a class=\"graphic graphic_table graphicRef58094 \" href=\"mobipreview.htm?38/6/39019\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/57\">",
"     57",
"    </a>",
"    ]. (It should be noted that a stool DNA test, previously available, is no longer commercially available in 2012.) The US Preventive Services Task Force also issued updated guidelines for colorectal cancer screening in 2008 and did not recommend barium enema, CTC or sDNA as screening options, however [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/58\">",
"     58",
"    </a>",
"    ]. Both guidelines endorse fecal occult blood testing using either a high-sensitive guaiac reagent or an immunochemical test; lower-sensitivity guaiac tests are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96786412\">",
"    <span class=\"h2\">",
"     Digital rectal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;One in four colorectal cancers is in the rectum, and many are within an examiner&rsquo;s reach on digital rectal examination.&nbsp;However, there is little evidence to support the effectiveness of digital rectal examination for the detection of rectal cancer, and it is not recommended in current colorectal screening guidelines.&nbsp;The screening tests discussed above for colorectal cancer detect tumors in the rectum, so there is little need for a separate rectal examination specifically for early detection of rectal cancer. Additionally, a single office-based gFOBT performed following a digital rectal examination has low sensitivity for advanced neoplasia or colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/76\">",
"     76",
"    </a>",
"    ] and is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPARISON OF TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88004299\">",
"    <span class=\"h2\">",
"     Test attributes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many factors influence the choice of a screening test: strength of the evidence of effectiveness, magnitude of the effect (eg, reduction in incidence or mortality from colorectal cancer [CRC]), safety, convenience, comfort, availability, cost, and cost per year of life saved (cost-effectiveness).",
"   </p>",
"   <p>",
"    The options for screening differ substantially in many of these dimensions (",
"    <a class=\"graphic graphic_table graphicRef71954 graphicRef63768 \" href=\"mobipreview.htm?10/5/10333\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/43\">",
"     43",
"    </a>",
"    ]. Testing options for colorectal cancer screening are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A brief summary of relative benefits and disadvantages of testing options follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stool guaiac tests have low sensitivity for polyps and relatively low specificity for significant disease, leading to workup for many false-positive results. The test is non-invasive and inexpensive, but requires compliance with annual testing and colonoscopy for follow-up of positive results.",
"     </li>",
"     <li>",
"      Immunochemical stool tests (fecal immunochemical testing, FIT) are more expensive than guaiac-based tests, but have the potential to be more cost effective if fewer colonoscopies are needed for follow-up. Studies have suggested that immunochemical tests, compared to stool guaiac tests, may have better performance characteristics for screening, with increased sensitivity without loss of specificity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/77\">",
"       77",
"      </a>",
"      ]. Patient willingness to be tested may also be higher with FIT compared to screening by stool guaiac [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/78\">",
"       78",
"      </a>",
"      ], flexible sigmoidoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/78\">",
"       78",
"      </a>",
"      ], or colonoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stool DNA requires collection of an entire bowel movement and the test is expensive. The significance of false-positive findings is unknown.",
"     </li>",
"     <li>",
"      Double-contrast",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema studies visualize the entire large bowel and are relatively safe but detect one-half of large (&gt;1 cm) polyps, and abnormalities must be followed by colonoscopy. Use has declined with increasing use of endoscopic and CT procedures, and procedural expertise in double-contrast barium studies may be declining in countries where other options are available.",
"     </li>",
"     <li>",
"      Flexible sigmoidoscopy can only identify lesions in the distal 60 cm of the bowel but can be performed with minimal patient preparation, does not require sedation, and is often performed by trained clinicians who are not specialized in gastroenterology. Abnormal findings in the distal bowel may require colonoscopy for visualization of the entire colon.",
"     </li>",
"     <li>",
"      Colonoscopy has the benefit of high sensitivity and specificity. Also, lesions can be removed during the same procedure. However, colonoscopy requires conscious sedation and a vigorous bowel preparation. The procedure carries a risk of perforation and bleeding. Some polyps and cancers may be difficult to detect because of their location. Studies have called into question how well screening colonoscopy prevents death from colorectal cancer in the right colon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/80,81\">",
"       80,81",
"      </a>",
"      ] or how well colonoscopy protects against the onset of right-sided CRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Although colonoscopy has greater sensitivity than immunochemical stool testing for detecting CRC, the initial rates of detection of CRC were the same in a randomized trial from the Netherlands comparing the two methods of screening, because subjects in the FIT group were more likely to participate in screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/79\">",
"       79",
"      </a>",
"      ]. Colonoscopy, however, identified more adenomas than FIT.",
"     </li>",
"     <li>",
"      CT colonography is nearly as sensitive as optical colonoscopy. It generally requires aggressive bowel preparation, but newer techniques, which tag stools and subtract their image electronically, may overcome this disadvantage. CTC does not require sedation and does not risk bowel perforation if findings are negative; positive findings require colonoscopy follow-up. Extracolonic findings often trigger further evaluation with little evidence of benefit. The cumulative dose of radiation, with repeated screenings, may increase cancer risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993407\">",
"    <span class=\"h2\">",
"     Cost and cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cost-effectiveness models have found that all CRC screening options are as \"cost-effective\" as other accepted screening tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Costs rise steeply with shorter screening intervals, with much smaller increases in effectiveness.",
"   </p>",
"   <p>",
"    Charges for the various screening tests cover a large range. These charges are borne up front whereas the benefits (reduction in CRC incidence and mortality) take several years to accrue. Insurance coverage is variable in the United States. Patients with high-deductable health plans are more likely to be screened with fecal occult blood tests (FOBT) than with colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost effectiveness is estimated from models based on assumptions about the cost, effectiveness of the various tests, and progression of the disease over time. Models differ in the screening program they simulate with respect to compliance, age of onset and stopping, and testing interval. Models also vary based on assumptions of the relative effectiveness of different tests in detecting CRC.",
"   </p>",
"   <p>",
"    It is reassuring that several different models used within the Cancer Intervention and Surveillance Modeling Network (CISNET) of the National Cancer Institute (NCI) in the US, which were designed independently, come to generally similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/85\">",
"     85",
"    </a>",
"    ]. These models found cost per year of life saved to be in the same range for well-established tests: a sensitive stool test for blood (Hemoccult Sensa or an immunologic test) annually, flexible sigmoidoscopy every five years with an annual sensitive stool test, or colonoscopy every 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/85\">",
"     85",
"    </a>",
"    ]. This is largely because all positive tests lead to colonoscopy for diagnosis and surveillance, and colonoscopy is the most expensive part of the screening program. Therefore, cost-effectiveness is not, in itself, a compelling reason for choosing one of these tests over another.",
"   </p>",
"   <p>",
"    An annual FOBT with a less-sensitive test (eg, Hemoccult II) or sigmoidoscopy alone every five years were somewhat less cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/85\">",
"     85",
"    </a>",
"    ]. From the US perspective, all tests were within the generally accepted threshold for being &ldquo;cost-effective&rdquo;&mdash;that is, less than $50,000 per year of life saved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/84\">",
"     84",
"    </a>",
"    ], although CT colonography (CTC) was substantially less cost-effective than other tests in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other models have reached slightly different conclusions. One Canadian model reported that screening with a fecal immunologic test (FIT) prevented more CRC deaths, and saved more costs, than other commonly used CRC screening tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/87\">",
"     87",
"    </a>",
"    ]. A more recent modeling study also found that FIT screening dominated other strategies, but only when rates of screening uptake using FIT were optimal and greater than US rates in 2012; this analysis also found that colonoscopy may be cost-effective compared to sigmoidoscopy, depending on rates of screening uptake and adherence and the ability of colonoscopy to reduce proximal CRC by 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some models have found that colorectal cancer screening is cost saving, because of the soaring cost of treatment of advanced colorectal cancer with new, targeted therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/87,89\">",
"     87,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88004394\">",
"    <span class=\"h2\">",
"     Patient preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient preferences have also been evaluated. One of the largest studies to evaluate procedure preferences in detail involved 614 high-risk patients who underwent colonoscopy, CTC, and double-contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema (DCBE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients preferred colonoscopy to the other two procedures and were least satisfied with DCBE.",
"   </p>",
"   <p>",
"    Randomized trials have found that participation rates in screening were greater for patients who were assigned to screening with fecal immunochemistry than to stool guaiac or flexible sigmoidoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/78\">",
"     78",
"    </a>",
"    ] or to colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/79\">",
"     79",
"    </a>",
"    ], suggesting that preference was greater for the convenience of FIT than guaiac and greater for the ease of stool testing than more invasive procedures.",
"   </p>",
"   <p>",
"    In one randomized trial comparing patient perception of burden for colonoscopy or CT colonography (CTC), patients reported greater expected burden for colonoscopy but experienced somewhat greater burden for CTC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients undergoing CTC received a noncathartic bowel preparation that was associated with post-procedure diarrhea. A lower participation rate for those invited for screening by colonoscopy, compared to CTC (22 versus 34 percent), may have selected against patients more likely to experience burden with colonoscopy.",
"   </p>",
"   <p>",
"    Findings from these studies represent the average preference for groups of patients. The clinical challenge is to determine the test that each individual patient prefers and to plan a screening strategy based on individual preference, individual risk, test effectiveness, resource availability, and cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88004424\">",
"    <span class=\"h2\">",
"     Test availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Availability of colonoscopy and other operator-dependent tests varies by country and region within countries. Greater use of colonoscopy or sigmoidoscopy, instead of FOBT for screening, would require more endoscopy resources than currently exist in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3759928\">",
"    <span class=\"h2\">",
"     Other factors that may impact screening test choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patient factors have been identified that may influence the optimal test for a given patient, based on their risk of disease and whether they have had prior screening. It should be noted, however, that tailoring the choice of testing strategy to a patient&rsquo;s characteristics has not been incorporated into current guidelines, and risks adding further complexity to decision making around CRC screening. &nbsp;",
"   </p>",
"   <p>",
"    The choice of screening modality may differ depending on whether screening is first-round or interval screening following an initial negative screen. Since the risk of disease is significantly lower for second-round screening and beyond, options for subsequent testing may include no screening or testing using less invasive or less costly modalities. In the absence of trial data, a computer simulation model found that, compared with no screening, rescreening by any method following an initial negative colonoscopy reduced the risk of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/93\">",
"     93",
"    </a>",
"    ]. Rescreening with colonoscopy was projected to cause more complications and greater cost compared with other modalities (highly sensitive stool guaiac, fecal immunochemical testing, or CT colonography), with equivalent benefit measured as life-years.",
"   </p>",
"   <p>",
"    Some have proposed that the choice of initial screening modality be based on the patient&rsquo;s risk for advanced neoplasia. In a study of over 10,000 consecutive screening colonoscopies, the risk of advanced neoplasia was 1.1 percent for women less than 70 years of age (compared with 2.2 percent for men of comparable age) and was 0.86 percent for women who had no distal neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/94\">",
"     94",
"    </a>",
"    ]. Thus, based on lower cost and fewer adverse effects, sigmoidoscopy (with or without fecal occult blood test) might be preferable to colonoscopy as a screening strategy for average-risk women aged 50 to 70 years. Adding fecal occult blood testing to high-quality flexible sigmoidoscopy that reaches the splenic flexure would further lower the small risk of missing proximal neoplasia that might be visualized by colonoscopy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Guidelines for average risk screening'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF A SCREENING PROGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for colorectal cancer (CRC) requires an ongoing program of appropriate testing and follow-up. One-time testing is insufficient; colon cancer incidence continues to increase with age into the ninth decade. Additionally, patients who are initially screened with tests other than colonoscopy must be willing to undergo colonoscopy for further evaluation of abnormal results and polyp removal as needed.",
"   </p>",
"   <p>",
"    A robust screening program should assure that the following elements are reliably implemented:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening people at the appropriate age to identify those with an increased likelihood of disease.",
"     </li>",
"     <li>",
"      Ongoing screening at specified intervals for people with negative initial findings.",
"     </li>",
"     <li>",
"      Follow-up abnormal screening results with diagnostic testing to determine if polyps or cancer are present, with biopsy or excision when necessary.",
"     </li>",
"     <li>",
"      Surveillance of high-risk people (typically those in whom a large adenomatous polyp has been found) for new lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, longitudinal studies show a significant rate of failure to follow-up after initial screening, compromising the effectiveness of a screening intervention. This failure occurs both as lack of follow-up for a screening test that is abnormal and lack of ongoing screening after first round testing has been accomplished. In a population of veterans age 70 years and older, 58 percent of those who had an initial positive stool guaiac test had no colon evaluation within one year, in some part due to comorbidity indicating that screening should not have been initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/95\">",
"     95",
"    </a>",
"    ]. Compliance with annual stool testing is low: almost one-half of an insured population who had an initial screening stool guaiac test failed to have a second screening procedure for colon cancer over a two year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/96\">",
"     96",
"    </a>",
"    ]; in data from a veteran&rsquo;s program, only 14 percent of those who were screened by fecal occult blood tests (FOBT) had submitted at least four annual samples over a five year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/97\">",
"     97",
"    </a>",
"    ]. Program components to improve screening implementation are discussed below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Improving screening implementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR AVERAGE RISK SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for colorectal cancer (CRC) screening need to take into account multiple factors, including effectiveness, sensitivity, false-positive rate, safety, cost, cost-effectiveness, and patient preference. Two major US guidelines, from the Multi-Society Task Force and the United States Preventive Services Task Force (USPSTF), were released in 2008 with somewhat differing sets of recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Additionally, the American College of Gastroenterology (ACG, also represented on the Multi-Society Task Force) issued separate guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/54\">",
"     54",
"    </a>",
"    ] that differ somewhat from the multi-society guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Multi-Society Task Force guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint guidelines from the American Cancer Society, the United States Multi-Society Task Force on Colorectal Cancer (ACS-MSTF), and the American College of Radiology were published in 2008 (",
"    <a class=\"graphic graphic_table graphicRef58094 \" href=\"mobipreview.htm?38/6/39019\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62904 \" href=\"mobipreview.htm?23/8/23693\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/57\">",
"     57",
"    </a>",
"    ]. Two additional test options, computed tomographic colonography (CTC) and fecal DNA testing, have been added to the five screening options recommended in the earlier 2001 consensus guidelines (fecal occult blood testing [FOBT], sigmoidoscopy, FOBT plus sigmoidoscopy, double contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema [DCBE], and colonoscopy). (It should be noted that a stool DNA test, previously available, is no longer commercially available in 2012.)",
"   </p>",
"   <p>",
"    The ACS-MSTF 2008 guidelines distinguish between tests that can detect cancers at an early treatable stage (eg, stool tests) and tests that also detect adenomas and so lead to cancer prevention (eg, structural examination of the colon, by DCBE, sigmoidoscopy, colonoscopy, or CTC). The guidelines recommend that clinicians help patients make an informed choice between the two classes of tests and then choose specific tests within the classes. The guidelines stress that prevention, rather than early detection, should be the primary goal for most patients and emphasize tests that are sensitive at a single point in time over repeated testing (",
"    <a class=\"graphic graphic_algorithm graphicRef59784 \" href=\"mobipreview.htm?12/22/12640\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Screening rates and preferred tests vary substantially from country to country, even in those with similar colorectal cancer rates and medical resources. In practice within the US, the frequency of colonoscopy is increasing, while use of FOBT, DCBE, and sigmoidoscopy is falling. CTC was first formally endorsed for screening in 2008 and is not yet incorporated into routine coverage by many insurance plans in the US. Medicare does not pay for screening by CTC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations are based upon the 2008 ACS-MSTF guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Offer screening beginning at age 50 years for average-risk patients. Colorectal cancer does occur in asymptomatic average-risk people under the age of 50, but infrequently enough that the costs and risks of screening outweigh the benefits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Discontinue screening when the individual's estimated life expectancy is less than 10 years.",
"     </li>",
"     <li>",
"      No single test is of unequivocal superiority. Incorporating patient personal preferences may increase the likelihood that screening will occur.",
"     </li>",
"     <li>",
"      Screening should be supported by a program that assures proper follow-up of abnormal findings and ongoing testing at identified intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Early detection and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening options that can detect both early-stage colon cancer as well as precancerous lesions include (",
"    <a class=\"graphic graphic_table graphicRef62904 \" href=\"mobipreview.htm?23/8/23693\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonoscopy every 10 years.",
"     </li>",
"     <li>",
"      Computed tomographic colonography (CTC) every five years.",
"      <br/>",
"      <br/>",
"      CTC should be performed with state-of-the-art technology and interpreted by specially trained radiologists. Follow-up optical colonoscopy is required for all polyps &gt;10 mm and three or more polyps &gt;6 mm. For practical purposes, 2008 guidelines suggest that patients with any polyp &gt;6 mm be referred for optical colonoscopy and polypectomy. Short-term CTC surveillance may be appropriate for patients with smaller polyps.",
"     </li>",
"     <li>",
"      Flexible sigmoidoscopy every five years.",
"      <br/>",
"      <br/>",
"      The procedure should be performed by clinicians specially trained in sigmoidoscopy, and there should be a minimum visualization of 40 cm of bowel.",
"     </li>",
"     <li>",
"      Double-contrast",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema every five years (now infrequently used as a screening strategy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mainly early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening options that mainly identify early cancer include (",
"    <a class=\"graphic graphic_table graphicRef62904 \" href=\"mobipreview.htm?23/8/23693\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fecal occult blood testing (FOBT) by sensitive guaiac method, performed annually",
"     </li>",
"     <li>",
"      Fecal immunochemical-based testing (FIT) for blood, performed annually",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stool FOBT by guaiac should be performed by a trained technician on three consecutive stool samples using a sensitive guaiac test (eg, Hemoccult SENSA) without rehydration. Older guaiac tests (eg, Hemoccult II) are not sufficiently sensitive for screening.",
"   </p>",
"   <p>",
"    The need for diet restrictions prior to FOBT is uncertain, although avoiding nonsteroidal antiinflammatory drugs for seven days (including more than one",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    per day) and eliminating high-dose (1000 or more",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    vitamin C and red meat for three days is recommended by the manufacturer. Positive tests should be followed by colonoscopy. Repeating the stool test is not adequate. Samples obtained by office rectal examination may be useful for clinical diagnosis but are not sufficient for screening.",
"   </p>",
"   <p>",
"    Immunochemical-based stool testing is performed on two or three stool samples and processed in a laboratory. It does not require diet modification. Positive tests should be followed by colonoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13101193\">",
"    <span class=\"h2\">",
"     USPSTF guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) also issued guidelines for colorectal cancer screening in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/58\">",
"     58",
"    </a>",
"    ]. These guidelines, based on a systematic literature review and a simulation decision model, did not value identifying premalignant lesions (prevention) over the detection of cancer (screening). The models found three screening strategies to be roughly equivalent and more effective than annual Hemoccult II or flexible sigmoidoscopy every five years when performed alone. The task force found insufficient evidence of harms and benefit for CTC or fecal DNA testing.",
"   </p>",
"   <p>",
"    The USPSTF recommends three screening options for adults age 50 to 75 years (",
"    <a class=\"graphic graphic_table graphicRef75708 \" href=\"mobipreview.htm?12/44/13005\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annual fecal occult blood testing (FOBT) with a sensitive test",
"     </li>",
"     <li>",
"      Flexible sigmoidoscopy every five years, with sensitive FOBT every three years",
"     </li>",
"     <li>",
"      Colonoscopy every 10 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13101152\">",
"    <span class=\"h3\">",
"     Why major guidelines differ",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF and ACS-MSTF guidelines are based on the same evidence but their recommendations differ. The reasons reflect differing methodologies and value judgments by the guidelines panels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ACS-MSTF gave preference to tests that can prevent cancer by detecting pre-malignant polyps over those that mainly offer early detection of cancers.",
"     </li>",
"     <li>",
"      The ACS-MSTF was more inclusive in the tests it recommended, based on the belief that the best test is the one patients will take.",
"     </li>",
"     <li>",
"      The USPSTF was more explicit about its process, incorporated a modeled decision analysis, and required a higher level of evidence for including a test.",
"     </li>",
"     <li>",
"      The USPSTF was more explicit about the age to stop screening. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening in older adults'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     American College of Gastroenterology guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Gastroenterology (ACG) 2008 guidelines recommend a \"preferred\" strategy, prioritizing options listed in the ACS-MSTF guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/54\">",
"     54",
"    </a>",
"    ]. The ACG recommends colonoscopy as the preferred",
"    <span class=\"nowrap\">",
"     screening/prevention",
"    </span>",
"    test and fecal immunochemical test as the preferred",
"    <span class=\"nowrap\">",
"     screening/detection",
"    </span>",
"    test for patients who decline cancer prevention tests. Additionally, the ACG recommends initiating screening at age 45, rather than 50, for African Americans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     NCCN consensus guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Comprehensive Cancer Network (NCCN), a multispecialty panel, issued revised screening guidelines for CRC in January 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/100\">",
"     100",
"    </a>",
"    ]. These guidelines recommend colonoscopy every 10 years, when available, as the preferred screening strategy. Suggested alternatives are annual stool testing with guaiac or immunochemical reagent or sigmoidoscopy every five years with or without annual stool testing. The NCCN advises",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema only when colonoscopy cannot be performed and did not come to consensus regarding CT colonography as a screening modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13101260\">",
"    <span class=\"h2\">",
"     American College of Physicians Guidance Statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Physicians issued a 2012 statement reflecting their review of existing guidelines from other organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/56\">",
"     56",
"    </a>",
"    ]. They recommend individualized assessment of patient risk for CRC in all adults; screening average-risk patients starting at age 50, choosing either a stool-based test, flexible sigmoidoscopy, or colonoscopy; screening patients with high risk starting at age 40 (or 10 years younger than age of affected relative at diagnosis) with colonoscopy; and stopping screening at age 75 years or in adults with a life expectancy less than 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19381882\">",
"    <span class=\"h2\">",
"     Council of the European Union",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2012, the European Council has recommended only the fecal occult blood test for screening men and women aged 50 to 74 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/101\">",
"     101",
"    </a>",
"    ]. However, while not specifically endorsing other modalities for screening, the 2012 European Guidelines do provide quality assurance recommendations when using a variety of screening modalities, including colonoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other groups have developed guidelines for screening for CRC. A compendium of such guidelines can be accessed through the database available at",
"    <a class=\"external\" href=\"file://www.guidelines.gov\">",
"     www.guidelines.gov",
"    </a>",
"    , maintained by the Agency for Healthcare Research and Quality. Guideline recommendations vary, depending on the prevalence of disease in a given population, the availability of resources, healthcare priorities, aggressiveness with which preventive health care is promoted, and other factors in addition to the evidence base for screening effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Screening in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening trials have included too few older patients to provide reliable estimates of screening effectiveness for this age group. It takes several years for screening to lower cancer rates and the decision to stop screening should depend upon whether an individual patient's life expectancy justifies the risk and inconvenience of screening.",
"   </p>",
"   <p>",
"    One study modeled the potential impact on life expectancy of screening colonoscopy in different age groups based upon the prevalence of benign neoplasia detected at screening colonoscopy and estimations of the lag time from polyp to carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/102\">",
"     102",
"    </a>",
"    ]. Colonoscopy was predicted to increase survival by 0.13 years in people &ge;80 years, compared to 0.85 years for people 50 to 54 years of age. However, age alone is only one determinant of the impact of screening; in one modeling study, screening individuals aged 67 to 69 with three or more comorbidities would save fewer lives than screening individuals aged 75 to 79 with no comorbidity (81 versus 459 lives saved per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/103\">",
"     103",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The decision whether to recommend screening for a patient over 70 years of age should depend upon the patient's health status, anticipated life expectancy, risk for colorectal cancer, and personal values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. The following factors should be considered in this decision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a life expectancy less than five years would not be expected to benefit from colorectal screening, since studies indicate benefit from screening accrues after about five years.",
"     </li>",
"     <li>",
"      Colonoscopy carries increased risk in older adults, with significant complications occurring in 0.3 percent of 600 veterans aged 70 to 75 undergoing screening, compared to 0.01 percent for sigmoidoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/107\">",
"       107",
"      </a>",
"      ]. The risks of colonoscopy increase with age and comorbidities including cardiopulmonary disease, diabetes mellitus, and history of stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/108\">",
"       108",
"      </a>",
"      ]. If such patients are nevertheless expected to live long enough to benefit from screening, CT colonography might be a preferred initial choice.",
"     </li>",
"     <li>",
"      Sigmoidoscopy has reduced sensitivity in older adults because advanced neoplasias tend to occur more proximally in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most guidelines recommend that screening for colorectal cancer stop when the patient's life expectancy is less than 10 years. The USPSTF guidelines recommend that patients over age 85 not be screened, and recommend against screening in adults 76 to 85 years, unless there are individual considerations that favor screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the implementation of screening in older patients appears not to be appropriately targeted, with significant numbers of healthier patients not getting screened and many patients who would not be expected to benefit receiving screening. As an example, a study of colorectal cancer screening among US veterans aged 70 or older (n = 27,068) found that screening studies were done for only 47 percent of patients whose life expectancy was greater than five years but were performed for 41 percent of patients with severe comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/109\">",
"     109",
"    </a>",
"    ]. Another study in US veterans aged 70 and older found that 38 percent of those who had a positive stool guaiac test without follow-up at one year either had comorbidity precluding follow-up or declined complete colon evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/95\">",
"     95",
"    </a>",
"    ]. Additionally, a study of Medicare patients who had a negative screening colonoscopy found that repeat colonoscopies were performed within seven years of the initial study in 46 percent of the sample, with marked geographic variation, indicating deviation from the guideline-suggested frequency of screening (every 10 years) and likely overuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SCREENING FOR PEOPLE AT INCREASED RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for how high-risk patients should be screened is weaker than for average-risk patients. Thus, guidelines are based mainly upon arguments relating to knowledge of the biology of colorectal cancer (CRC):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is at risk for earlier onset CRC (eg, first-degree relative with onset of CRC before age 50), screening should begin earlier.",
"     </li>",
"     <li>",
"      If the patient is at risk for more rapid progression of disease, screening should be performed more frequently.",
"     </li>",
"     <li>",
"      If the patient is at risk for more proximal lesions (eg, hereditary nonpolyposis colorectal cancer [HNPCC]), screening should be performed with colonoscopy.",
"     </li>",
"     <li>",
"      If the patient is at risk for a greatly increased incidence of disease (eg, HNPCC or familial adenomatous polyposis [FAP]), they should be screened with colonoscopy, the most sensitive test for complete examination of the colon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strategies for screening high-risk patients are shown in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef59784 \" href=\"mobipreview.htm?12/22/12640\">",
"     algorithm 1",
"    </a>",
"    ) and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Family history of FAP or HNPCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with one of several known familial colon cancer syndromes is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance refers to follow-up testing in patients who have a history of polyps, cancer, or inflammatory bowel disease. Surveillance is conceptually different than screening (which applies to patients without disease or symptoms) and is discussed on separate topics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of polyps &mdash; Once polyps have been identified by screening, the patient should be entered in a colonoscopy surveillance program. Recommendations for follow-up are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of colorectal cancer &mdash; Patients should have full visualization of the colon at the time of diagnosis to exclude synchronous cancers and polyps, and then have surveillance optical colonoscopy at regular short intervals. The surveillance interval would be determined by what is found at each colonoscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"       \"Surveillance after colorectal cancer resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease &mdash; In patients with long-standing extensive inflammatory bowel disease, surveillance colonoscopy should be considered, to look for dysplasia as a marker of colorectal cancer risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     IMPROVING SCREENING IMPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maximize the impact of screening, it is not sufficient to recommend a procedure to patients. Screening must be targeted to appropriate patients, performed properly at appropriate intervals, and supported by patient education and systems to ensure implementation and follow-up.",
"   </p>",
"   <p>",
"    Rates for colorectal cancer (CRC) screening in the United States for 2010 were 58.6 percent overall, based on data from that National Health Interview Survey (NHIS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/111\">",
"     111",
"    </a>",
"    ] and 65.4 percent according to the Behavioral Risk Factor Surveillance Survey (BRFSS) data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/4\">",
"     4",
"    </a>",
"    ]. While much higher than the 20 to 30 percent in 1997, there remains opportunity for improvement. People with lower levels of income and education, living in underserved communities, or who are uninsured are less likely to receive screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRC occurs at an earlier age and mortality is higher in blacks than whites. Screening rates in the US are lower for blacks than for whites in the US (51 to 59 percent, compared to 57 to 63 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/112\">",
"     112",
"    </a>",
"    ]. In one analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/113\">",
"     113",
"    </a>",
"    ], a greater number of CRCs in blacks could be prevented if screening rates could be increased by 10 percent, than if the age to initiate screening in blacks were lowered to 45, as recommended by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Increasing screening rates depends on numerous factors, including clinician recommendation, patient and clinician reminders, decision aids, and organization of office staff to support a program of patient education, monitoring, outreach, and follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/114\">",
"     114",
"    </a>",
"    ]. A systematic review evaluated strategies to increase the quality of CRC screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/115\">",
"     115",
"    </a>",
"    ]. Interventions considered were at the level of the patient, provider, or health care system. Those programs that involved changes in the system of care, such as providing a patient navigator or eliminating barriers to providing FOBT cards, were most effective and increased the absolute rate of screening 7 to 28 percent. A consensus statement from the National Institutes of Health regarding CRC screening advises eliminating financial barriers to screening, identifying which screening programs are most effective for specific target populations, implementing systems to ensure follow-up, developing systems to assure high-quality screening, and ongoing study to determine the most effective screening modality in usual practice settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/116\">",
"     116",
"    </a>",
"    ]. One study found that offering patients a choice of screening options (FOBT or colonoscopy), compared with only offering colonoscopy, improved screening uptake, particularly among racial and ethnic minority participants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to underutilization when screening is appropriate, CRC screening is overutilized in patients with advanced age or comorbidities, as well as younger adults, who would not derive benefit, and misutilized when abnormal results are not appropriately followed-up or inadequate testing is performed (eg, stool testing on samples from an office visit). Screening practices consistent with guidelines were performed by a minority of US physicians in one nationally-representative survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/118\">",
"     118",
"    </a>",
"    ]. While most studies have evaluated interventions to improve underutilization, less attention has been paid to limiting overuse and misuse of CRC screening. A study of timing of repeat colonoscopy after a negative screening colonoscopy in a representative sample of 24,071 Medicare patients found that 46.2 percent had a repeat examination in less than seven years, with no clear indication for early colonoscopy in nearly half and considerable geographic variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/110\">",
"     110",
"    </a>",
"    ]. Additionally, studies find overuse of colonoscopy in shortened surveillance intervals following a positive study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/10/37034/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=see_link\">",
"       \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for colorectal cancer (CRC) can identify premalignant lesions and detect asymptomatic early stage malignancy. Screening has been shown to decrease mortality from CRC. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Tests used for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommendations below apply to usual-risk patients and require that patient history be assessed to determine if they are at increased risk for CRC. We initiate risk assessment no later than age 20 and update the information at a minimum of every five years.",
"      <br/>",
"      <br/>",
"      Patients at sufficiently-increased risk to change screening recommendations are those who have:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A personal history of CRC or adenomatous polyp",
"     </li>",
"     <li>",
"      A genetic syndrome predisposing to CRC (ie, hereditary nonpolyposis colorectal cancer [HNPCC], familial adenomatous polyposis [FAP])",
"     </li>",
"     <li>",
"      One or more first-degree relatives with CRC",
"     </li>",
"     <li>",
"      Two or more second-degree relatives with CRC",
"     </li>",
"     <li>",
"      IBD causing pancolitis or longstanding (&gt;8 to 10 years) active disease",
"     </li>",
"     <li>",
"      A personal history of childhood cancer requiring abdominal radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from some organizations (the American College of Physicians and the American College of Gastroenterology) identify African Americans as being at sufficiently-increased risk to recommend an earlier age (40 to 45 years) for initiating screening; other guidelines do not specify this.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that average-risk patients aged 50 and older be screened for colorectal cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that screening be continued until the life expectancy for an individual patient is estimated as less than 10 years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For most patients, it is reasonable to stop screening at age 75 years or 85 years at the latest. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines for average risk screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening in older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be advised of the risks and benefits of different screening options. The decision about which option to select should be made between the patient and clinician, weighing factors of effectiveness, safety, cost, and availability of the screening tests. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Tests used for screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"       \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because a structural colon examination can lead to prevention of colorectal cancer, as well as detecting early-stage disease, we suggest that patients undergo screening tests that visualize or image the colon (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Polyps &gt;6 mm should be biopsied. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines for average risk screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following screening strategies are options for visualizing the colon in average-risk patients (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines for average risk screening'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Colonoscopy (optical colonoscopy) every 10 years",
"     </li>",
"     <li>",
"      Computed tomographic colonography (CTC or \"virtual colonoscopy\") every five years",
"     </li>",
"     <li>",
"      Flexible sigmoidoscopy (FS) every five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For some patients, colon imaging or visualization may not be feasible and alternative testing (evaluation of stool samples) is an alternative and far preferable to foregoing screening. The following are options for stool testing (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines for average risk screening'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fecal occult blood test (FOBT) with immunochemical testing (iFOBT or FIT, annually on two to three samples)",
"     </li>",
"     <li>",
"      FOBT with guaiac reagent (gFOBT, annually on three samples)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When guaiac FOBT tests are performed, we suggest testing with a sensitive stool guaiac reagent (eg, Hemoccult SENSA) rather than less-sensitive guaiac reagents (eg, Hemoccult II) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link&amp;anchor=H5#H5\">",
"       \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Sensitive gFOBT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Stat Fact Sheet; colon and rectum. National Cancer Institute. Available at: file://seer.cancer.gov/statfacts/html/colorect.html (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: Colorectal cancer screening, incidence, and mortality--United States, 2002-2010. MMWR Morb Mortal Wkly Rep 2011; 60:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/5\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/6\">",
"      Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Use of colorectal cancer tests--United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep 2008; 57:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/8\">",
"      Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/9\">",
"      Henley SJ, King JB, German RR, et al. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006. MMWR Surveill Summ 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/10\">",
"      Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/11\">",
"      Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/12\">",
"      Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008; 299:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/13\">",
"      Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 355:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/14\">",
"      Saitoh Y, Waxman I, West AB, et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001; 120:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/15\">",
"      Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/16\">",
"      Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001; 93:1307.",
"     </a>",
"    </li>",
"    <li>",
"     Burt R, Jass JR. Hyperplastic polyposis. In: WHO International Classification of Tumors, Hamilton and Aaltonen (Ed), IARC Press, 2000. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/18\">",
"      Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006; 56:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/19\">",
"      Laiyemo AO, Murphy G, Albert PS, et al. Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med 2008; 148:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/20\">",
"      Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/21\">",
"      Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer 1999; 85:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/22\">",
"      Jessup JM, McGinnis LS, Steele GD Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/23\">",
"      Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011; 34:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/24\">",
"      Th&ouml;rn M, Bergstr&ouml;m R, Kressner U, et al. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birth cohort. Cancer Causes Control 1998; 9:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/25\">",
"      Stewart RJ, Stewart AW, Turnbull PR, Isbister WH. Sex differences in subsite incidence of large-bowel cancer. Dis Colon Rectum 1983; 26:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/26\">",
"      Mamazza J, Gordon PH. The changing distribution of large intestinal cancer. Dis Colon Rectum 1982; 25:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/27\">",
"      Vukasin AP, Ballantyne GH, Flannery JT, et al. Increasing incidence of cecal and sigmoid carcinoma. Data from the Connecticut Tumor Registry. Cancer 1990; 66:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/28\">",
"      Schub R, Steinheber FU. Rightward shift of colon cancer. A feature of the aging gut. J Clin Gastroenterol 1986; 8:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/29\">",
"      Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/30\">",
"      Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/31\">",
"      Roy HK, Bianchi LK. Moving toward personalization of colorectal cancer screening: Comment on \"Influence of race and sex on prevalence and recurrence of colon polyps\". Arch Intern Med 2010; 170:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/32\">",
"      Flood DM, Weiss NS, Cook LS, et al. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control 2000; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/33\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/34\">",
"      Lieberman DA, Holub JL, Moravec MD, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 2008; 300:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/35\">",
"      Brenner H, Altenhofen L, Hoffmeister M. Sex, age, and birth cohort effects in colorectal neoplasms: a cohort analysis. Ann Intern Med 2010; 152:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/36\">",
"      Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/37\">",
"      Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/38\">",
"      Tomeo CA, Colditz GA, Willett WC, et al. Harvard Report on Cancer Prevention. Volume 3: prevention of colon cancer in the United States. Cancer Causes Control 1999; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/39\">",
"      Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/40\">",
"      Botteri E, Iodice S, Bagnardi V, et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300:2765.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.gov/colorectalcancerrisk (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/42\">",
"      Freedman AN, Slattery ML, Ballard-Barbash R, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 2009; 27:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/43\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/44\">",
"      Ziogas A, Horick NK, Kinney AY, et al. Clinically relevant changes in family history of cancer over time. JAMA 2011; 306:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/45\">",
"      Raj KP, Taylor TH, Wray C, et al. Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis. J Carcinog 2011; 10:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/46\">",
"      Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/47\">",
"      Petersen GM. Genetic epidemiology of colorectal cancer. Eur J Cancer 1995; 31A:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/48\">",
"      Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/49\">",
"      Burt RW, Bishop DT, Lynch HT, et al. Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990; 68:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/50\">",
"      Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/51\">",
"      Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/52\">",
"      Cottet V, Pariente A, Nalet B, et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 2007; 133:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/53\">",
"      Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/54\">",
"      Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/55\">",
"      Cash BD, Banerjee S, Anderson MA, et al. Ethnic issues in endoscopy. Gastrointest Endosc 2010; 71:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/56\">",
"      Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012; 156:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/57\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/58\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/59\">",
"      Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006; 355:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/60\">",
"      Rundle AG, Lebwohl B, Vogel R, et al. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 2008; 134:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/61\">",
"      Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 2007; 56:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/62\">",
"      Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: implications for age at initiation of screening. Br J Cancer 2007; 96:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/63\">",
"      Hoffmeister M, Schmitz S, Karmrodt E, et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol 2010; 8:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/64\">",
"      Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012; 156:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/65\">",
"      Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 2012; 30:2552.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.survivorshipguidelines.org/pdf/ColorectalCancer.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/67\">",
"      Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005; 128:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/68\">",
"      Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006; 166:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/69\">",
"      Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/70\">",
"      Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/71\">",
"      J&oslash;rgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/72\">",
"      Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/73\">",
"      Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/74\">",
"      Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/75\">",
"      Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst 2011; 103:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/76\">",
"      Collins JF, Lieberman DA, Durbin TE, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/77\">",
"      Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/78\">",
"      Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/79\">",
"      Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/80\">",
"      Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/81\">",
"      Singh H, Nugent Z, Demers AA, et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010; 139:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/82\">",
"      Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/83\">",
"      Sonnenberg A, Delc&ograve; F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/84\">",
"      Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/85\">",
"      Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/86\">",
"      Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010; 153:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/87\">",
"      Heitman SJ, Hilsden RJ, Au F, et al. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010; 7:e1000370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/88\">",
"      Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 2013; 108:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/89\">",
"      Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/90\">",
"      Bosworth HB, Rockey DC, Paulson EK, et al. Prospective comparison of patient experience with colon imaging tests. Am J Med 2006; 119:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/91\">",
"      de Wijkerslooth TR, de Haan MC, Stoop EM, et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 2012; 61:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/92\">",
"      Rodr&iacute;guez-Moranta F, Trapero-Bertran M, Castells A, et al. Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. Gastroenterol Hepatol 2008; 31:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/93\">",
"      Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/94\">",
"      Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF. Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med 2012; 125:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/95\">",
"      Carlson CM, Kirby KA, Casadei MA, et al. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up? Arch Intern Med 2011; 171:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/96\">",
"      Fenton JJ, Elmore JG, Buist DS, et al. Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med 2010; 8:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/97\">",
"      Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 2011; 106:1125.",
"     </a>",
"    </li>",
"    <li>",
"     www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&amp;id=220&amp; (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/99\">",
"      Imperiale TF, Wagner DR, Lin CY, et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002; 346:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/100\">",
"      Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/101\">",
"      Lansdorp-Vogelaar I, von Karsa L, International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Introduction. Endoscopy 2012; 44 Suppl 3:SE15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/102\">",
"      Lin OS, Kozarek RA, Schembre DB, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA 2006; 295:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/103\">",
"      Gross CP, Soulos PR, Ross JS, et al. Assessing the impact of screening colonoscopy on mortality in the medicare population. J Gen Intern Med 2011; 26:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/104\">",
"      Ko CW, Sonnenberg A. Comparing risks and benefits of colorectal cancer screening in elderly patients. Gastroenterology 2005; 129:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/105\">",
"      Gross CP, McAvay GJ, Krumholz HM, et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 2006; 145:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/106\">",
"      Kistler CE, Kirby KA, Lee D, et al. Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med 2011; 171:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/107\">",
"      Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/108\">",
"      Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 2009; 150:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/109\">",
"      Walter LC, Lindquist K, Nugent S, et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med 2009; 150:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/110\">",
"      Goodwin JS, Singh A, Reddy N, et al. Overuse of screening colonoscopy in the Medicare population. Arch Intern Med 2011; 171:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/111\">",
"      Centers for Disease Control and Prevention (CDC). Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/112\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/113\">",
"      Gupta S, Shah J, Balasubramanian BA. Strategies for reducing colorectal cancer among blacks. Arch Intern Med 2012; 172:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/114\">",
"      Pignone MP, Lewis CL. Using quality improvement techniques to increase colon cancer screening. Am J Med 2009; 122:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/115\">",
"      Holden DJ, Jonas DE, Porterfield DS, et al. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med 2010; 152:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/116\">",
"      Steinwachs D, Allen JD, Barlow WE, et al. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010; 152:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/117\">",
"      Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med 2012; 172:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/118\">",
"      Yabroff KR, Klabunde CN, Yuan G, et al. Are physicians' recommendations for colorectal cancer screening guideline-consistent? J Gen Intern Med 2011; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/10/37034/abstract/119\">",
"      Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med 2004; 141:264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7565 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37034=[""].join("\n");
var outline_f36_10_37034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adenoma-carcinoma sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6271688\">",
"      Right-sided versus left-sided lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection of increased risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors that affect screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Strong genetic risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other significant risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8750286\">",
"      Other risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TESTS USED FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96786412\">",
"      Digital rectal examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPARISON OF TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88004299\">",
"      Test attributes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H993407\">",
"      Cost and cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88004394\">",
"      Patient preference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88004424\">",
"      Test availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3759928\">",
"      Other factors that may impact screening test choice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHARACTERISTICS OF A SCREENING PROGRAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GUIDELINES FOR AVERAGE RISK SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Multi-Society Task Force guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Early detection and prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mainly early detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13101193\">",
"      USPSTF guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13101152\">",
"      - Why major guidelines differ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      American College of Gastroenterology guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      NCCN consensus guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13101260\">",
"      American College of Physicians Guidance Statement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19381882\">",
"      Council of the European Union",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Screening in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SCREENING FOR PEOPLE AT INCREASED RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Family history of FAP or HNPCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      IMPROVING SCREENING IMPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7565|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/22/12640\" title=\"algorithm 1\">",
"      Algorithm for CRC screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7565|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/17/37151\" title=\"figure 1\">",
"      Incidence of CRC with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/63/40957\" title=\"figure 2\">",
"      Risk of colon cancer assoc w fam history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7565|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/58/30628\" title=\"picture 1\">",
"      Colonic polyps Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/19/8504\" title=\"picture 2\">",
"      Familial polyposis Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/19/33083\" title=\"table 1\">",
"      Colorectal CA risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/6/39019\" title=\"table 2\">",
"      Test early detection CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/15/31996\" title=\"table 3A\">",
"      Screening tests for CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/15/8443\" title=\"table 3B\">",
"      Complix of screening in CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/8/23693\" title=\"table 4\">",
"      Scrn CRC MSTF recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/44/13005\" title=\"table 5\">",
"      Scrn CRC USPSTF recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_10_37035="High chol treat PI";
var content_f36_10_37035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Academy of Pediatrics recommendations on screening for and treatment of high cholesterol in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        When to perform screening tests*?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If family history of high cholesterol or early cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If family history unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If child has risk factors (obesity, high blood pressure, medical illness that increases risk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform testing every 3 to 5 years beginning at age 2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        When to begin lifestyle changes (diet, exercise)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At 1 year of age, begin reduced-fat (2 percent) milk for children at risk due to obesity or family history of cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In children with elevated serum LDL-C, the recommended diet should have saturated fat &lt;7 percent, trans fat &lt;1 percent, dietary cholesterol &lt;200 mg/day, and fiber intake equal to child's age plus 5 g/day (up to 20 g/day at 15 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage physical activity to manage weight and treat high triglyceride levels and low HDL cholesterol levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        When to consider medication for high cholesterol?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider medication in children at least 8 years of age or older, if LDL &ge;190 mg/dL or &ge;160 mg/dL with positive family history or two additional risk factors or &ge;130 mg/dL with type 1 diabetes mellitus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Screening tests usually include blood tests for total cholesterol, HDL (high density lipoprotein), LDL (low density lipoprotein), and triglycerides, drawn before the first meal of the day.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37035=[""].join("\n");
var outline_f36_10_37035=null;
var title_f36_10_37036="Vitamin D recommendations for individuals with cystic fibrosis";
var content_f36_10_37036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for vitamin D intake and treatment for children and adults with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Routine dosing* of vitamin D3 (IU)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Step 1",
"        <sup>",
"         &bull;",
"        </sup>",
"        <br/>",
"        dose increases (IU)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Step 2",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <br/>",
"        dose titration maximum (IU)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Step 3",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         0 to 12 months",
"        </strong>",
"       </td>",
"       <td>",
"        400 to 500",
"       </td>",
"       <td>",
"        800 to 1000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        Refer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1 to 10 years",
"        </strong>",
"       </td>",
"       <td>",
"        800 to 1000",
"       </td>",
"       <td>",
"        1600 to 3000",
"       </td>",
"       <td>",
"        4000",
"       </td>",
"       <td>",
"        Refer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         11 to 18 years",
"        </strong>",
"       </td>",
"       <td>",
"        800 to 2000",
"       </td>",
"       <td>",
"        1600 to 6000",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        Refer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Over 18 years",
"        </strong>",
"       </td>",
"       <td>",
"        800 to 2000",
"       </td>",
"       <td>",
"        1600 to 6000",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        Refer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Stepwise approach to vitamin D replacement and monitoring, as recommended by the cystic fibrosis foundation. Target serum 25-hydroxyvitamin D (25OHD) levels are at least 30 ng/mL (75 nmol/L). Serum 25OHD levels should be checked at least annually (preferably near the end of winter), and approximately three months after a change in vitamin D dose.",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis; IU: international units.",
"     <br>",
"      * Routine dosing of vitamin D3 (cholecalciferol) is achieved with use of CF-specific multivitamins.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Step 1: If serum 25OHD is less than 30 ng/mL (or &lt;75 nmol/L), with good adherence to supplements, increase to step 1 dose as shown.",
"       <br>",
"        &Delta; Step 2: If serum 25OHD is 10 to 20 ng/mL (or 25 to 50 nmol/L), with good adherence to supplements, or if unable to achieve a serum 25OHD level of at least 30 ng/mL after treatment with step&nbsp;1 doses, increase dose and titrate as needed, up to the maximum dose shown.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Step 3: If serum 25OHD is less than 10 ng/mL (or &lt;25 nmol/L), with good adherence to supplements, or if unable to achieve a serum 25OHD level of at least 30 ng/mL after treatment with step 2 doses, refer to a specialist with expertise in vitamin D therapy.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tangpricha V, Kelly A, Stephenson K, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: Evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012; 97:1082. Copyright &copy; 2012 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37036=[""].join("\n");
var outline_f36_10_37036=null;
var title_f36_10_37037="Prednisone in nocturnal asthma";
var content_f36_10_37037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Timing of prednisone dosing in nocturnal asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 240px; background-image: url(data:image/gif;base64,R0lGODlhAQLwAMQAAP///wAzmf8AAICAgAAZTAAAAH8AAMDAwEBAQKCgoDAwMBAQEFBQUCAgINDQ0HBwcODg4PDw8LCwsGBgYJCQkAAMJj8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAABAvAAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIVXDhQDCRE6CQgOdBEJAxSMOQ8IdpKUljiOkIahRAWkBZk5AwUHcxEKpgULnTYIBXWtr7GoqqK8QQkAEKTAAxKYEiKKAwgJDgwMsgDNCLSrDhMID5YSDAgTqxDXE6BeBwUKANQAmN2QEMTXDhLYJvIMDbUA2wgUIxTTDxAAONonptw5au6KITgGINmyZs9KSEtnDZs2bt6AhRvXqyOKAw8KDABQrsEAV5BI/ylYUKCBqwkkICxYoEyVTAUDFpxLUIDBAJ83cy4Ac0tBA5gATD5Y0IAkKVpM7/0aIcHcgHv5eoZ8AGBCgQcnQX5lUIAfUVdGYZY8WSClOZYuCyAVIZMmQp05d/b8OSDoTI+ATzj66nRk1ZGmGu5K3K/Ar1QHKBQ4FhKR1V+SJ9Rc5SXCBKbmGIFEwLIwulrlRo4gG5AWALKMVr7eu4rpgFSnvngGrSBC6qyIM0EGwFiE5MeqJFNuKxknZrmbA0snQe3378TDiyteBXm4d1pfU2m+HdCL5JFkifWU4Mq0698jXJ+eP9+zq8ktbysKc372AOsiESfcYrltt513u9QUHv905E0H2AE4hVQABOV4g5KABmpXDgMHUONATwc0MBQFDxzAEwMfKiABSBxtwZMCEDqWCjFY/fZegCPMKAFW51XFQFcUiEVBeiaq9sWLMSZQYYwpDbiKhiB6CKKIAJBoYk8prvhAiw6GAsF9DRxTEixTYUdgCSHptEsC9ygAyY6kRMSeSuV5sVR+ANzSQI0B3mhknrTsic+dEeUEC1e7wfKnnXCNNOYCZTqJIQlpurIKm+a8eU9PjMxpTp1dSgdfqKSaVuqpKxzAmQ2jojpdq67GisyistZq660s3IbrrrySquqvKeja67DE9lKKMCgIW+yyzAJCCrDJ0trstF8coN//tdhmq+223Hbr7bfghvsfFU9xOIK1104j7rrstuvuu/DGK++89NZr773xrtqCMvj266+3CEh7RCrPvjaAVwuUh65+6gJcAQEQRyzxxBRXTEAFFhig8cYcd+zxxxYE/G+8CDxs8ckoX5zxxyy3vHHII5Nscso0R4yxyzizDLO3+uYqcB/KLkGhqrKkc0LQyRIQwNJMN+3001AHQIABAlRt9dVYZ621AT87MYDSUYctttRUa2322VZzfcXXY7ft9NRox2222jwgDYjdTUB4MCzQ5Ng1MmC7LTjcchdeNd1VsC344GUbLjfiVCi++NiEO/743zLg7YfmQt/nZrCYSz65/9iVW3425FOIPnrUpZu+NeZLqL762427PjfsMNi9cLs9j8F5Fr8DPjvptduONepSyD48060bnzbuSSi/fPPOHw69C3YPMHPNNl+PRfBrhx748rRXnzXyUUg/ffHmow+F+rNTX737NWQ//uIEeB++GODDHz/789NfEfy3OvkZj35eux/5yGa+8wlQBfaL3wMjN8Em9E+BCzSg7RBoQQyST4Ou4yATCDg5EIawgkejFQmflj80gM8KF1wgCwHoPBHGzoPra+DVbKiEFTJOhztEoQkiWEAhvs+I0ROfDMsHRAHwMHo4HJ4JLfdEJPjQbVOkIhL9NsQohq2FZ3hh4pS4RP/m0fCAW6ybFwt4xg2mcQdXbFsWHVfFfalwjVADIwl+tap5zMAByxCCGCmYKzyWsI0nXJsh8YdI09XRCHGkXCMd+UYijk6PIzjWAppEA1j1YJCpI2MZGdjERw5wkT8s5Rt1EEniNdF6n7yjBE0gDMn8KDHg+IclEsCNbERAGQwQ01euwZCKZAMHoHwCugJWyFEubY6FMyURWulKVSrSmdCMZiVlWURaoiYxienQ3mCSCp80AEI0QclaUOKXc9wgmU5YpijLmM24SXMI1PziJOm4SlSgUo775GcsuzjLEpCCLb9gTAKukRimiMA3ptjbfwJ0GOWooy3v7Cc+57nEeqL/7Z6C/CdAXwnSIOQzjwE1XEmHyM1L0uopgcTQVsqRieLQVD+qClBqENS7GMDziM3EZkovd02hklSj7xRpNa1Zt5aW8KX4yGQmaCEBnmSCLEHi0EyURAElyYVJH+IQlTLKP47K0KOnQ6oNTorSoxaVnkMlalMJ2k2DRlUEiXEAS2iRiUQ1AALNIEWYysESSIkAU58jaxhiaFSmJk6pS9XhSn/AViY6lpVOxZ9aIblZypo1g3H9aGdnUFnLSna0mYMs60Ir2oGWoJWYJMNPn8DYUaL1dm+Fq1thqNq27haOmR0cagU5XOAG1basxS1vnUlKIE7WB6U14yuduE26utSF/8XF7HF1e9nU9da3zs0u9r5r2tO6lgSwFS90t5gArkzzsx9M7uty21H5OpC+oJ3uc7n4WqXG1ncTHNqvrhED39RpE4sA3Xbr+9vIkbe87VPvgvPbYFSocHvcu5iE50oDgh2rQCw4QHpG4ApauDOFE6ZwePGrYvMuF7n6rW4Jdseuni52ggeYyTQQ0AAQr6AUqvHRbBjC0hTHt8LJe3DTbjvfF3O3u8jc8PcqiIkc+XgFM0JGgLJMEmwxE8tKli6U0xfmZ9r3eFIOVpmZ3GTjEmK2dBkHYCFYCs5wOctcpvGXIVhmqa0sZ4A2gAXSnDTmshnNLM4hkhU7CDhXtW8pEP+wJbgsGa6ExCxFBrOhRWYvG9O2z4cOYqKleGZEc7jRE0zFAsQxgwN4JSPBOOc9QIVe+E6P0Kc0dKmfN+r/xfi8goAzBCiwqQZUAgbHwgemGjAVFGsam7ieJqh3DUsnM3jRa412KHHggDtdeb1GvnUdoivmFVv7rNSutptRze3PaMektpaitkOqa2x/urFjzrYJaLwuT39B2FcphbneG255j3va9k4gvs297hz9OdAaGzR26ydYCtCauAUv6BzIbeaEd3DhLm44MkK7XwtOkAIZSWLG67pxhOf73jD2eOZUSPJ5dzjA+nIAlzy78uvSgePNDbmDQd7AkjeE5m6ceIf/azENdHwb2IWG9sHr/XKFx7zqpEV6IsOYaqZP9emnVrOhbQ4EoIea1+dusdAtPMSaK520qlAAjBQAdpEfDdRkp6zLGT70q/Od7a91+4yhBYNPnACQzQ67T5P97h7Is+dPnTrRA9hrNv5a8Q0RPAk0ufNg7cIE7vB3/SY4kB37EQiPf7Zt8w7dva89yZOnPOYHoPlM1sKWDWHGSH6JgGCKYCI2IQYmRhL6PK1DNf7wfe79MYFdTgPTsyor5DUreb8XPe8cPzva7U77pNvVKTVlSS1WwhYH1GUz5TAFS7w6EhEN4AFN2QpZjqGSe8BE/mWpdQ0cIZDEE1z19MR6n+R6/9dXeZeUbtQFdZnnfZsnEq6QUO70IQHjFZTgGNvxG4fxGzOhGQGhE3nSExgSAQ1lErihf0vndFYUbxonB2aXbkbHSmuGgEaXPbWHV6YQU4xxU7dhLQmiCgAyUSPRDPeQMIwBTqcATiS4H/wFdyg4MCrIcixIgBFmgId0edxXg8RxV5MCAFsVGV7FIdWhUyJhI0pCC4ElAanAD0V4VWM4CSYId1dBgv5Xdk/ocy1HdX8He9ZXgLOHhcgiVSMQWC2xHGqSU44yhgFCFi3xCxFAFgvgXmuYJ+5GE2+YOYxXd9oFgB0lgGqEh69HZrFXQzKGXlgofZ2ULXPIc5p4VpwIR/9SKHuPFYpopIDdt3VmAGcmN33CVX1P9onvE4NWmImkyIBlgIsjVIeR93OvKIpUyEjBCHjDaIvFKGUGdi58pGCrmEGtCIOeyIexuIdT2IfEKFsbJmI4koWlgI18Nna8eG15CIrgCIvCmCOleGM1wEe/0nkoAGS2R3iZto5Sp4zdGI7f2Iu+OHpD9HAQJ3FcVwOM13hYdo7lsip6hozUJ5CyKI3elZEaGWX7Bi+i1wVwpi2pmCN1pmVG4hMIozBeZpG7iJHxOItpd2Qy51PbqHJGIGkoaQJG849iF5B3yJFa1IyphHUzVwhwZno75l4u4GpfRRI4gTCQdnS6iEU3iUz/yyiTBemO76hvbzZBD4mJDZiOX6IS+lhbAdiO6FaTPQSMbPkCxugGcdlDLmmVaql2BNl3BumNrMRpMfOX+LJnNDARp4dx2fhBV5lUAymPGxmTWqkD/AaYkjkvIbkC9/EUA1SXcpSYa5WV46iHe5mX1IJsPNEVo4WWm3iXNNmVMBeajDmaLqAK51Rl/weQq6eaisaaVueazAibMWASXgGCtfmTtwmTvPmZ8HicyOmbKqBzjRgRwxl1xRmUjtmRycmVB8mcBmUilYl51pWWxomdogma4jme2nkCDugNqqKP3tlf7Biea2mUNySUQ3meKwAeHyYEqWeb4EmdyklJRIlF/zLImXsQAcTGaSUJmbchmNLZn1G4mL25lfEpn/ZpfjjJn6kJn3j5mtc5obppn16jmZRDoB3mmdb5i/QpUCAKQyJKOiRKWqCmkBCnM9jnlhS6oilYlZuJm1Lkl/TSnVCUoir1onrwAFORCJmpoyPKoysYB9k3oDiKAr6hAOrJDUl6mOKmoYjJpAf4jFEqAul3LHNhmBjKilxqhw9anSeKo+7QY7dxbNF5d+/pnxlKpxvKoV8aDRe3UUrqomeajHa6mh+6ooTJlC3gALfRbAg2lVSJpQanpVkaqLk5qCC6KZj5AsfiXiVmDupInA7qpHj3p0VJqfYpnDLwCx9SC0I2f//R0qdfRKQ+FaqQ6mtvqZ0MYKgyEGuKMRJ51pKuyjqwmjuyKqmk5qVfOg0rsZR0VjAiwKp4hiMV+at5FKxwOaxp+p8AmqdjmZ+R9iuMEAG0cKSEcWmt6qhNCgdmR63jJaTapK07UJYiAwGxFiITUq5lqo2i+pLESqs3qp3rsGPQpwJhWjDLlqCoaaazeq5v8KTGmqf4WQoJOo8NWqfX+qnoaqOkep4wIgKa0XRk6qkUC6pzWrEemp04mn/qEDBi6ZX3uqUJC4Uia1syOqMgo651wFcvQZvwJq0sZLM8+zY+a66X5KM/6q4SAR7PoCR8KrRoGrPTSbL4arRtcLBRu6//CiuXaxa00tEXk6AfEWt33xmyFzuyTiu2UqsDqvCwK8toIIuwVguzY/u0Z7sDBxABDsBH7Am27gmUUFu1fRupc+sDd7ueV9qygFu2Zou1fBu4OyAhl4p6C9qir5qvdvmygMq4O6AoiaqfkfuzS6a1beu3TophGWYxFQC60mESFxq6Lvu2TQsHkSkvQIq5LoAJ+Vi4rHu4cSu3tOubaou7E+u2f6u7vTuaXbu5cRq2wou4y1u8xvu14Ma0l8u8ouu81GKlOSq9F+m602u908Imt5u8e8u7C2ut3jstvyu+6GW+u2ux57ssx6uES2u4j8q92/u+04KG7pC3EoG8JHGN//aau/U7vAOMv8siISI2piyQqTaYjgEcvNVbvmRrwMSyajCiDIUXDcjyLKrSqRDcugR8tRS8K2nrams7Arqahb1Hkb6qvfoawnA7wryCAEaBVcv6eUPWrHuTMGDawvQrwmygPaVbM6crw8uiVyrBqMDgrYBigSXQk68lucBaB7Eru0bMLAfAvyUAr+ShN1L5wHK6uFc8xmUwAQAhAwNrE55zllI8rWT8xmYAHgqQYOqbI+wLx3jcBcVwDyeMkC5cuXkcyHo8AXwMvGFMvoKcyFMgx3A6vwIMxIocyUxgxnu6s3+8o5KcyXxAtSCsyZ6sBI14KJzlucyDup98tjh7jv8f+8HEe8quHASTIQI6u8qH7L6vfMs9QInPybn8QsrPZMq4/KWOG8tBsJ+PHMPBnMw4kHxE5sisXMDKHM1gwMmtLM3WDDyhQ7pDTDFFfM3ezAXgU8X58s3k7AIWqqeGXM7qHAVfhsF1vM7wfASAxBTTsAB9fHPxnM95k2wL0MyWrM8AnQRGuroBXdBEMLhZDAPoQmSL6sEG/dA+MMxrO7Cqsakn5pMQndGZSxP+ywIUIhCJsarEjNEaXdI2oLo0wEv9vKss3WXpAswmfb62S7iex6wPsBLIwavQ6sNIIGAdTCo+XcmigNAJ/cbpiwI6aXtVMq4oS9IDlGyl4mGq7BH/Rz3G8Qu9OeITZNEU8zprYFwDCTF8v4ePATE0IdEUhDAJ24AiYIqPjCAeqiLUd6DWzgAK+Fi30aAqtKDAV+wbfv0CcGIKoFCwDn2PT7F+p3EsfyIVhRAoroDWjMcdLREwSmwHjt0SDXySdEEKco2/PBF3uEqHdEtRU20CPIHWhCAf7ZEC7RVwoa0Hqq2FJ/BqeOwS5+TOzswqYjgS/zoNzcbYjY0P8qGUj7BHEJkHwy3cSgkKwVCvcFzCs/zPOPCDAoEtdobZhpDcs3ItAcEAmnEPMP0C2n103C0Ce53HR4ETj5jOnbTbKRABLOHPgjDeyVJYrw3bwi3bxs3DeFwV/6TA37kd0wIOA4hqcaM84AgOAwxwDjJxmuGd4JhLzNEt2hBe4Sog4fecdVCAhgYuAmg4LhYOxwzwiORazJ3rBCGxEjw8sPId4iPsAJvSG7zMoDYQ1gsx1nwEKiI4IoTx0ZKR4WdA12xNAhXBAFidB0LeIkV+5DJc1OzdavlxIQ+ryjQFfiTAE3xNB5eN2sBgFRPwI8EdF1weDFEJ5oLssU442oZR2vsWTsURASLS2W8Q20TeEg/QyINA54Fo53iex7h94DlA3b0dU7/HqUIWDSKixW5A3x5OGpwa3OathfLAEhedxyGhrO+s0F91IfE7Lr9xD9tggTnGIPgd6YXhav8r8hfyEQjanRqonmNDsepwXNXSfQOPErG/4QCusN6KcSylPh+pUZaZQh+snt+FIeyfI+saPZdgyuYuHs0RgAnN0OLRG+jO/uzJrIiuZua0jO0QXhYIYC1AbpPe/uyTEe69p9C3QWT4WNjlPuCfARpMTtGZrd/R9+4WHsq87gIfbVU26I9RjO8C7wIqzRATeS48PfAxnSaw42GccdOGZTAr2cMvrfAD7t/MqgJJbYNPjMMBb/ExfRURAOfewxdbDZU7PJXMDvLJHBYQ4g2Kng+bUtzIzsYsb9JS/bjdfvMBXXqYHuA8H/RY9uBC7+dEX/RwvPJIj+1Kv/Qu3vROb+G0UB/1ED71VB/Txnz1RZ/1Wo/0Vt/1OH/0YI+/Xz/2GV32Zv/QaJ/2Bb32bA/Qbv/2+Rz3cg/PdF/36nz3eC/JRPNQk0DHzrb3Jv3ZnGHR7i74AS0TBSPS1K73iJ/HO9aDOq0a0fr4cF9nFJAw6fCslJ8ts2v5ySxpUx4ZTB2woG/Sg+sKldDVzn36CW40hO36sj/7tF/7tn/7uJ/7ur/7vN/7vv/7wB/8wj/8xF/8xn/8YhACADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of the timing of the prednisone dose on the percent overnight fall in FEV1. Compared to placebo, only the 3 pm dose reduced the fall in FEV1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Beam, WR, Weiner, DE, Martin, RJ, Am Rev Respir Dis 1992; 146:1524.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37037=[""].join("\n");
var outline_f36_10_37037=null;
var title_f36_10_37038="Long QT genotype outcome";
var content_f36_10_37038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Outcome in long QT syndrome is related to genotype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 498px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Kaplan-Meier estimate shows that patients with LQT1 or LQT 2 have a significantly higher probability of a cardiac event compared to those with LQT3 (63 and 46 percent versus 18 percent, p&lt;0.001). Bottom panel: Although patients with LQT1 have a higher mortality by age 15 (2.9 versus 0.4 and 1.5 percent for LQT2 and LQT3, (p = 0.006), there is no difference in mortality at the age of 40.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zareba W, Moss AJ, Schwartz PJ, et al. for the International Long-QT Syndrome Registry Research Group, N Engl J Med 1998; 339:960.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37038=[""].join("\n");
var outline_f36_10_37038=null;
var title_f36_10_37039="Congenital lobar emphysema chest radiograph";
var content_f36_10_37039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a two-year-old girl with congenital lobar emphysema and minimal clinical symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest radiograph was obtained due to a mild acute upper respiratory tract infection. The marked hyperinflation of the left upper lobe was an incidental finding. Early signs of deformity of the left chest wall due to the hyperinflation can be seen. In retrospect, her family recalled that she had always been somewhat tachypneic, even at rest, and had some exercise intolerance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_10_37039=[""].join("\n");
var outline_f36_10_37039=null;
